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Thesis abstract 
DNA repair mechanisms are essential for genome maintenance and adaptive 
immunity. A careful balance must be achieved whereby highly accurate and 
efficient canonical repair protects the genome from accumulating mutations that 
lead to aging and cancer, and yet mutation and error-prone non-canonical repair 
is required for generating immune diversity. 
 
Immune diversity is achieved within a tightly regulated environment in which 
mutator proteins are directed to the antibody locus to introduce a swathe of DNA 
damage. This produces high affinity antibodies that recognise an infinite number 
of invading pathogens. This process of secondary antibody diversification is 
dependent on both active transcription and DNA repair.  
 
Downstream of histone signalling, DNA repair nucleases are recruited to remove 
the damaged bases. The structure of damaged regions in the DNA can have very 
different conformations depending on whether the source of the damage is 
endogenous or exogenous. Specific DNA nucleases recognise particular DNA 
substrates and generate DNA intermediates that are repaired in conjunction with 
polymerases and ligases.  
 
Despite their multitude and importance to DNA repair, very few nucleases have 
been characterised, while the activities of some studied nucleases remain 
controversial. Conventional techniques for studying DNA nucleases have several 
disadvantages; they are hazardous, laborious, time-consuming, and capture 
nuclease activity in a discontinuous manner. Recognising a need for a safer, 
faster alternative, a fluorescence-based method has been developed for the 
study of DNA nucleases, nickases and polymerases. 
 
Key histone modifications that are known to orchestrate canonical DNA repair 
have since been discovered to regulate non-canonical repair at the antibody 
locus. The Kat5 histone lysine acetyltransferase functions highly upstream of 
DNA repair and promotes active transcription, yet a role for Kat5 in secondary 
antibody diversification has not yet been established. Using chemical inhibitors 
to prevent the catalytic activities of Kat5, and the genetic method of an inducible 
degron system for rapid and reversible downregulation of Kat5, a role for Kat5 in 
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secondary antibody diversification is recognised, and the research contributes to 
our current understanding of the DNA repair signal transduction pathway.  
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1 General Introduction 
 
1.1 DNA repair, immunity and cancer 
DNA repair is a tightly regulated process that is integral for maintenance of genomic 
integrity and adaptive immunity. In this regard, there is a conflict whereby, on one 
hand, highly efficient repair is essential for genome maintenance and protection from 
aging and cancer and, on the other hand, we need mutation and the subsequent repair 
pathways to generate the diversity we need for an effective innate and adaptive 
immune response (1,2). As will be discussed in detail, mutation and subsequent 
recombination of the DNA at the immunoglobulin locus enables the immune system to 
produce a vast repertoire of antibodies from a relatively small segment of the genome 
(3). This intentional DNA damage takes place at two developmental stages of B cells 
and is very acutely controlled (3,4). Loss of these constraints can lead to the 
uncontrolled accumulation of genomic mutations and tumourigenesis, or 
immunodeficiencies may develop that increase susceptibility to pathogenic invasion. 
A careful balance must therefore be achieved to minimise and/or localise  
mutagenesis (5).  
 
1.2 Histone modifiers and DNA nucleases drive DNA repair at polar ends of the 
DNA damage signalling pathway 
This thesis examines proteins functioning upstream and downstream of DNA damage 
during the process of DNA repair signalling (Fig. 1). Once damage has been inflicted 
on the genome, proteins that scan the integrity of the DNA and recognise deformation 
in the duplex structure alert histone modifiers to induce local changes in the chromatin 
and recruit enzymes that directly repair the damage. DNA damage can exist in several 
different forms, such as breaks, chemical adducts or pyrimidine dimerization, and in 
all stages of the cell cycle, each of which determine the most appropriate form of  
repair  (6–8).  
 
The DNA damage response is a complex network of interacting pathways that 
determine the cellular response to damage; this involves halting cell cycle progression, 
inducing apoptosis when the damage is too extensive, altering the transcription profile 
of the cell and increasing expression of repair proteins in order to carry out the 
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necessary repair programmes (9) (Fig. 1). In the first instance following DNA damage, 
sensory proteins that scan the genome recognise sites of damage (9–11), and signal 
to ‘transducer’ proteins (9). These include histone proteins that undergo grand scale 
remodelling at the break site, altering chromatin structure, and ataxia telangiectasia 
mutated (ATM) kinase, which activates a series of ‘effector’ repair proteins to resect 
along the damaged region, ligate broken DNA ends, and replicate across the  
break (9,12). 
 
Kat5 is a histone acetyltransferase with known roles supporting both DNA repair and 
transcription. DNA repair and transcription are mutually important for the secondary 
antibody diversification processes of somatic hypermutation (SHM) and class switch 
recombination (CSR), which produce high affinity antibodies during the adaptive 
immune response. A role for Kat5 in the context of SHM and CSR has yet to be 
established. With the use of chemical and genetic methods, the role of Kat5 in CSR is 
explored. A more detailed description of Kat5 is provided below and in Chapter 5. 
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FIGURE 1 
 
 
Figure 1 | General outline of the DNA repair signal transduction pathway 
Illustration of the DNA repair signalling pathway and outcomes broadly summarises the sequential 
process of 1) accumulating damage, 2) signalling and sensing the damage by ‘sensory’ proteins that 
scan the DNA helix for breaks and distortions, 3) alerting ‘transducers’ that co-ordinate and activate 
‘effectors’ that directly repair the damage.  Arrowheads represent activation events and perpendicular 
ends represent inhibitory events. (Source: Zhou NB and Elledge, SJ, 2000, p433) (9). 
 
Many DNA nucleases involved in these processes have yet to be characterised, and 
the activities of known nucleases have yet to be fully elucidated. Several techniques 
have been developed to study nuclease activity and their binding partners, yet they 
are either too time-consuming and hazardous to health, such as using radiolabelled 
DNA nucleotides (13), or the technology is not universally accessible (14,15). As such, 
there is a need for a simple, fast, inexpensive and safe alternative to support the study 
of nucleases, and this has been achieved using the commercially available DNA dye, 
PicoGreen.  
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1.3 DNA damage signalling upstream of the DNA break site 
 
1.3.1 Kat5 promotes transcription and DNA repair 
Kat5 is a member of the MYST family of histone acetyltransferases, based on their 
founding members ((MOZ, Ybf2/Sas3, SAS2, Tip60/Kat5). These play diverse roles in 
gene regulation, DNA damage repair, chromatin remodelling, and tumourigenesis 
(16,17). Recombinant Kat5 acetylates core histones H2AK5, H3K4, H4K5, H4K8, 
H4K12 and H4K16 in vitro (16,17). Kat5 predominantly functions as part of transient 
multiprotein complexes with the appropriate binding partners. The majority of Kat5 
exists within the NuA4-Kat5 complex which performs most of its transcriptional and 
DNA repair functions (18). Members of this complex include p400 (an ATPase with 
chromatin remodelling activity) (19,20), RuvBL1/2 (ATP-dependent chromatin 
remodelling complexes) (21) and Brd8 (recognises acetyl-lysines in cellular proteins 
and histones to regulate gene transcription) (22,23).  
 
Kat5 is proposed to function upstream of both error-free homologous recombination 
(HR) and error-prone nonhomologous end-joining (NHEJ). During HR-mediated DSB 
repair, repressive chromatin complexes are rapidly recruited to the DSB, including the 
Suv39h1/kap-1/HP1 H3K9 methyltransferase complex (24). This complex briefly 
tethers itself to H3K9me2/3 through the HP1 chromodomain (25), and radiates rapidly 
either side of the DSB to form compact nucleosomal arrays (24,26).  
 
Transitioning to an open chromatin state first requires recruitment of the Kat5 complex 
to DSBs. The shift from the repressive to an open chromatin state requires a 
mechanism dependent on its key subunits, H2A.Z exchange by p400, coupled with 
rapid acetylation of histones H2A/H2AX and H4 by Kat5 (20,27–29).  
 
Histone H2A.Z possesses an extended acidic domain that binds to the H4 tail, holding 
the chromatin in a compact state (30,31). Removal of H2A.Z by NuA4-Kat5 provides 
an opportunity for Kat5 to rapidly acetylate the liberated H4 tail on lysine 16 (32). 
Acetylation at this site prohibits further interaction with acidic patches on replacement 
histones, and loosens the chromatin structure (30,31). It also promotes HR by 
disrupting the formation of a salt bridge between the positively charged H4K16 and 
 19 
 
negatively charged Glu1551 in the NHEJ-promoting 53BP1 Tudor domain (33). 
H4K16ac also prevents 53BP1 binding to the adjacent H4K20me1/2, which is also 
present at sites of DNA damage (33). Loss of 53BP1 encourages binding of BRCA1, 
and thus favours repair by HR. At sites of active transcription, with elevated local 
acetylation already in place, BRCA1 accrues at the site while 53BP1 is specifically 
obstructed (33).   
 
BRCA1 activates 5’–3’ end resection of DSBs by MRN and CtIP to generate tracts of 
single-stranded DNA (ssDNA) (34–38). This resection intermediate is coated in Rad51 
recombinase and, together, invade the sister chromatid to seek a complementary 
region to functions as a template for repair (39).  
 
Kat5 may also function upstream of NHEJ through activation of ATM kinase 
(40,41). ATM phosphorylates a number of targets involved in DNA repair, 
including HP1 to release it from the chromatin and unveil H3K9me3 for Kat5 
binding (24,28). Kat5 binds H3K9me3 directly through its chromodomain following 
phosphorylation by c-Abl kinase on Tyr44. Concordantly, treatment with Kat5 
preparations from IR-treated cells with λ-phosphatase reduces binding affinity of 
Kat5 to this motif (42). Interestingly, the phosphorylation status of Kat5 bears no 
effect on its acetylation of H4, yet interaction between Kat5 and H3K9me3 is 
necessary to stimulate Kat5-mediated acetylation of ATM at Lys-3016 (42). 
Therefore, H3K9me3 binding functions as an allosteric regulator by increasing 
Kat5 catalytic activity (28,43). Mutations within the chromodomain that prohibit this 
interaction also attenuate Kat5 acetylation of ATM. Correspondingly, mutation of 
the ATM acetylation site inhibits activation of ATM’s kinase activity, indicating Kat5 
is required for its activation (43). 
 
Along with HP1, ATM also phosphorylates H2AX (γH2AX) (44), which is a marker 
for DNA repair, and functions as a binding site for several downstream DNA repair 
proteins. Indeed, phosphorylation of H2AX mediates recruitment of E3 ubiquitin 
ligases, RNF8/RNF168 through MDC1 (45,46). These generate polyubiquitin 
binding sites, H2AK14/15ub, for 53BP1. 53BP1 recognises moieties 
H2AK14/15ub and H4K20me2, and γH2AX is itself a platform for 53BP1 binding 
(46,47). As such Kat5 is implicit highly upstream of both homologous and 
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nonhomologous DSB repair, and factors such as cell cycle stage may influence 
the pathway of repair (26).  
 
FIGURE 2 
 
 
Figure 2 | Overview of Kat5-mediated repair in NHEJ and HR 
Illustration of the Kat5 DNA repair pathways that ultimate in recruitment and binding of 53BP1 for NHEJ, 
or binding and activation of BRCA1 and specific obstruction of 53BP1 for HR (Source: Sivanand S, Mol 
Cell, 2017, p453) (48). 
 
In addition to its role in DNA repair, Kat5 is also a transcriptional regulator (18). 
For example, Kat5 can directly acetylate and stabilise the Myc family of 
transcription factors; these directly influence G1/S progression by regulating 
genes required for growth, DNA replication and apoptosis (49). Kat5 can also be 
recruited to Myc-dependent transcription promoters and enhance Myc 
transactivation activity (50). Whilst Kat5 is generally involved in transcription 
activation via recruitment of other complexes, it can also co-repress transcription 
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factors, such as CREB binding protein (51). Intriguingly, dynamic H2A.Z exchange 
observed at DSBs has also been reported at transcription start sites of many 
poised genes, and its ejection may allow progression by RNA polymerase II. 
Whether the Kat5 complex is involved is not yet known (26,52,53).  
 
1.4 Transcription and DNA repair are integral for SHM and CSR 
 
1.4.1 AID relies on active transcription to induce DNA mutations requisite for 
somatic hypermutation and class switch recombination 
Both somatic hypermutation (SHM) and class switch recombination (CSR) are initiated 
by the mutator protein AID. AID is a small protein of 198–210 amino acids, and is 
encoded by the Aicda gene in humans and mice (54). It is a member of the RNA-
editing APOBEC family of cytidine deaminases and converts cytidine residues to uracil 
exclusively in single-stranded DNA, resulting in a C:G to T:A transition. Processing of 
uracil by base excision repair (BER) and mismatch repair (MMR) pathways leads to 
the broader spectrum of point mutations characterising SHM, and to DNA double-
stranded breaks (DSBs) which are necessary intermediates of CSR (55,56). 
 
AID activity, and therefore CSR and SHM, is dependent on the ssDNA revealed during 
transcription. AID interacts with RNA polymerase II and its subunits in vivo (57), 
enabling it to access ssDNA in the wake of the transcription complex. Mutations 
directed to the human Vλ promoter resulted in abrogation of gene rearrangement and 
limited production of high-affinity antibodies (58), indicating AID’s reliance on 
transcription. With regards to CSR, placing a non-functional IgH transgene under the 
transcriptional control of its natural RNA polymerase II-dependent promoter, an RNA 
polymerase I promoter, or no promoter entirely, saw the mutation frequency in cells 
lacking a promoter to be greatly diminished in comparison (59).  
 
It is appropriate that AID is linked to transcription considering its affinity for mutating 
ssDNA rather than RNA or dsDNA. R loops are RNA:DNA structures that occur 
naturally as a by-product of transcription, and contribute towards transcriptional 
pausing (60,61). R loops are generally quite rare yet are prevalent during CSR. R loop 
formation requires high G content on the non-transcribed strand, DNA supercoiling 
and DNA cleavage, all of which are abundant in S regions (62).  
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The precise mechanism by which AID deaminates cytidines is unclear. While 
APOBEC family members may have similar structures, their binding mechanisms and 
functions differ (63). Indeed, AID binds to DNA structures in a specific manner that is 
not shared by other APOBECs (64). Evidence suggests that AID acts on cytidines that 
have been flipped out of alignment. Other deaminases, such as tRNA adenosine 
deaminase (tadA) and adenosine deaminase acting on dsDNA (ADAR) both act on 
pre-flipped bases (65,66). Base flipping is employed by other DNA-modifying enzymes 
such as methyltransferases and uracil glycosylases (67–69). APOBEC3G requires the 
target cytidine to be flipped out into its catalytic pocket (70), which is likely to be 
replicated by AID as it deaminates R loop structures that are likely to force DNA bases 
out of alignment caused by torsional constraints (71). UNG actively flips its target uracil 
from duplex DNA through a ‘pinch-push-pull’ mechanism (72), but as AID acts on 
ssDNA, it is unlikely to entail such a complicated mechanism.  
 
1.4.2 Error-prone DNA repair of AID-induced mutations introduces further 
sequence mutations 
In both mice and humans, SHM mutates the recombined V(D)J region to an 
accelerated rate of 10-5–10-3 mutations per base pair per generation, far exceeding 
the basal rate of mutation in other cells of ~10-9 mutations per base pair per generation 
(73).   
 
AID recognises ‘hotspot’ motifs within the V region, selectively mutating WGCW (74). 
Upon deamination of the target cytosine, a combination of the BER and MMR 
pathways co-ordinate to repair the break via error-prone mechanisms. In BER, uracil 
DNA glycosylase (UNG) recognises and cleaves the damaged base, triggering APE1-
mediated excision of the abasic site, and re-synthesis of the damaged region by error-
prone polymerases (75). 
 
MMR, however, is the major repair pathway in SHM (76). MutSα (Msh2/Msh6) 
recognises the U:G mismatch and recruits the MutL complex (MLH/PMS2) and 
proliferating cell nuclear antigen (PCNA). PMS2 exhibits endonuclease activity and 
introduces nicks spanning the damaged site. Exo1 is a 5’–3’ nuclease which resects 
from this nick and through the damaged region (77).  
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PCNA helps accumulate mutations at Ig variable regions by recruiting error-prone 
translesion polymerases, such as θ, η and ζ (78). This is dependent on its mono-
ubiquitylation and, correspondingly, B cells of PCNAK164R mice display reduced 
mutations at A:T sites. In wild-type B cells, mutations at A and T bases are caused by 
polymerase η, which is particularly error-prone when copying A and T (79,80). It is the 
accumulation of A:T mutations visualised in SHM and not CSR that indicates that MMR 
is the dominant pathway in SHM. UNG-deficiency has no impact on A:T mutations at 
V regions, whereas deficiency in any of the MMR proteins results in cells lacking 80-
90% of all A:T mutations (76).  
 
1.4.3 B cells are reliant on DNA repair factors to induce CSR to distinct antibody 
isotypes 
Prior to activation, B cells express solely IgM or IgD antibodies, which have identical, 
low affinity variable regions. CSR allows for the expression of the IgM and IgD constant 
region genes (Cµ and Cδ) to be replaced by downstream Cγ, Cε or Cα elements to 
express IgG, IgE or IgA (81,82) (Figure 1). In doing so, antibody class, or isotype, 
switching alters the effector function of the antibody (81,82). 
 
Antibody isotype confers the localisation of the antibody within the body, and its 
functions in response to antigen. IgM is exposed on B cells prior to secondary 
diversification, and so binds with very low affinity. This is compensated by its ability to 
form pentamers, endowing high overall avidity. IgM also most efficiently activates the 
complement system, which involves the sequential proteolytic cleavage of inactive 
components to cleave and activate enzymes that coat the pathogen surface (83). IgE 
is found in the mucus and saliva, and antigen-binding triggers mast cells to release 
potent chemical mediators to induce coughing, sneezing, vomiting and diarrhoea (84). 
IgA and IgG both neutralise toxins, viruses and bacteria to prevent their adhesion to 
host cells and inhibit pathogenesis. IgG antibodies typically exhibit higher affinity, and 
opsonises viruses and bacteria for phagocytosis (85).  
 
Each antibody isotype is associated with a unique upstream G-rich switch (S) region, 
which is preceded by an intervening (I) exon. The importance of S regions in CSR was 
observed following deletion of most of Sµ, which dramatically reduced CSR to 
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downstream CH regions (86,87). Furthermore, deletion of Sγ1 prevents isotype 
switching to IgG1 (88,89), without affecting CSR to other isotopes (90).  
 
The cytokines secreted by T cells directs CSR to specific isotypes. For example, IL-4 
induces germline transcription from upstream of the S regions of the un-rearranged 
Cγ1 and Cε genes to induce CSR to IgG1 and IgE (91,92).  IL-4 concomitantly 
downregulates germline transcription of the Cγ2b gene to inhibit CSR to IgG2b (93). 
In contrast, TGF-β and LPS-stimulated B cells induce CSR to IgA, while impeding IgM 
and IgG secretion (94,95). The mouse CH12F3-2A cell line is a model of CSR, and 
specific switches from IgM to IgA-presenting cells in the presence of anti-CD40, IL-4 
and TGF-β (96). 
 
The germline transcripts direct AID to the specific S region where AID deaminates 
cytosine to uracil, prompting uracil excision by UNG (uracil DNA glycosylase). The 
frequency of AID-induced mutations and subsequent base-excision generates double-
stranded breaks, and ultimately results in a recombination event described above.  
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FIGURE 3 
 
Figure 3 | Illustration of the CSR process 
a, Represents the IgH locus which has already undergone V(D)J recombination in the V regions by this 
point. The CH region is composed of each isotypic element. Each isotype is associated with an upstream 
(S)witch region, which is itself associated with an (I)ntervening exon; b, Class switching proceeds when 
Eµ binds to 3’Eα; c, This brings the Sµ and Sα regions close together as a consequence; d, CSR 
machinery targets this loop for recombination, removing Cµ; e, this allows for expression Cα, which 
corresponds to IgA. 
 
Numerous components of DNA repair pathways have been implicated in efficient CSR. 
Processing of the AID-induced DSBs requires ATM (97–103), γH2AX (104–107), 
MDC1 (45,108–110), 53BP1 (111–115), MSH2 (116–118), MSH6 (119–121), MLH1 
(116,117,122), PMS2 (117,123), Exo1 (116,124), and is debatable for MRN (125–
132), Ku70/80 (133–136), DNA-PKcs (137–141), XRCC4-DNA ligase IV complex 
(142,143). These proteins are representative of classical-NHEJ, alternative-NHEJ, HR 
and mismatch repair. Alternative DNA repair proteins, such as DDX1 helicase has 
been found to have a role in CSR (144), whereas PARP1 and PARP2, have been 
shown not to be required (145). Essentially, CSR is highly dependent on the activities 
of a number of DNA repair factors from diverse repair pathways; HR, classical-NHEJ, 
alternative-NHEJ, MMR. The extent of their individual contributions in CSR will be 
discussed in the following review.  
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1.4.4 Several histone modifiers have been implicated in SHM and CSR 
The published review followed at the end of the introduction discusses all known 
histone modifications and related histone writers and readers that orchestrate SHM 
and CSR. The sheer number of histone marks that specifically promote an open 
chromatin state, or recruit AID or DNA repair factors, suggests that Kat5 may also 
make a valuable contribution to SHM and CSR.  
 
1.5 DNA damage signalling downstream of the DNA break site 
 
1.5.1 Nuclease primary sequences are too poorly conserved to accurately 
predict function and substrate specificity 
DNA nucleases maintain genome integrity. DNA is subjected to exogenous stresses, 
including reactive oxygen species, radiation, UV light and carcinogens, which all 
modify the DNA. Endogenous factors can also harm the DNA or form unusual 
structures, and are generated during replication, recombination, or as the result of 
mutagenic proteins. It is essential that these errors are corrected to avoid changing 
the genomic sequence or entangling the DNA, and the vast range of DNA repair 
mechanisms that have evolved, including base excision repair, nucleotide excision 
repair, mismatch repair and DSB repair, gives some indication of the range of insults 
that can be inflicted on the genome (6,146).  
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TABLE 1 
 
 
Table 1 | DNA repair pathways, target lesions and diseases associated with repair defects 
(Source: repurposed from Saccà HS, et al, 2012) (6). 
 
The primary sequences of nucleases are poorly conserved, except for motifs related 
to their catalytic sites (147,148). Active sites typically contain acidic and basic residues 
that coordinate catalytically essential divalent cations, such as magnesium, calcium, 
manganese or zinc as a cofactor to stabilise reaction intermediates. Cleavage 
reactions take place either at the terminal end or within the DNA, categorising 
nucleases as either exonucleases or endonucleases, respectively. Exonucleases can 
then be classified further as 5’ or 3’ processing due to their polarity of consecutive 
cleavage (147).  
 
Tertiary structures of nucleases offer more resolute properties, and fold into more 
conserved features that facilitate classification into enzyme families (147,148). Despite 
these preserved features, the specific activity and substrate preferences remains 
wildly divergent. Furthermore, crystalizing nucleases has often proven tricky to 
perform. Either because the nuclease under study is 1) too toxic when overexpressed 
 28 
 
(149,150), 2) insoluble without its proper substrate (150–152), 3) not pure enough 
because it co-precipitates with non-specific binders (150), or 4) the substrate is 
unknown hence the lack of adequate enzyme:substrate structure which is more 
informative than enzyme structure alone (153). The DNase I-like fold is observed in 
DNase I (154), ExoIII (155), Ape1 (156,157) and some phosphatases (147). While 
similarities are present in the active sites, the topology surrounding the active sites are 
different. As such, while both DNase I and ExoIII digest ssDNA and dsDNA, ExoIII 
exhibits 3’–5’ polarity, resecting just one strand of duplex DNA. Likewise, FEN1 and 
Exo1 share a resolvase-like domain, and both cleave 5’ overhangs, such as is required 
in Okazaki fragment processing during replication (158), only Exo1 exhibits a powerful 
5’–3’ exonuclease function that is important for repair of mismatched nucleotides, 
replication and meiotic recombination (159,160). Therefore, quick and high throughput 
biochemical analyses are essential to be combined with structural analysis to fully 
decipher the specific roles of nucleases. Understanding their structural preferences 
and directionality will ultimately determine how they are implicated in repair.  
 
1.5.2 DNA repair nucleases are generally structure-specific and not sequence-
specific 
As illustrated by the above examples of FEN1, Exo1 and DNase I, DNA repair 
nucleases recognise specific structures rather than nucleotide sequence to trigger 
cleavage. This is typical of most DNA repair nucleases involved in replication, repair 
and recombination (148). Most DNA polymerases possess proofreading 3’–5’ 
exonuclease activities to minimise incorporation of non-complementary nucleotides. 
DNA polymerases recognise the geometry of correct base pairing, slow catalysis and 
transfer the mismatch into the exonuclease active site (161); this quality control 
process is thought to enhance replication fidelity 100 to 1000-fold (162–164). Pold1 or 
Pole1 exonuclease-deficient mice exhibit 10-fold more mutagenesis and exhibit 
cancerous phenotypes and reduced survival (165–167). Furthermore, sequence 
changes have been identified in POLD1 in human colon cancer cell lines and patient 
tumour samples (168). While most of these changes bore no functional effect, an 
R689W mutation caused lethality when modelled as a homozygous mutant in the 
catalytic subunit of POLδ in S. cerevisiae (169).  
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In some cases, nucleases do exhibit some sequence preference. The E. coli 
Exonuclease III recognises short 3’ overhangs, yet it has been suggested that it 
preferentially cleaves bases C>A~T>G (170). DNase I has also shown a general 
proclivity for AT base pairs as opposed to GC base pairs (171).  
 
1.5.3 DNA nucleases rarely act autonomously 
DNA nucleases tend to function as part of larger complexes for improved efficiency. 
Nbs1 is critical for triggering Mre11 endonuclease activity in the MRN complex for 
optimal DSB repair (15). The MRN complex also functions as a processivity factor to 
maintain Exo1 on DNA and promote extensive resection (15). Human SOSS1, a 
protein that shares structural homology to E. coli single-stranded binding protein 
(SSB), also promotes long-range resection by Exo1 (14), whereas BLM helicase 
increases Exo1 affinity for DNA ends (172). Artemis is an end-processing nuclease in 
the error-prone DSB repair mechanism of nonhomologous end-joining. Independently 
it possesses 5’-3’ exonuclease activity, and interaction with DNA-PKcs permits its 
endonucleolytic processing of hairpin loops (173). This ability to open hairpin loops is 
particularly important for V(D)J recombination. It represents the primary stage of 
antibody diversification which involves the rearrangement of antigen-binding variable 
(V), diversity (D) and joining (J) regions. Here, hairpin-capped DSBs are generated by 
the RAG1/2 recombinase. Terminal deoxynucleotidyl transferase (TdT) incorporates 
nontemplated nucleotides to the ends before the break is sealed, introducing more 
diversity into the coding sequence (173). Defects in either Artemis or DNA-PKcs are 
associated with the immune disorder severe combined immunodeficiency (SCID) 
(174,175). 
 
To date, only 8 autonomously-acting 3’–5’ DNA nucleases have been identified 
(176,177). These may support polymerases that lack intrinsic 3’–5’ exonuclease 
activities; of the 14 human DNA polymerases, only 3 display proofreading capabilities 
(178), and these autonomous nucleases may provide this, such as is suspected for 
Trex1 and Trex2 (179,180).  
 
1.6 Current methods for characterisation of DNA nucleases 
Conventional nuclease assays predominantly involve the use of radioactive labelling 
to visualise DNA substrates on an agarose gel (181–183). The use of radioactive 
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isotopes delivers highly specific, sensitive assays that are free from interference. 
However, these assays are often inefficient, time-consuming, qualitative, and 
potentially hazardous (184,185). Additionally, the assays are discontinuous, and must 
be stopped at discrete, often arbitrary, time points before measuring readouts (13). 
Whilst this can provide an indication of reaction rate, it does not allow for real-time 
visualisation of the catalytic resection activity.  
 
Radiolabelled oligonucleotides are gradually being replaced with fluorescent nucleic 
acid stains such as DAPI (186) and other commercially-available dyes including, but 
not limited to, Midori Green, SYBR Green I and Acridine Orange (187). PicoGreen 
(PG) is a commercially available dye that emits a fluorescent signal upon intercalation 
with double-stranded DNA (dsDNA), emitting a fluorescent signal 1,000-fold stronger 
compared to when it is free in solution. The superior sensitivity can quantify picogram 
or nanogram levels of dsDNA, respectively, unlike other fluorescent dyes, including 
Hoechst (188), ethidium bromide (188), EvaGreen (189), SYBR Green (189) and 
YOYO-1 (189).  
 
One particularly impressive technique is the recently published design of DNA curtains 
for single-molecule imaging (14,15). DNA is tethered to one end of a fluid lipid bilayer 
and targeted by nucleases stained with fluorescently-tagged antibodies. Reaction 
progression is captured through a total internal reflection fluorescence microscope 
(TIRFM) (14,15). This technique aims to obtain statistically relevant information on 
these biochemical reactions. Although effective and highly sensitive, this technology 
may not be accessible to researchers worldwide.  
 
Several other sophisticated fluorescent techniques have been devised, building upon 
the use of FRET, whereby fluorescence is either quenched or dequenched following 
nuclease activity (190). A recently published DNA curtain method involving graphene 
oxide surfaces (191), electrochemical redox reactions (192–194), complexing of DNA 
with a polycationic polymer (195), or immobilising nucleotides on magnetic beads 
(196) have also been developed. While highly sensitive, these methods have been 
designed purely for the detection of a very limited number of DNA and RNA nucleases 
rather than for general characterisation (197). 
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A very different technique studies the kinetics of proteins following DNA damage to 
measure their stepwise recruitment in vivo (198). Using transgenic cell lines that stably 
express eGFP-tagged DNA repair proteins, under the control of their own regulatory 
sequences, ensures the expression of these proteins at close to physiological levels 
(198). Again, this offers a new perspective on repair and provides a global view of how 
dysregulation of one repair factor affects the entirety of DNA repair kinetics (198).   
 
1.6.1 Development of an alternative nuclease resection assay 
Despite the myriad techniques available to study DNA nucleases, there exists a need 
for a rapid, cost-effective and safe protocol that monitors reaction progression in real-
time and is accessible to all lab groups. With these parameters, a highly versatile 
fluorescence-based nuclease resection assay has been developed to study nuclease 
activity on a selection of DNA substrates with the sensitivity to calculate reaction 
kinetics.  
 
1.7 Research objectives 
DNA nucleases function downstream of Kat5 signalling to remove damaged bases in 
the genome and to generate DNA substrate intermediates that are subsequently 
replicated and ligated by DNA polymerases and ligases (6,146,199). Many of the DNA 
nucleases directly involved in DNA repair have yet to be fully characterised, while 
many have yet to studied at all. Conventional techniques for studying nuclease 
activities are hazardous, laborious, time-consuming, and capture activity in a 
discontinuous manner (13,184,185). As such, there is a need for a safer alternative 
method that can visualise reaction progress in real-time. Using the commercially 
available dsDNA dye, PicoGreen, it is hoped that the methods described in Chapters 
3 and 4 represent that safer alternative.  
 
Chapters 3 shall describe: 
1) The stabilisation of PicoGreen; 
2) DNA substrate optimisation to generate a highly fluorescent substrate that is 
less-sensitive to photobleaching; 
3) The development and validation of a real-time nuclease assay using well-
characterised nucleases. 
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Chapter 4 shall describe: 
1) The further improvement of the assay to study the kinetics of both single- and 
double-stranded DNA nucleases and nickases; 
2)  The development of the assay to study DNA polymerisation; 
3) The expansion of the DNA substrate library to include physiologically relevant 
DNA modifications.  
 
Evidence suggests that Kat5 functions upstream of both canonical homologous and 
non-homologous repair pathways (26,200,201). Kat5 also promotes transcription by 
acetylating histone proteins at promoter regions (202–204). Yet, although CSR is 
dependent on both transcription and DNA repair, no known role for Kat5 in secondary 
antibody diversification has been described. This may be due to the fact that, as Kat5 
is essential for viability (205), it is a challenging protein to manipulate intracellularly. It 
is hoped that the studies described in Chapters 5 and 6 shall contribute towards 
elucidating the mechanistic pathway leading from the histone code and culminating in 
DSB repair in both DNA canonical repair and in CSR (18).  
 
Chapters 5 shall describe:  
1) The optimisation of Kat5-specific chemical inhibitors; imatinib (206), iChromo 
and TH1834 (207), which differentially target Kat5 activities 
2) The comparison of the phenotypes that result from chemical inhibition should 
enable separation of function analyses of Kat5 during DNA repair; 
3) The use of a CH12F3 mouse cell line that models CSR (96) to quantify class 
switching efficiency in the presence of these inhibitors;  this will establish a role 
for Kat5 as an essential component of class switching.  
 
Chapter 6 shall describe: 
1) The design of mouse and human inducible Kat5 degron constructs to avoid the 
lethality of Kat5 knockout cell lines (208).  
 
 
 
 
  
 33 
 
2 Review: Epigenomic modifications mediating antibody maturation 
 
This review was published in Frontiers in Immunology on 26th February 2018 and has 
been resubmitted as part of this thesis. 
https://doi.org/10.3389/fimmu.2018.00355 
 
Epigenetic modifications, such as histone modifications, DNA methylation status, and 
non-coding RNAs (ncRNA), all contribute to antibody maturation during somatic 
hypermutation (SHM) and class-switch recombination (CSR). Histone modifications 
alter the chromatin landscape and, together with DNA primary and tertiary structures, 
they help recruit Activation-Induced Cytidine Deaminase (AID) to the immunoglobulin 
(Ig) locus. AID is a potent DNA mutator, which catalyzes cytosine-to-uracil 
deamination on single-stranded DNA to create U:G mismatches. It has been shown 
that alternate chromatin modifications, in concert with ncRNAs and potentially DNA 
methylation, regulate AID recruitment and stabilize DNA repair factors. We, hereby, 
assess the combination of these distinct modifications and discuss how they contribute 
to initiating differential DNA repair pathways at the Ig locus, which ultimately leads to 
enhanced antibody–antigen binding affinity (SHM) or antibody isotype switching 
(CSR). We will also highlight how misregulation of epigenomic regulation during DNA 
repair can compromise antibody development and lead to a number of immunological 
syndromes and cancer. 
 
2.1 Chromatin landscape modulates DNA repair and antibody diversification 
B cells experience dramatic fluctuations in their epigenomic landscape throughout 
haematopoiesis. During B cell development, the genetic rearrangement of germline 
variable (V), diversity (D) and joining (J) gene segments in the Immunoglobulin heavy 
chain locus (Igh) and V and J gene segments in the Immunoglobulin light chain locus 
(Igk) creates a diverse B-cell receptor (BCR) repertoire, which mediates a primary 
antibody response upon antigen encounter. To ensure an effective and long-lasting 
antibody response, upon binding of antigen to the BCR, in a T-cell dependent 
response, B-cells are triggered to enter the germinal centre (GC) microenvironment. 
Here, the affinity of the BCR is increased via a process called somatic hypermutation 
(SHM) and the class of the constant region is switched to increase the effector function 
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in a process called class switch recombination (CSR). Subsequently, class switched 
B-cells expressing a high affinity BCR will be positively selected in the light zone of the 
germinal centre and will differentiate into long lived plasma cells and memory B-cells. 
It has become increasingly apparent that epigenetic modifications are indispensable 
for the antibody maturation processes during SHM and CSR at antibody producing 
genes. Both SHM and CSR are initiated by the mutator protein, Activation-Induced 
Cytidine Deaminase (AID), which catalyses cytosine-to-uracil deaminations on single-
stranded DNA (ssDNA) at immunoglobulin genes, to create U:G mismatches, which 
ultimately leads to immune diversity (209). It is the divergent downstream processing 
of this regulated DNA damage, by DNA repair mechanisms, which forms the highly 
mutated antibody-binding variable (V) regions in SHM. This ultimately gives rise to B-
cell receptors (BCR) of differing affinities. Furthermore, the double-stranded breaks at 
the Switch (S) regions integral for CSR, give rise to a range of BCR constant regions 
which results in secretion of antibodies with varying effector functions (210,211).  
 
Precursory circulating IgD+ naïve B cells that have yet to undergo antibody 
diversification have hypermethylated immunoglobulin (Ig) loci and minimal histone 
acetylation signatures, rendering the underlying DNA inaccessible to transcriptional 
machinery and AID catalysis. This is in stark contrast to activated GC B cells, which 
accumulate open chromatin marks at the Ig loci that correlate with the induction of 
SHM and CSR, and the onset of transcription-coupled AID-dependent mutations (212–
214). Specific histone modifications are responsible for relaxing local chromatin 
structure (such as H3K4me3 H3K14ac), whereas others directly propagate DNA repair 
pathways (such as H2AK119ub and H4K20me2; discussed below). More recently, 
both histone marks and RNA-based structures have been implicated in targeting AID 
to the Ig locus (Figure 3) (214,215). 
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FIGURE 1 
 
 
Figure 1 | Epigenomic modifications directing antibody-diversification processes somatic 
hypermutation (SHM) and class switch recombination (CSR).  
Green core histones and associated modifications are involved in chromatin de-compaction and enable 
transcription through the immunoglobulin (Ig) locus. All factors above the locus are important for the 
generation of DSBs while everything below encourages mutagenic repair at the V region, and DSB 
repair at donor and acceptor S regions (Sμ and Sx, respectively). Blue histones and affiliated 
modifications help recruit or tether AID and other factors that facilitate production of DSBs. Purple DNA 
and RNA are linked with sequences and structures that facilitate AID recruitment or targeting. Red core 
histones and accessory modifications recruit DNA repair proteins to ensure excision of intervening 
CH region for successful class switching as well as error-prone polymerases to the V region.  
 
The physiological activity of AID is critical to maintain immune diversity, while high-
fidelity DNA repair factors are important to maintain genome integrity. Misregulation 
of, or mutations in, these DNA repair processes can have serious consequences, 
spanning cancerous transformation (216), developmental defects (217), autoimmunity 
(218) and immunodeficiency syndromes (219). In this review, we aim to provide a 
cohesive understanding of higher-order epigenomic processes critical for the 
regulation of B cell maturation, manipulation of DNA repair mechanisms, and insights 
into the development of debilitating cancer- and immune-based diseases.  
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2.2 Epigenomic factors target AID to V Regions for SHM 
SHM enhances antibody affinity through the accumulation of point mutations at the 
antigen-binding V region (220). Histone marks help target AID to key sites of the Ig 
locus. AID preferentially deaminates cytosines in WRC motifs. These AID ‘hotspots’ 
are present in Ig genes undergoing SHM (Igh, Igk) and CSR (Igh) which are mutated 
in high abundance. However, these hotspots are also prevalent at non-Ig genes, but 
carry significantly less mutational load (221), indicating that the presence of these 
hotspots alone is insufficient to recruit AID. Rather, higher order mechanisms must be 
in place to regulate AID activity and targeting. RNA structures, specifically coding 
messenger RNAs (mRNA), non-coding RNAs (ncRNAs), and defined histone 
signatures, represent additional mechanisms for AID targeting.  
 
2.3 Role of mRNA and ncRNA in SHM 
Sense mRNA transcripts have been detected at Cµ regions, which seem refractory for 
AID-induced mutations, while both sense and antisense transcripts have been 
observed at the neighbouring V and S regions (215). Interestingly, V and S regions 
are susceptible to AID deamination, but not C regions. Whether that is due to efficient 
error-free repair or lack of AID targeting remains to be addressed (222–224). The 
sense and antisense transcripts are thought to be free to bind to complementary 
regions on both stands of the transcription bubble during SHM and CSR. This forms 
an R-loop, a three-stranded DNA:RNA hybrid and the associated non-template ssDNA 
that can provide a ready target for AID the biochemistry (54).  This should be reflected 
in the mutation profile observed at the V region, which should be equally prolific along 
the V region. Instead, most mutations take place within the first few hundred base 
pairs, before tapering off as distance from the TSS increases. Antisense transcripts 
originating from downstream of the recombined VDJ region should compensate for 
this, and AID should be equally able to access this downstream DNA. As there is no 
clearly defined antisense TSS, it is possible that there is reduced antisense 
transcription relative to sense. It is also possible that anti-sense transcripts suffer 
shorter half-lives (225). Regardless, this offers further proof that RNA transcripts 
support SHM and CSR, despite the imbalance in mutation frequency along the V 
region. 
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2.4 V region histone modifications stabilize AID substrates and recruit DNA 
repair proteins to support SHM 
Various histone modifications have been implicated in SHM. Many of these are 
generally associated with open chromatin and active transcription, while others appear 
to have more defined roles in actively supporting antibody maturation (Figure 3) (226). 
A significant histone mark enriched at sites of SHM and CSR is H3K4me3. 
Transcription elongation factor Spt5 helps to introduce H3K4 tri-methylation through 
the trans-histone modification pathway (227), alongside the Facilitates Chromatin 
Transcription (FACT) complex, to support transcription elongation. Spt5 has an 
additional role as an adapter protein to link AID and RNA polymerase II (228).  
 
H3K4me3, SMARCA4 and FACT complex components are equally important for 
recruitment of Topoisomerase I (Top1) (229). Top1 typically acts to correct 
transcription-induced negative supercoiling caused by RNA polymerase II by nicking 
one strand of the DNA helix, passing the other strand through the break, and re-ligating 
the nicked end. Reduction of Top1 increases SHM mutagenesis, whereas 
overexpression of Top1 downregulates SHM. Interestingly, treatment with the Top1 
catalytic inhibitor, camptothecin, suppresses SHM. These results indicate that the 
cleavage activity of Top1 is required for SHM, and not its ligation activity (230).  
 
The H3.3 histone variant is another feature associated with SHM and is enriched at 
the VDJ region in chicken DT40 cells (228). H3.3 appears to be responsible for 
stabilising the ssDNA substrate for AID activity. R-loops are often cited as a 
predominant AID substrate in C regions, although treatment with RNase H to remove 
these R-loops from the V region of wild type and H3.3-null DT40 cells identified that 
loss of these structures does not impede accumulation of AID-induced point mutations. 
H3.3 may instead be responsible for mediating RNA polymerase II pausing, prolonging 
exposure of the transcription bubble, and promoting AID targeting (231,232). Other 
structures have been proposed to facilitate ssDNA exposure, such as the formation of 
negative supercoils upon activation of RNA polymerase II transcription. It appears that 
topoisomerase is unable to repair this topological strain at the same rate that RNA 
polymerase II progresses (233), and this creates localised denaturation bubbles that 
are ideal substrates for AID (234). Unfortunately, the mechanism by which H3.3 
stabilises ssDNA substrates remains elusive. 
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Ubiquitination of proteins is an essential modification to propagate repair of mutated 
regions in SHM; histones and Proliferating Cell Nuclear antigen (PCNA) are well-
known targets. Ubiquitinated (Ub) H2AK119 and H2BK120 are specifically associated 
with V regions, but not with constant region exons (CH) (Figure 3). These histones co-
localise with translesion DNA polymerase η, which possesses a ubiquitin-binding 
domain that binds to mono-ubiquitinated PCNA at lysine 164. DNA polymerase η 
introduces all the A:T mutations in SHM, but limited mutations in CSR, indicating 
polymerase η of mismatch repair (MMR) is the dominant repair polymerase only in 
SHM (235,236). It is not known whether PCNA is ubiquitinated before or after being 
recruited to V regions (237). Surprisingly, the E3 ubiquitin-ligase RNF8 is known to 
ubiquitinate PCNA, yet has only been shown to support CSR (238–240). It is therefore 
possible that although mono-ubiquitinated PCNA enhances the mutation profile for 
SHM, its downstream repair effects in CSR are selected against, as large regions of 
DNA containing these mutations are disposed of following recombination at S regions.  
 
Resolution of mismatched bases is heavily dependent on “corrupted” repair 
mechanisms. However, there are conflicting reports over the relative involvement of 
MMR and BER components. DNA uracil glycosylase recognises and cleaves uracil 
bases from the genome in BER, while MutSα recognises mismatched bases and 
recruits several downstream effectors during antibody diversification, e.g. 
exonuclease I (Exo1) in MMR (241). MSH6 likely promotes SHM and CSR following 
recruitment by mono-, di- and tri-methylated H3K36 through its PWWP motif. Many 
other proteins involved in DNA damage responses and histone modifications also 
carry this PWWP motif to promote chromatin interactions (242), including PCNA. 
Indeed, MMR has been implicated as the principle repair pathway in SHM, following 
observations that the absence of UNG of the BER pathway has very little impact on 
the accumulation of A:T mutations, and loss of MSH2, MSH6  and Exo1 lose 80-90% 
of A:T mutations independently (243). Interestingly, PCNA also interacts with MSH6, 
which may account for its targeting to appropriate regions during antibody maturation 
(237,244). However, it is worth noting that these latter chromatin modifications are not 
specific to antibody genes and could happen genome-wide. Though it is possible that 
they acquire added importance by being combined with antibody gene-specific 
chromatin valencies (245). 
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One histone modification without a clear role in SHM is H2BS14ph (246). While it 
serves as a marker for SHM in B1-8 GC B cells, the implications of losing this 
modification are unknown. H2BS14ph is not present at VJλ1, VH or Sµ in naïve B cells, 
or B cells 14 days post-activation, but was reproducibly detected at day 10. Consistent 
with these observations, the only known H2B kinase, Mst1, is present at these sites 
only at day 10 (246). It is possible that this histone mark is linked to a distinct DSB 
repair response at V regions around day 10, whereas γH2AX is associated with DSB 
repair at S regions (104,246). The strict temporal restriction of the occurrence of this 
histone mark at day 10 may signify that AID-dependent lesions occur at earlier stages 
of the GC response, or it may only be required at earlier stages, perhaps for 
recruitment of downstream proteins (246). 
 
2.5 DNA and RNA structures target AID to S regions for CSR 
CSR is achieved through the generation of DNA DSBs and subsequent ligation of two 
distal S regions (220). Transcription alone cannot determine deamination targets for 
AID, as many genes transcribed in activated B cells are not targeted by AID (247). 
Instead, S regions encode unusually high densities of the overlapping AID hotspot 
WGCW sequences that place two WRC motifs in on opposite strands of the dsDNA 
helix. AID preferentially deaminates the underlined cytosines and, in the event of 
parallel deaminations, the resulting nicks on each strand (following UNG and APE1 
activity) would inevitably produce a DSB. CGC is yet another hotspot, although it rarely 
appears within S regions. Indeed, WGCW density correlates strongly with CSR 
efficiency, much better than when WRC alone was considered to predict S region 
quality (74).  
 
2.5.1 DNA secondary structures affect mutation targeting preference 
Recent work has shown how AID preferentially binds guanine-rich DNA quadruplex 
structures compared to linear DNA of the same sequence (64). Through dissection of 
the core quadruplex unit, it was determined that AID binds to the adjacent ssDNA 
strands at a stoichiometry of AID2/DNA (64). It requires a binding site of at least 5 
nucleotides (64). By studying the distance of the deoxycytidine (dC) in hotspot (AGCT) 
and cold spot (TTCT) motifs from the quadruplex, it became clear that peak 
deamination occurs when dC is at third position, and is independent of the sequence, 
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suggesting that the quadruplex structure overrides sequence motif preferences (64). 
However, as the dC is shifted further from the quadruplex, this preference for AGCT 
is approximately double that of the TTCT, recapitulating hotspot preference seen in a 
multitude of in vitro and in vivo assays (248,249). Interestingly, in S regions, a dC is 
often present at precisely the third position from the G-repeat (64). This binding 
preference is also observed in RNA quadruplexes (64). Accordingly, AID has two 
DNA-binding faces: the substrate binding channel and the ‘assistant patch’ (64). In 
such a model, the assistant patch enhances AID affinity for the substrate, and 
increases its deamination activity. This bifurcate binding structure is unique to AID, 
and is not seen in AID homologues, explaining why this bifurcate binding phenomenon 
and cooperativity is not observed in APOBEC3A or APOBEC3G (64). 
 
This preferential binding to quadruplex DNA has previously been observed, whereby 
AID targets proto-oncogenes to introduce translocations at c-MYC and BCL6, among 
others (247). Lymphomas in which these proto-oncogenes are unstable derive from 
germinal centre B cells. For example, a hallmark of Burkitt’s lymphoma is c-MYC 
recombination with S regions, promoting deregulated expression of this crucial gene 
(250). In addition, c-MYC, PAX5 and BCL6 translocations are associated with 
progression from follicular lymphoma to the more aggressive diffuse large B cell 
lymphoma (251), and PAX5/IgH translocations have been identified in a subset of non-
Hodgkin’s lymphomas (252). This genomic instability does not correlate with WRC 
sequence, but instead correlates with G-rich regions (247). Furthermore, this G-
richness does not characterise translocation breakpoints in AID-null B and T cell 
malignancies (247). Most translocations associated with leukaemias in AID-null cells 
results from a mechanism that is independent of G-rich content, yet the data suggest 
that in germinal centre B cells in which AID is highly expressed, AID preferentially 
targets transcribed G-rich regions, and therefore its stringent targeting to the Ig region 
is essential to maintain genomic stability.  
 
2.5.2 RNA secondary structures also contribute to mutation targeting 
Transcription through S regions has been associated with AID targeting to the IgH 
locus through the formation of R-loops and the interaction between AID and RNA 
polymerase II (232). While germline transcripts through IH-SH-CH regions have been 
implicated in antibody diversification, their mechanistic function has only recently been 
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demonstrated. AID binds directly to sense germline transcripts as well as to telomere 
RNA (253). These transcripts are also G-rich and form G-quadruplex structures. 
Ablating the G-quadruplex structure through G-to-C mutations, or inhibiting the splicing 
machinery that supports formation of these secondary structures, disrupts AID 
interaction with the transcripts and concomitantly reduces CSR (253). Amino acids 
130–138 in AID show homology to the RNA-binding domain of RHAU, a known binder 
of G-quadruplex RNAs. Mutations in this binding region also perturb AID:RNA binding 
capacity, consistent with hyper-IgM patients possessing a G133V mutation (253). 
Whether this mutation impedes AID:DNA binding is unknown, though it may be 
involved in the transfer of AID from its RNA guide to the DNA substrate. This is also 
suggests that some RNA splicing proteins such as PTBP2 and CTNNBL1 may also 
play an indirect role in CSR by shaping the ncRNA architecture (253–255).  
 
Although this provides a detailed explanation of the mechanism behind AID targeting 
to S regions for CSR, it fails to explain AID targeting to V regions. More research is 
needed to determine if this RNA binding capability is indeed distinct for CSR, as it may 
be responsible for deviance in processes downstream of AID-induced mutation in 
SHM and CSR. As previous reports have shown that the C-terminal amino acids 189-
198 are vital only for CSR (256,257), it is unlikely that the RNA-binding region explains 
this whole process. 
 
Studies suggest that the RNA exosome complex is recruited to S regions in an AID-
dependent manner, and makes the transcribed strand accessible to AID deaminations 
by degrading the complementary-bound nascent RNA strand (258). Knockdown of the 
RNA exosome reduces CSR by 30–50% compared to controls. The RNA exosome 
also promotes quality control on the antisense transcription of ncRNA from TSSs, 
which have the ability to both recruit AID and generate ssDNA substrates for its 
catalytic activity (259). By degrading superfluous antisense RNAs, which increases 
the formation of RNA:DNA hybrid structures and heighten risk of premature 
transcription termination and genomic instability, the RNA exosome protects genomic 
integrity (259). In addition, the RNA exosome appears to control a long ncRNA 
(lncRNA) expressed from a divergent enhancer element, which directly regulates the 
3’RR of the IgH locus by enhancing the looping activity known to promote CSR 
activity(260,261) (Figure 3). Unexpectedly, although histone acetylation and 
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deposition of H3K4me3 coincides with B cell development stages along the Igh locus, 
major epigenetic alternations have not been detected at the 3’RR upon splenic B cell 
activation (262,263). 
 
2.5.3 miRNA Control of Antibody Production by Regulation of SHM and CSR 
It has been well-documented that miRNAs can regulate SHM and CSR in B cells,  
chiefly through modulating AID and Blimp-1 expression (261,264–267). miRNAs such 
as miR-155, miR-181b and miR-361 can silence AID expression (264,266,268,269), 
whereas miR-30a and miR-125b can silence Blimp-1 expression (270–272) which is 
required for plasma cell differentiation and antibody production. These miRNAs bind 
to evolutionary conserved target sites in the 3'UTR of Aicda and Prdm1 mRNAs. More 
recently, histone deacetylase inhibitors have been reported to repress the expression 
of AID and Blimp-1 by upregulation of these miRNAs (273).  
 
In particular the more prominent role of miR-155 in regulating activated B-cells and the 
GC response is becoming more established. MiR-155 is directly repressed by BCL-6, 
the master regulator of GC formation, which is upregulated in the dark zone, 
repressing genes involved in cell cycle arrest, DNA damage response and plasma cell 
differentiation and thus allowing SHM to take place. miR-155 deficiency in B-cells has 
been shown to decrease the number of IgG1+ plasma cells and memory B cells and 
abolish the production of high affinity IgG1+ antibodies indicating that miR-155 plays 
a key role in affinity maturation and CSR. More recently, miR-155 has been reported 
to be involved in the survival of positively selected GC B-cells (274–278).  
 
What is now beginning to emerge however, is the notion that miRNA can be 
transferred from one immune cell to another through an understudied “epigenetic 
shuttle” called exosomes that can transport RNA and protein factors (279). Exosome 
‘shuttling’ of miRNAs and antigen between B and T cells occurs following construction 
of the immune synapse (280–282). This may indirectly support CSR by potentiating a 
feedback loop between T helper cells and activated B cells. B cells persistently 
stimulate T helper cells to secrete cytokines that promote CSR, such as TGFβ1, IL-2, 
and IL-4 (283). 12% of B cell-internalised antigen is spared destruction and is instead 
secreted on exosomes that are received by the bound T helper cells to encourage 
cytokine production (284). A specific role for miRNAs in directing this targeted 
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approach towards antibody maturation has yet to be elucidated and further research 
in the regulatory potential of this process is required. 
 
2.6 Histone modifications decorate the donor and recipient S regions to recruit 
AID in CSR 
Specific cytokine stimuli act on activated B cells to drive recombination between donor 
and desired recipient S regions to select for a particular Ig isotype. The Sµ region is 
always primed for class switching as histone modifications that are generally 
associated with an open chromatin state (including H2BK5ac, H3K9ac, H3K14ac, 
H3K27ac, H4K8ac, H3K4me3 and H3K36me3) are enriched at this site prior to 
antigen-engagement. As such, Iµ-Sµ-Cµ transcripts are also constitutively expressed 
(213,285–291). The remainder of the chromatin modifications could be broadly 
categorized into two general pools, targeting modifications upstream of AID 
recruitment and downstream modifications mostly associated with the general DNA 
damage response (Figure 3). Indeed, acetylated H3 and H4 fall broadly within these 
two categories as H3ac correlates with germline transcription in unstimulated splenic 
B cells, while H4 acetylation is observed following B cell activation, likely in response 
to AID-induced DSBs (285). This is observed in the 1. B4.B6 B cell line. These B cells 
undergo CSR to γ3 upon treatment with LPS+CD40, and CSR to γ1 and ε1 following 
treatment with LPS+CD40+IL-4. Following LPS+CD40 treatment, γ3 GLTs are 
induced, while γ1 and ε1 GLTs are repressed. Correspondingly, H4ac levels at Sµ, Iγ3 
and Sγ3 are increased, whereas S regions and promoters for γ1 and ε1 loci are 
marginally affected. The reciprocal is observed upon LPS+CD40+IL-4 treatment for 
GLT expression and H4ac. This suggests that regions of chromatin are specifically 
remodelled to identify the S region for AID mutation (285).  
 
Permissive transcriptional histone marks are abundant in S regions, including 
H3K4me1/2/3. NHEJ-compliant protein PTIP typically facilitates distribution of these 
marks through its interaction with MLL3/MLL4 to support DNA repair and transcription. 
Unexpectedly, the interaction between PTIP and MLL3/MLL4 is dispensable for Igh 
germline transcription and is mostly responsible for H3K4me1/2 production. Recently, 
a sub-complex made up of PTIP-PA1 appears to promote H3K4me3 formation through 
other unidentified histone methyltransferases. The function of this complex facilitates 
the transcription preceding AID deaminations, promoting CSR to IgG isotypes, and 
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appears to have very little influence on DNA repair(35,292). Nevertheless, MLL4 is 
important for maintaining effective CSR; it is frequently mutated in diffuse large B cell 
lymphoma and follicular lymphoma (293), and hypogammaglobulinaemia is common 
in the heritable Kabuki syndrome, often attributed to MLL4 mutations (294).  
 
Specific chromatin modifications have been implicated as markers for the donor and 
recipient, and thus as possible recruiters of AID and/or other components of the CSR 
machinery. Tri-methylation of H3K4 is facilitated by the FACT complex. Knockdown of 
FACT components SSRP1 and SPT16 in the CH12 B cell lines results in a significant 
decrease in IgA switching (290), and corresponds with an overall decrease in H3 
methylation in the Sµ region, and a specific reduction of H3K4me3 in the Sα region. 
The components acting downstream of the H3K4me3 marker that lead to CSR remain 
elusive, although DNA cleavage assays have shown that breaks in the Sµ and Sα 
regions are significantly reduced in SSRP1 and SPT16 knockdown cells (290,295). 
 
H3K4me3, SMARCA4 and FACT help mediate CSR through recruitment of Top1, as 
they do for SHM (229,290). Reduced levels of Top1 renders it unable to keep pace 
with RNA polymerase II, accumulating negative DNA supercoiling at the rear. Repeat 
sequences and palindrome-rich regions are prone to this non-B DNA structure, and 
are prevalent in S regions (296). In addition, there is an interesting relationship 
between AID expression and Top1 levels. AID overexpression coincides with abated 
Top1 mRNA translation, the mechanisms of which have not been thoroughly explored 
(296). 
 
AID has recently been shown to interact with Suv4-20H H4K20me methyltransferases, 
though whether this is a direct interaction, or mediated through other proteins or RNA 
structures, is not known (297). Without AID, Suv4-20H is not recruited to S regions, 
and the level of H4K20me3 is reduced at these sites(297). Concordantly, Suv4-20h 
double-null mice are defective in CSR (298). It has been proposed that H4K16ac and 
Suv4-20H-mediated H4K20me3 play antagonistic roles in RNA pol II pausing. 
H4K16ac promotes release from pausing, while H4K20me3 prolongs RNA pol II 
pausing (299). AID-induced mutations are long-understood to be reliant on RNA pol II 
pausing, so it is possible that AID reinforces this pausing step through Suv4-H20 
recruitment (232). However, this has not been confirmed.   
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Histones H3K9me3 and H3K9ac decorate S regions that undergo recombination 
(213,289). These modifications are dependent on cytokine stimulation but are 
independent of AID expression. It has therefore been suggested that the two histone 
marks precede AID-induced mutations and recombination, and perhaps even function 
in the recruitment of AID to the appropriate sites (289). H3K9me3 has been shown to 
be essential for general DSB repair through its direct interaction with the lysine 
acetyltransferase Kat5 and loss of H3K9me3 results in defective DSB repair (300,301). 
The link between DSB recognition and H3K9 methylation is currently unknown, 
however it is understood that it participates in NHEJ, indicative of a role in CSR, but 
not SHM or the preceding V(D)J recombination. H3K9 is methylated by its 
methyltransferase, Suv39h1, which exists in a complex with kap-1 and HP1. HP1 
possesses a chromodomain, which binds to the newly tri-methylated histone and 
retains the complex at the S region site.  
 
There is specific evidence supporting a role for H3K9me in CSR. The kap-1 and HP1 
complex functions as the structure that tethers AID to Sµ (214). Similar to the G-rich 
quadruplexes mentioned previously, the binding of AID to kap-1 is not reliant on its C-
terminal domain and, as such, it is unlikely that this association explains the requisite 
of the C-terminus for CSR (214).  
 
H3K9ac phosphorylated at serine 10 (S10ph) is another histone modification that has 
been implicated as a marker of donor and recipient S regions. This mark has been 
found to be enriched at the donor Sµ region and, after B cell activation, in the cytokine-
selected recipient S region (302). 14-3-3 adapters interact directly with H3S10ph and 
the affinity of this interaction is increased with the addition of an acetyl group on lysine 
9 of the same histone (303,304). ChIP assays have shown that, upon 
lipopolysaccharide stimulation, 14-3-3 is recruited specifically to the S regions 
enriched in H3K9acS10ph (302). Upregulation of the 14-3-3 complex coincides with 
CSR. The complex directly binds AID and associates specifically with 5’-AGCT-3’ 
motifs that occur frequently in S regions and are particularly common within the V 
region. Reduced 14-3-3 activity correlates with a decrease in AID at active S regions 
(305). This implies that 14-3-3 is an important factor for recruiting AID and associated 
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proteins to recombination sites for CSR. It seems H3K9acS10ph recruits and/or 
stabilises 14-3-3, which in turn recruits AID to the appropriate S region.  
 
2.7 Chromatin modifications recruit DSB repair proteins in CSR 
Chromatin markers participate in the recruitment of the required repair proteins. 53BP1 
is one protein confirmed to hold an essential role in DSB repair, and promotes NHEJ 
for CSR by bridging the broken ends (306–312). Recruitment of 53BP1 to DSBs is 
dependent on various chromatin modification pathways (Figure 4). It is a bivalent 
chromatin reader and interacts directly with the histone marker H4K20me2 through its 
tudor domain, which recognises methylated histones (313,314). Independent of its role 
in S region DSB repair, 53BP1 exerts a secondary influence on CSR by enforcing the 
temporal separation of Sµ and Sγ breaks and ensures that subsequent ligation of the 
broken ends results in a deletion event (315). It does this by orchestrating the 
preferential breaking of the upstream switch region Sµ. 53bp1-/- B cells lose the ability 
to ensure Sµ breaks first, which introduces inversional rearrangements that negatively 
impact CSR efficiency (315). 53BP1 recognises H4K20me1 in vitro, but it is its specific 
recognition of di- and tri-methylated H4K20 made accessible to 53BP1 during the DNA 
damage response that may regulate break order in CSR (313).  
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Figure 2 | DNA damage repair pathways dictate class-switch recombination (CSR) efficiency.  
An overview of the histone modifications, and the writers and readers associated with them that are 
essential for CSR, as well as suggestions of additional likely factors. Color = confirmed in NHEJ and 
CSR, Gray = DNA damage repair factors not yet shown to affect CSR. The key proteins and histone 
modifications that have been shown to be essential for resolving the DNA double-strand breaks in CSR 
are summarized. A common theme is the recruitment of 53BP1, which is essential for efficient repair 
and isotype switching. Importantly, these repair pathways also function in NHEJ. Additional DNA 
damage repair proteins and histone modifications that have not yet been shown to play a role in CSR 
are indicated in gray. Some proteins and histone marks involved in other repair pathways, such as 
homologous recombination (HR), are also indicated in the figure. As these pathways inhibit the NHEJ 
pathways, they may provide negative control of CSR. Indeed, knockdown of BRCA1 has been shown 
to increase isotype switching efficiency. 
 
Depleting cells of SUV4-20H1/H2, the predominant methyltransferases producing 
H4K20me2, slows the rate of 53BP1 accumulation at break sites and reduces CSR 
efficiency by 50%, however, the absence of the H4K20me2 mark has no impact on S 
region break order (316). This may be due to the activity of another H4K20me1 
methyltransferase called MMSET that had not been considered by Rocha et al. 
Indeed, loss of MMSET hampers H4K20me2 enrichment, significantly reduces 53BP1 
binding, and leads to inefficient CSR (317). MMSET specifically methylates 
H4K20me1 and H4K20me1/2/3 are all locally increased at DSBs (Figure 4) (318). This 
may explain why the loss of SUV4-20H1/H2 only slows 53BP1 recruitment and does 
not completely abolish it. Additionally, MMSET, and not SUV4-20H1/H2, is uniquely 
overexpressed in GC B cells, possibly ascribing MMSET as the dominant 
methyltransferase in antibody diversification (319). MMSET is activated and recruited 
after ATM-mediated phosphorylation during typical DNA repair, allowing it to complex 
with MDC1. MDC1 binds γH2AX, a mark only introduced once DNA repair signalling 
has been initiated (318). MDC1 is important for enlisting ubiquitin ligases RNF8 and 
RNF168, which lay a polyubiquitin motif also recognised by 53BP1 (239) (Figure 4).  
 
Unfortunately, it is impossible to study the impact of H4K20me1 knockdown on CSR 
efficiency as it is a global histone mark implicit in proliferation and cellular viability 
(320), however, introducing a single point mutation in the 53BP1 Tudor domain, 
preventing it from recognising H4K20me1/2, disrupts S region break order. Taken 
together with the aforementioned findings that the absence of H4K20me1 has no 
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impact on S break order, these suggest that the dimethyl mark is dispensable, and 
that it is the H4K20me1 mark that determines break order (315). 
 
Ubiquitin ligases are proving to be pervasive in DNA repair, including CSR. RNF168 
monoubiquitinates H2A on 13 and 15 lysine residues (321,322). Knockdown of either 
RNF8 or RNF168 results in a decrease in 53BP1 accumulation at AID-induced DNA 
breaks, and a corresponding reduction in CSR is observed (239). Furthermore, 
expression of a ubiquitin-H2AX fusion protein can rescue 53BP1 recruitment to DSBs 
in RNF8- or RNF168-deficient cells (323). In the absence of DNA damage, Polycomb 
group protein L3MBTL1 and demethylase JMJD2A mask H4K20me2. RNF8 and 
RNF168 are responsible for ubiquitinating these proteins, removing them from the 
damage site to expose H4K20me2 (324,325). This secondary role of the ubiquitinases 
has not been explored in the context of CSR. The bivalent binding by 53BP1 to 
H4K20me2 and ubiquitin marks could serve to correctly orientate 53BP1 for it to bridge 
across a DSB. Delayed accumulation of these histone marks might prevent 53BP1 
from orientating correctly, which would thus lead to increased CSR inversion events. 
Methyl and ubiquitin modifications appear to have different influences on 53BP1. 
H4K20me2 more likely serves as a signal to recruit 53BP1 to the DSB, while 
ubiquitination H2A/H2AX serves as an anchor to 53BP1, maintaining it at the site of 
the DSB, such that 53BP1 can bridge the gap between donor and recipient S regions 
for isotype switching.  
 
Upstream in the signalling cascade, a deubiquitination event also promotes DNA 
repair and CSR. Ubiquitination of H2BK120 is associated with an open chromatin and 
interferes with chromatin compaction. DSB repair cannot occur until histone 
H2BK120ub is deubiquitinated to allow access to NHEJ factors (326). A genome-wide 
loss-of-function RNAi screen identified several components of the SAGA 
deubiquitinase module required for CSR and DSB repair, including Usp22, Eny2, and 
Atxn7. Knockdown of any of these components using shRNAs or CRISPR/Cas9 
reduces CSR (327). Knockdown did not impair AID function indicating that the defect 
lies somewhere downstream. Interestingly, Eny2 knockdown also interferes with ATM 
and/or DNAPK activity, and thus indirectly limits γH2AX formation, which further 
reduces CSR (327,328).  
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BET family member Brd4 interacts with acetylated histones via its two bromodomains 
(329). Studies have shown that, upon induction of AID, occupancy of Brd4 at Sµ and 
Sα regions increases. ChIP and immunoprecipitation assays have confirmed an 
interaction between Brd4, the modified histones H4 and γH2AX, as well as between 
Brd4, 53BP1 and UNG (330). Treatment with the Brd4 inhibitor JQ1 or siBrd4 
knockdown significantly reduces CSR frequency. The levels of both 53BP1 and UNG 
are reduced, without affecting the levels of H4ac. Brd4 is therefore thought to  function 
as a chromatin-bound platform that recruits 53BP1 and UNG to DSBs (330) (Figure 
4). Finally, the chromatin remodelling complex INO80 has also been implicated as a 
regulator of CSR (331). Knockdown of INO80 in various mammalian cell lines has 
been shown to inhibit 53BP1 accumulation at DSBs (332). More recently, MEFs from 
mino80 knockout mice contradict this observation. Rather, INO80 is suggested to 
participate early on during DSB repair, where it first binds γH2AX, and then exposes 
H4K20me2 for 53BP1 recruitment. Paradoxically, INO80 is involved in 5’–3’ DNA end 
resection to support repair by homologous recombination (333). How it then functions 
to support NHEJ in CSR is yet another mystery.  
 
2.8 Potential role for other repair proteins in CSR 
The histone modifications and DNA damage repair proteins important for CSR (Figure 
4) have parallel roles in NHEJ. This is particularly interesting because a multitude of 
proteins, modifiers, and readers involved in NHEJ have not yet been implicated in 
CSR. These include the E2 ubiquitin-conjugating enzyme Ubc13, which functions in 
complex with RNF8 and RNF168. Ubc13, and its γH2AX independent recruitment 
through the Kat5 complex (27,334–336) are potential important factors in CSR. 
Indeed, H2AX-deficient mice experience reduced CSR (104), while a link with SHM 
fails to be seen (246). A SUMOylation pathway,  initiated by PIAS4 (337,338) and 
further expanded by  STUbL RNF4 (339), provides a potential role of SUMO-ubiquitin 
cross-talk in CSR. The importance of this pathway in general DNA damage repair is 
exemplified by Ataxin-3, which counteracts the RNF4-mediated ubiquitination. As a 
result, Ataxin-3 promotes prolonged retention of MDC1, resulting in reduced 
recruitment of 53BP1 and BRCA1 (316).  
 
The possible impact of NHEJ regulatory factors specifically should be considered on 
antibody diversification. The recently discovered tudor interacting repair regulator 
 51 
 
(TIRR) stabilises 53BP1 in the nuclear fraction, but blocks NHEJ-directed repair by 
binding the tudor domain and guarding against H4K20me2 binding upon DNA damage 
(340). As such, it may act to hinder CSR when either over- or under-expressed, and 
would determine whether the turnover rate or instability of 5BP1 will compensate for 
more favourable H4K20me2 binding. Equally, the contribution of RIF1 in suppressing 
DNA resection for NHEJ and separating the 53BP1-TIRR complex may similarly serve 
to deregulate CSR at differential expression levels (341). The HR pathway also 
represents a potential research avenue as it may provide inhibitory effects on CSR 
efficiency. Knockdown of BRCA1, a key HR factor, has been shown to increase 
isotype switching (342). Similar effects are observed from downregulation of other 
inhibitory modifications, such as the H2AXK15ac by the Kat5 complex, which inhibits 
the RNF8 mediated ubiquitination of H2AXK15 (343).  
 
2.9 Influence of AID and TET activity on the DNA methylome during B Cell 
Development 
 
2.9.1 Role of AID in DNA Demethylation via Deamination 
Aside from its mutagenic activity, AID has been associated with coordinating DNA 
demethylation during zebrafish development (344), stem cell reprogramming (345), 
and primordial germ cell formation (346). The combined results of these studies 
support the notion that AID could function as a genome-wide epigenetic regulator by 
deaminating 5-methylcytosine (5mC) to 5-methyluracil (5mU); thereby replacing a 
5mC base with an unmethylated C or a thymine (T) via base excision repair (BER). 
GC B cells have more heterogeneous DNA methylation patterns than naïve B cells 
(212), and this has established a potential role for AID during this maturation step. 
 
Several studies have debated whether AID is responsible for DNA demethylation or 
activated gene expression in B cells (347). The methylation status of CpG motifs at 
VDλ1 is unchanged between naïve and day 14 GC B cells (246), AID does not induce 
demethylation at either Sµ or Cµ (297), and 5mC is a poor substrate for AID, although 
it does not prevent its activity on neighboring cytosines (348,349). In contrast, fewer 
studies have found that DNA demethylation events can be attributed to AID. CpGs 
have been observed to have increased methylation pattern variation in wild type 
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tissues, compared to AID-null tissues. Interestingly, 90% of the methylome alterations 
seen in naïve to GC transition were lost in AID-null mice (350). SHM targets are also 
suggested to be enriched with AID-dependent hypomethylation, and the significant 
reduction of both demethylation and SHM ex vivo (such as in the contribution by Fritz 
et al) is due to these two events being coupled in vivo (350). Furthermore, a recent 
study suggested that cytosine demethylation is over-represented in WRCG/CGYW 
motifs in follicular lymphomas, which overlays the WRC AID hotspot motif and the 
methylated CpG dinucleotide. This contrasts SHM of immunoglobulin genes whereby 
cytosine demethylation is under-represented at WRCG/CGYW motifs. Thus, this 
mutational process appears distinct from conventional SHM, and is solely applied to 
the CpG methylation/demethylation process (351). 
 
2.9.2 Role of TET Protein in DNA Demethylation via Hydroxylation 
As the involvement of AID in DNA demethylation remains to be fully established, the 
regulation of DNA methylation by another family of proteins is now being explored. 
Ten-eleven translocases (TET1, TET2, and TET3) oxidize 5mC to 5-
hydroxymethylcytosine (5hmC), and further oxidises 5hmC to 5-formylcytosine (5fC) 
and 5-carboxycytosine (5caC) (352,353). TET proteins predominantly support 
demethylation via dilution through successive rounds of replication(352). 
Nevertheless, it is possible that TET enzymes support active (replication-independent) 
demethylation. TET enzymes often accompany transcription-associated H3K36me3 
histone modifications, and possibly RNA polymerase II, depositing 5hmC and 
generating a more accessible DNA substrate for subsequent cycles of transcription 
(354). TET enzymes are involved in iterative rounds of 5mC oxidation to 5fC and 5caC 
(355). Demethylation could then be achieved either ii) indirectly via  thymidine DNA 
glycosylase (TDG) which recognises and excises 5fC an 5caC (356); or ii) directly by 
yet unidentified decarboxylases (357), (358).  
 
TET proteins appear to be important for programming B cell methylation throughout 
development. 5hmC is enriched in lineage-specific transcription factors, such as Bcl6, 
EBF1 and IRF4, which are important for germinal centre transition (359,360). The 
methylation status of follicular B cells from conditional Tet2-/Tet3- double knockout 
mice were partially hyper-methylated when compared to wild type cohorts. Single 
knockout mice failed to show such noticeable effects on methylation levels (359). Of 
 53 
 
the sequences that are specifically demethylated in wild type B cells during 
differentiation into germinal centre B cells, 95% are prevented in Tet2-/Tet3- mice, 
providing some evidence that TET proteins may be responsible for most DNA 
demethylation that occurs at this stage (359). In addition, the Igκ locus is known to 
undergo DNA demethylation during antibody diversification, and this demethylation 
step is not observed in Tet2-/Tet3-  knockout mice (359).   
 
2.9.3 Cooperation between AID and TET Proteins during Epigenomic Regulation 
In addition to regulating B cell development, TET proteins are essential tumour 
suppressors in B cells. Of all patients diagnosed with diffuse large B cell lymphoma, 
5.7% carry a Tet2 deletion or loss-of-function mutation (361). In mouse genetic 
studies, Tet1-deficient B cell progenitors developed B cells lymphomas (362); in 
analogous human studies, the Tet1 promoter was found to be hypermethylated with 
concomitant reduction in Tet1 expression in patients with non-Hodgkin lymphoma 
(362). In additional studies, mice with a combined Tet2- and Tet3- deficiency in 
developing B cells developed B cell lymphoma and succumbed to disease within 5–6 
months of age, much earlier than the 15–20 months observed in Tet1/Tet2-deficient 
mice (363,364).  
 
It has been proposed that the product of TET protein-dependent 5mC oxidation may 
be a target for AID. Few studies have addressed the cooperative activities of TET 
proteins and AID. Some have concluded that it is unlikely that AID deaminates 5mC 
or 5hmC:  5mC is deaminated only at 10% the rate of cytosine due to the steric 
hindrance of the methyl group (349). 5hmC is an even poorer substrate for AID (365). 
Deamination of 5hmC in vitro has not been observed, and in vivo studies 
overexpressing AID have also failed to generate 5hmU (349). As 5hmU is not yet 
detected in genomic DNA, AID targeting 5hmC as a target for deamination was 
claimed unlikely, and further supports a role for TET enzymes in B cell developmental 
demethylation (349). On the contrary, a study in 2011 found that AID quite significantly 
promotes 5hmC demethylation in HEK293 cells and in mouse brain. While 
overexpression of AID had little effect on the demethylation of a strand of 5mC-GFP 
DNA, it led to a significant decrease of 5hmC levels induced by TET1 and significant 
increase of 5hmU (366). This is significant because there no detectable endogenous 
5hmU in HEK293 cells. Additionally, the pattern of 5hmC demethylation events were 
 54 
 
broadly distributed along the 5mC-GFP DNA, 5hmC was also selectively demethylated 
at WCR ‘hotspot’ motifs, and demethylation showed strand bias in the same manner 
as AID deamination (366). Taken together, this could indicate that AID and TET may 
act in tandem to promote DNA demethylation. Whether this is replicated in the context 
of antibody diversification is yet to be seen. 
 
2.9.4 Epigenomic Role of Immune Diversification in Disease Development 
AID defects are associated with hyper-IgM syndrome, causing severe 
immunodeficiency (367). The epigenetic effect of AID on health however, particularly 
lymphomas, is poorly understood. DNA methylation’s role in gene silencing makes it 
essential in regulating normal development, with epigenetic mutations allowing cells 
to grow and reproduce uncontrollably, leading to tumorigenesis. DNA methylation can 
have malignant effects through two main alterations: hypermethylation of tumour 
suppressor genes and hypomethylation of oncogenes. It has come to light in recent 
years that such mutations are a common cause of B cell lymphomas, with 
hypomethylation in GCB-derived lymphomas correlating with AID expression (368). 
Off target effects of AID are also seen in non-B cell cancers, for example, T cell 
malignancy (369), and also in non-lymphatic cancers, such as stomach cancer (370),  
lung cancer (371), breast cancer (372), and liver cancer (373).  
 
From this observation it could be hypothesised that ectopic AID expression plays a 
critical role in lymphomagenesis. Increased epigenetic heterogeneity in lymphomas 
reflects diverse tumour cell populations, which increases risk of resistance to 
cytotoxic drugs (368). Understanding AID, and its role in lymphomas, could provide 
guidance in the development of new epigenetic drugs. Currently the main epigenetic 
cancer therapy drugs are azacytidine and decitabine which function as DNA 
methyltransferase inhibitors, combating DNA hypermethylation. These drugs have 
shown substantial potency in reactivating epigenetically silenced tumour suppressor 
genes in vitro (374). Reducing levels of AID could be used in a similar way against 
hypomethylation or the resistance caused by epigenetic heterogeneity in 
lymphomas. The protein HSP90 is important in the protection of AID from 
proteasomal degradation, with inhibition by the drug 17-AAG, leading to 
polyubiquitination and degradation of AID (375). 17-AAG is currently in clinical trials 
for the treatment of other cancer types, due to its role in inhibiting the degradation of 
 55 
 
proteins involved in tumour cell proliferation and survival (376). The above 
observations suggest a possibility of using 17-AAG in the treatment of 
hypomethylated lymphomas (Figure 3). In a recent study 17-DMAG, a derivative of 
17-AAG, has been found to reduce CSR and SHM in mice, while B-cell survival and 
proliferation remain unaffected (377). 
 
2.10 Concluding Remarks 
The epigenome is made up of several critical components that must work together to 
promote antibody maturation and diversification in B cells. This is an intricate process; 
each component simultaneously functions both independently and dependently on the 
others, and disruption at any step can have catastrophic downstream affects. For 
example, histone modifications relax the chromatin, allowing for AID transcription. 
Simultaneously, multiple different ncRNAs regulate transcription and target AID to 
mutate Ig region genes. Next, different histone modifications recruit DNA repair 
proteins which then multiple different ncRNAs target. The entire process is further 
complicated depending on which histone modifications are used and which ncRNAs 
are present whether a B cell is returned to the status quo, undergoes CSR, or 
undergoes SHM. It is a tremendously complicated process and abrogation at any step 
can result in various forms of cancer and/or immunodeficiencies. Despite 
advancements of our knowledge of this field, several important questions remain 
unanswered. These include the mechanisms controlling AID transcription and the 
mechanisms that direct AID to target neutral, CSR, or SHM region genes. 
Furthermore, we have yet to determine how ssDNA is stabilized for AID activity. 
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3 Development and optimisation of a fluorescence-based toolkit for 
real-time quantification of DNA resection activity 
 
3.1 Summary 
DNA nucleases are integral for maintaining genomic stability. Nucleases recognise 
particular structural features that arise following endogenous or exogenous sources of 
damage, and characterising their preferences is invaluable to understanding their 
specific roles in DNA repair. Understanding how nuclease activity is influenced by 
catalytic or structural mutations, binding partners, and different DNA structures, may 
illustrate how nucleases are implicated in cancer and age-related diseases. 
Contemporary methods used to study nucleases require radiolabelled substrates to 
visualise nuclease-dependent DNA digestion. While this is a robust approach, there 
are several flaws associated with this method; it is time-intensive, captures nuclease 
activity in a discontinuous manner, and it is inherently dangerous to work with 
radioactive substances. As such, an alternative method for capturing nuclease activity 
in a continuous fashion using the fluorescent double-stranded DNA (dsDNA) dye, 
PicoGreen, has been developed herein. Indeed, PicoGreen has proven to be a stable 
dye that is permissive to nuclease processivity. Furthermore, the dsDNA substrates 
have been optimised to emit a strong fluorescent signal upon PicoGreen binding.  
 
3.2 Nucleases in DNA repair 
Nucleases are a hallmark of the DNA damage response. They help dictate many DNA 
repair pathway choices by controlling the DNA damage substrates created 
downstream during the signalling cascade. The complex roles nucleases play in DNA 
repair pathways underpin several premature ageing-related syndromes, and 
cancerous transformation can result from structural or catalytic mutations in nuclease 
genes (reviewed in (378)). Nucleases hydrolyse the phosphodiester bonds between 
sugar residues in DNA, RNA, or both. DNA repair is critical for proof-reading genomic 
DNA during replication, halting the replication fork, Okazaki fragment processing and 
correcting many forms of genomic insults that require mismatch repair, base excision 
repair, nucleotide excision repair or double-strand break repair (DSB) (147). The 
defining characteristics of nucleases are their substrate specificity, directionality, and 
processivity.  
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3.3 Current approaches for studying nuclease activity and their limitations 
A significant limitation of nuclease studies has been the adequate identification of their 
catalytic functions and/or their relative activities against different DNA intermediates. 
Indeed, the activities of numerous DNA nucleases are debated (e.g. human Mre11, 
CtIP etc (379,380)), and yet there remain many more uncharacterised proteins with 
strong predictions for nuclease domains in mammalian genomes 
(381,382).Conventional nuclease assays predominantly involve the use of radioactive 
labelled 32P-dATP to visualise DNA substrates on an agarose gel (181,182). The use 
of radioactive isotopes delivers highly specific, sensitive assays that are free from 
interference. However, these assays are often inefficient, time-consuming, qualitative, 
and potentially hazardous (184,185). Additionally, the assays are discontinuous, and 
must be stopped at discreet time points before measuring readouts (13). Whilst this 
can provide an indication of reaction rate, it does not allow for real-time visualisation 
of the catalytic reaction.  
 
3.4 PicoGreen is a highly sensitive dsDNA dye used in discontinuous enzyme 
assays 
Radiolabelled DNA oligonucleotides are gradually being replaced with fluorescent 
nucleic acid stains such as DAPI (186) and other commercially-available dyes 
including, but not limited to, Midori Green, SYBR Green I and Acridine Orange (187).  
PicoGreen (PG) is a commercially available dye that emits a fluorescent signal upon 
intercalation with double-stranded DNA (dsDNA), emitting a fluorescent signal 1,000-
fold stronger compared to when free in solution. Its superior sensitivity can quantify 
picogram levels of dsDNA, unlike other fluorescent dyes, including Hoechst (188), 
ethidium bromide (188), EvaGreen (189), SYBR Green (189) and YOYO-1 (189).  
 
A method using PG to stain the DNA and monitor nuclease activity in real-time is 
faster, cheaper, and safer than conventional DNA resection assays using 
radioisotopes. It works cross-species and is platform agnostic. Furthermore, this 
protocol has the sensitivity for enzyme reaction kinetic calculations and can distinguish 
the structural preferences exhibited by an enzyme for its substrate. Similar to other 
nucleic acid dyes, PG has proven to be a versatile DNA stain in different experimental 
conditions. It has been used to visualise dsDNA in agarose electrophoresis as a quality 
control  marker to identify fragmented and nicked DNA (383). It has also been 
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implemented in flow cytometry analysis of cell-free DNA which can increase in certain 
pathologies, such as cancer and autoimmune syndromes (384). PG exhibits readily 
detectable, albeit reduced, fluorescence readings at temperatures of 37°C, despite 
manufacturer recommendations to work at room temperature (385), allowing for 
assays to run at physiologically-appropriate temperatures. As PG very preferentially 
binds dsDNA compared to ssDNA and RNA structures (386), it has been an important 
feature of discontinuous enzyme-mediated DNA-modifying studies, such as nucleases 
(387), helicases (388), polymerases (389,390), polymerase inhibitors (391), 
telomerases (392), and primases (393). However, the full potential of PG in real-time 
visualisation of reaction progression in a continuous assay remains limited (394). The 
discontinuous PG assay described herein will be advanced to create a continuous PG 
assay. 
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3.5 Materials and Methods 
 
3.5.1 Plasmid and oligonucleotide substrates 
DNA substrates were prepared by diluting pNIC28-BSA4 or CTIP in HyClone waterTM 
(GE healthcare), and unmodified HPLC-purified oligonucleotide substrates (Eurofins) 
in 1X annealing buffer (Sigma-Aldrich). Oligonucleotides were designed and optimised 
against secondary structure formation using the ‘Predict a Secondary Structure Web 
Server’ 
(https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predict1/Predict1.html) 
(114) and annealed at a 1:1 molar ratio. Table 1 shows all the oligonucleotides and 
their respective illustrations. 
 
Table 1  
Oligo code Sequence (5–’3’) 
RCOL381 GATACGGCATACGTCTATGGCTACTTGGAGCGAGTATCCTTCGAGCTTGCTCGAGCT
TGCCTACTTGGAGGATACGGCAT 
RCOL468 ATGCCGTATCCTCCAAGTAGGCAAGCTCGAGCAAGCTCGAAGGATACTCGCTCCAAG
TAGCCATAGACGTATGCCGTATC 
RCOL396 GGGTCTTAAAGTTAAACCTTAAGGTTCTCCTATAGTGAGTCGTATTAAGTATCAATG
TTCCGGACAAATTACCCTAATTA 
RCOL400 TAATTAGGGTAATTTGTCCGGAACATTGATACTTAATACGACTCACTATAGGAGAAC
CTTAAGGTTTAACTTTAAGACCC 
RCOL556 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTAC
TTGCCTACTTGGAGTGAACTTAG 
RCOL557 CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAG
TAGTAATAGACCAACAAACCATC 
 
3.5.2 Nucleases and buffers 
The nucleases used were RQ1 RNase-Free DNase I (Promega), T7 exonuclease 
(New England Biolabs), Exonuclease III (New England Biolabs). In preparation for 
each assay, nucleases used were diluted on ice in their appropriate storage buffers, 
omitting glycerol. All storage buffers and reaction buffers were made according to the 
recipes available on their respective NEB and Thermo Fisher web pages. DNase I 
storage buffer (10mM HEPES (pH 7.5), 10mM CaCl2 and 10mM MgCl2) and reaction 
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buffer (400mM Tris-HCl (pH 8.0), 100mM MgSO4 and 10mM CaCl2), T7 exonuclease 
storage buffer (10 mM Tris-HCl, 5 mM DTT, 0.1 mM EDTA, (Ph 8 at 25ºC)) and 
reaction buffer (50 mM potassium acetate, 20 mM Tris-Acetate, 10 mM magnesium 
acetate, 1 mM DTT), and Exonuclease III storage buffer (5 mM KPO4, 200 mM KCl, 5 
mM β-ME, 0.05 mM EDTA, 200 µg/mL BSA, (pH 6.5 at 25ºC)) and reaction buffer (10 
mM Bis-Tris-Propane-HCl, 10 mM MgCl2, 1 mM DTT (pH 7 at 25ºC)) were all filtered 
prior to use, and autoclaved where possible.  
 
3.5.3 Preparation of PicoGreen 
The PG reagent from the Quant-iTTM PicoGreenTM dsDNA Assay Kit (Invitrogen) was 
prepared immediately before use by making a 1:200 dilution of the PG in TE buffer (10 
mM Tris-HCl, 1 mM EDTA, pH 7.5) and 40% (v/v) glycerol.    
 
3.5.4 Discontinuous assay experimental procedure 
Each DNA substrate reaction mixture contained 50 nM DNA substrate, 1X reaction 
buffer (specific for each enzyme), 0.02 mg/mL streptavidin (cat. 21125, Thermo Fisher 
Scientific) if required, 0.25 mM dNTPs if required, 5 µL enzyme or relevant storage 
buffer. For the DNA nucleases, Milli-Q water was added to bring the total reaction 
volume to 50 µL. Reaction mixtures were prepared on ice and samples were tested in 
a 96-well, black flat bottom plate (cat. M9685, Sigma-Aldrich). The final components 
added were the storage buffers, then the enzyme mixtures to start the reaction. DNase 
I reactions were stopped with 5 mM EDTA, after which 50 µL PG solution was added 
and incubated on ice for 15 minutes.   
 
An i-control Infinite 200Pro (Tecan) was pre-heated to 37°C. Samples were read every 
40–50 s for 30–60 mins. Excitation and emission wavelengths used were 483-15 nm 
and 530-30 nm, with a shake before each read.   
 
3.5.5 Continuous assay experimental procedure 
Each DNA substrate reaction mixture contained 50 nM DNA substrate, 1X reaction 
buffer (specific for each enzyme), 50 µL PG solution, 0.02 mg/mL streptavidin (cat. 
21125, Thermo Fisher Scientific) if required, 0.25 mM dNTPs if required, 5 µL enzyme 
or relevant storage buffer. For the DNA nucleases, Milli-Q water was added to bring 
the total reaction volume to 100 µL. Reaction mixtures were prepared on ice and 
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samples were tested in a 96-well, black flat bottom plate (cat. M9685, Sigma-Aldrich). 
The final components added were the storage buffers, then the enzyme mixtures to 
start the reaction.  
 
Either a i-control Infinite 200Pro (Tecan) or a CLARIOstar microplate reader (BMG 
labtech) was pre-heated to 37°C. Samples were read every 40–50 s for 30–60 mins. 
Excitation and emission wavelengths used were 483-15 nm and 530-30 nm, with a 
focal height of 10.2, 20 flashes per well, with a shake before each read.   
 
3.5.6 Data analysis 
For statistical analysis of the data, one-way ANOVA with the Tukey’s post-hoc tests 
were used. This was implemented using GraphPad Prism v7.03. An example of the 
workflow is available in the appendix.  
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3.6 Results 
Here, PG is shown to be a highly sensitive dye to measure DNA nuclease activity in a 
continuous manner, developing upon the current discontinuous approaches 
published. Its specificity for DNA limits its utility to studying only DNA nucleases, as 
opposed to RNA nucleases (386). The methods to stabilise PG for real-time 
experiments and optimise its fluorescence are described within, alongside the 
approach taken to maximise the fluorescent signal emitted from the DNA substrates 
upon PG binding.  
 
3.7 Optimisation and development of the assay from a discontinuous to 
continuous methodology 
Several factors were considered before progressing to a continuous study of nuclease 
activity. First, it was integral to determine that the fluorescence signal could be 
measurably different between a substrate following nuclease-dependent degradation 
and a substrate not treated with a nuclease. Second, the stability of PG had to be 
ensured for it to be used to monitor enzyme activity over the period of the reaction. 
Third, it was necessary to determine whether PG would permit nuclease processivity 
and whether the products of the reaction (free nucleotides) would contribute towards 
the fluorescent signal. Fourth, the oligonucleotide substrates had to be optimised to 
produce a strong fluorescent signal to capture nuclease activity with precision.   
 
To address the first issue concerning the sensitivity of PG on DNase I-treated and 
untreated substrates, the activities of a range of DNase I concentrations on plasmid 
DNA were compared (Fig. 1a). It was only after the reaction was stopped that PG was 
added to the reaction mixtures. Higher concentrations of DNase I (200 nM) digested 
more of the substrate than lower concentrations (25 nM), which is to be expected. The 
results indicate that PG can be used to compare differential enzyme activity. In 
addition, the results also demonstrate the range of concentrations of DNase I that 
would cause an observable decrease in fluorescence over the course of the reaction. 
 
Secondly, the stability of PG was confirmed. Rapid photobleaching would be 
disadvantageous as it would create a very short window within which the reaction 
could be monitored, so a stable reaction mixture is essential. Unexpectedly, it was 
found that the fluorescent signal from PG was almost entirely lost after 5 minutes at 
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37°C (Fig. 1b). This indicates that PG is very unstable and is rapidly photobleached 
under these conditions. Furthermore, DNase I activity failed to be captured, suggesting 
that PG is generally unreliable. Fortunately, PG fluorescence has already been 
characterised, and was found to be stabilised upon addition of glycerol (395). In 
keeping with these results, 20% glycerol in the final reaction mixture was sufficient to 
prevent rapid photobleaching (Fig. 1c).  
 
To capture activity in real-time, PG was added before addition of DNase I. Free 
nucleotides (dNTPs) were added to the reaction mixture where the fluorescent signal 
was negligible, confirming that the reaction products do not contribute towards 
fluorescence signal to distort the results. This assay also established that the 
PG:dsDNA complex does not inhibit DNase I as it processes the DNA (Fig. 1d). 
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FIGURE 1  
 
Figure 1 | Assay progression from a discontinuous to a continuous methodology 
a, Discontinuous assay performed with a DNase I titration on 2 ng/µL 7284 bp plasmid. A dilution series 
was carried out to provide a range of DNase I concentrations: 0, 12.5, 25, 50, 100 and 200 nM. Reaction 
was run at 37°C for 15 minutes. PG was subsequently added, and the fluorescence was read after 10 
minutes incubation to allow for PG saturation of the dsDNA. Error bars represent standard deviation, 
n=2.  b, PG was added to the reaction mixture containing 2 ng/µL plasmid for 15 minutes prior to addition 
of different concentrations of DNase I. Two reads were taken in quick succession at 37°C, followed by 
a third read 5 minutes later to determine the extent of photobleaching. c, 20% glycerol was added to 
the reaction mixture and the fluorescent signal was observed after 5 minutes. d, Continuous assay run 
with 50 nM DNase I at 37°C and 5 mM dNTPs as a control. Error bars represent SD; n=2.  
 
3.8 Oligonucleotide sequence optimisation for highly fluorescent substrates 
Oligonucleotides are far more suitable than large plasmids to study nucleolytic activity 
on a range of different substrate termini. Oligonucleotides are far more versatile 
substrates than plasmids as they can be designed to have different terminal structures, 
such as 5’ or 3’ overhangs, Y-structures, Holliday junctions or strand invasions, 
amongst many more physiologically relevant structures (13,396). The much shorter 
length of the oligonucleotides ensures that each enzyme is exposed to a higher 
proportion of these alternative structures and, for these reasons, only oligonucleotides 
were used for furthering the development of the assay. The oligonucleotides used in 
this assay were designed to be 80 base pairs (bp) in length to emit a suitably high 
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fluorescent signal with the addition of PG (Fig. 2), and were sequence-optimised so 
as to reduce the likelihood of secondary structure formation (114) and thus increase 
the fluorescent read-out (Fig. 3 and 4). 80-bp was deemed an appropriate length due 
to limitations in synthesis. According to Integrated DNA Technologies and Eurofins, 
90–100-bp is typically the maximum length for HPLC-purified oligonucleotides, 
respectively. In addition, reducing the length of one strand to create overhangs would 
affect the fluorescent signal emitting from dsDNA, and would require synthesis of more 
control, ‘ladder’ sequences, rather than simply extending the length of one strand 
when required.  
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FIGURE 2 
 
Figure 2 | Calibration curve of substrates equal in length emit different fluorescent signals.  
Two 80-bp substrates composed of different nucleotide sequences and incubated with PG emit different 
fluorescent signals. Error bars represent standard deviation; n=3. 
 
Two 80-bp oligonucleotides (substrates v1 and v2) were treated with PG, and their 
fluorescence was compared (Fig. 2). Each substrate has a GC content of 53% and 
35%, respectively. As PG fails to show any base preference (395), it is probable that 
this disparity in fluorescence can be attributed to the likelihood of secondary structure 
formation. Secondary structures are the formation of intramolecular structures, such 
as stem loops (397). Secondary structure prediction software 
(https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predict1/Predict1.html) 
was used to calculate the likelihood of secondary structure formation for each 
oligonucleotide at 37°C (114). This was to cater for the fact that all enzyme assays are 
to be run at this temperature. The software uses thermodynamics, prediction of base 
pair probabilities, bimolecular structure prediction and other algorithms to calculate the 
probability of secondary structure formation in an RNA or DNA sequence. It attributes 
each oligonucleotide with a ΔG value, which is a measurement of a sequence’s 
thermodynamic stability. It is recommended to have a ΔG value that is more positive 
than -9 kcal/mole. Using the software as a guide, the sequences were edited to reduce 
the probability of secondary structure formation. 
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Substrate v1 was made up of two 80-mer oligonucleotides called 381 and 468. 
Secondary structure prediction software found a high probability of secondary 
structure formation in these sequences (ΔG is -16.9 kcal/mole and -15.6 kcal/mole for 
381, and -12.9 kcal/mole and -11.7 kcal/mole for 468; Fig 3). Substrate v2 is formed 
from two 80-mer oligonucleotides called 396 and 400 and have more positive (or less 
negative) predicted ΔG values (-4.1 kcal/mole and -3.9 kcal/mole for 396, and  
-6.9 kcal/mole and -6.2 kcal/mole for 400; Fig. 7). Substrate v1 exhibits the lowest 
fluorescent signal compared to substrate v2, and their ΔG values corresponded with 
their divergent fluorescence signatures. Substrate v1 was composed of two 80-mer 
oligonucleotides called 381 and 468. Their predicted secondary structures have very 
low ΔG values   
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FIGURE 3 
 
 
Figure 3 | Predicted secondary structures for the less fluorescent substrate v1 have ΔG values 
below the minimum recommended -9 kcal/mole 
Substrate v1 is composed of two oligonucleotides, 381 and 468. The predicted ΔG values for their 
secondary structures are -16.9 kcal/mole and -15.6 kcal/mole for 381, and -12.9 kcal/mole and  
-11.7 kcal/mole for 468. 
  
kcal/mole kcal/mole 
kcal/mole kcal/mole 
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FIGURE 4 
 
 
Figure 4 | Predicted secondary structures for the less fluorescent substrate v1 have higher ΔG 
values than the minimum recommended -9 kcal/mole 
Substrate v2 is composed of two oligonucleotides; 396 and 400. The predicted ΔG values of their 
secondary structures are -4.1 kcal/mole or -3.9 kcal/mole for 396, and -6.9 kcal/mole or -6.2 kcal/mole 
for 400. 
 
To confirm whether the secondary structures are responsible for the strength of the 
fluorescent signal, the less fluorescent substrate (substrate v1; 381/468) was edited 
to try and obtain a fluorescent signature that was equal to, or greater than, the signal 
produced from the more fluorescent substrate (substrate v2; 396/400). Using the 
secondary structure prediction software as a guide to edit the relevant bases, 
kcal/mole kcal/mole 
kcal/mole kcal/mole 
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oligonucleotides 556 and 557 (enhanced substrate v1) were successfully designed 
with more positive ΔG values (-2.8 kcal/mole for both predictions of 556, and -3.5 
kcal/mole for both predictions of 557; Fig. 5).  
 
FIGURE 5 
 
Figure 5 | Improved ΔG values for the edited low-fluorescence substrate  
Enhanced substrate v1 was composed of two oligonucleotides, 556 and 557. The predicted ΔG values 
of their secondary structures are -2.8 kcal/mole for 556 and -3.5 kcal/mole for 557. 
kcal/mole kcal/mole 
kcal/mole kcal/mole 
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As suspected, lower ΔG values cause a reduction in the likelihood of secondary 
structure formation. In turn, this enables a higher proportion of successful annealing 
between the two complementary oligonucleotides with an accompanying increase in 
fluorescence (Fig. 6). Although enhanced substrate v1 (556 and 557) does have the 
most positive ΔG compared to substrate v2 (396 and 400), there is no greater increase 
in fluorescence. This may be because the difference between their ΔG values is minor 
in comparison to enhanced substrate v1 and substrate v1 (381 and 468).   
 
FIGURE 6 
 
Figure 6 | Calibration curve of the two original 80-bp substrates and the enhanced substrate.  
A calibration curve of substrate v1 and substrate v2, including enhanced substrate v1, which was edited 
to reduce the formation of secondary structures at 37°C.  
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PG fluorescence is affected by buffer components 
Evidence suggests that certain compounds exert either a positive or negative influence 
on the PicoGreen fluorescence signal, some of which are present in enzyme storage 
and reaction buffers. 2% (v/v) BSA reduces the signal by 16%, and 200 mM NaCl 
reduces the signal by 30%. This list of compounds is not exhaustive, however, and so 
the differential effects of the DNase I storage and reaction buffers were explored (Fig. 
7). The storage buffer augments the fluorescent signal, whilst the reaction buffer has 
the opposite effect and reduces fluorescence. Altering the recommended 
concentrations of each buffer to 50% or 100% failed to make a significant difference 
to further improve the signal (Fig. 7 a-b).  
 
FIGURE 7 
 
Figure 7 | Effect of DNase I reaction and storage buffers on PicoGreen fluorescence 
a, and b, Comparisons of the fluorescent signal according to the DNase I storage and reaction buffers 
at both 50% and 100% of their recommended concentrations. The storage buffer augments 
fluorescence whilst the reaction buffer reduces the signal. Error bars represent SD; n=2 in all cases.  
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3.9 Optimisation of the assay using the non-specific DNase I 
 
FIGURE 8 
 
Figure 8 | Illustration depicting the concept of the continuous assay 
PG intercalates with dsDNA to produce a measurable fluorescent signal. Addition of a dsDNA nuclease 
or resection nuclease disrupts the PG:dsDNA complex, liberating the PG and triggering a nuclease-
dependent loss of fluorescence. 
 
To confirm whether PG could be used to study nucleases in real-time (as illustrated in 
Fig. 8), its applicability and robustness was first validated with a non-specific nuclease. 
DNase I digests ssDNA, both strands of dsDNA, and does not show absolute 
sequence specificity (although it has shown a general preference for AT base pairs as 
opposed to GC base pairs (171)).  
 
A calibration curve was established to determine the linear range in which the 
concentration of DNA is directly proportional to the fluorescent signal (Fig. 9a). Both 
plasmid DNA (13.1 kb) and oligonucleotide DNA (80 bp) were compared, and it was 
determined that the maximum concentration of DNA that could be used in the assay 
was 2.5 ng/µL, regardless of the length and structure of the DNA. Above 2.5 ng/µL, 
the fluorescent signal plateaued irrespective of the increase in DNA concentration (Fig. 
9a).  
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As an alternative to converting fluorescence to molar concentrations, which vary 
according to the length of the DNA substrate, a standard curve was generated based 
on the signal produced from 80-, 60-, 40- and 20-bp substrates, as well as a 0-bp 
single-stranded 80-mer oligomer to represent the final resection product of other 
resection nucleases (Fig. 9b). PG binds ssDNA with a lower affinity than dsDNA, as 
indicated by the standard curve. For resection nucleases, rather than DNase, this is a 
more appropriate end-point of the reaction rather than the comparatively minor 
fluorescent signal produced in the absence of substrate. This standard curve shows a 
linear increase in fluorescence with the length of duplex DNA (R2 = 0.99).  
 
The purpose of the standard curve is to enable the conversion of fluorescence units 
to DNA base pairs to calculate the length of substrate remaining following nucleolytic 
attack. To convert the data from fluorescence units, the data is first normalised to their 
relevant control (absence of enzyme). This has the additional benefit of accounting for 
the inevitable photobleaching effect. As such, any decrease in fluorescence recorded 
is a result of nuclease activity and not photobleaching of the PG dye. The standard 
curve is then converted to base pairs by finding the gradient (m) and intercept (c) of 
the curve at each time point, and from this it is possible to determine the length of 
dsDNA (x-axis) from the fluorescent signal (y-axis) at each time point and experimental 
condition. A worked example is available in the Appendix.  
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FIGURE 9 
 
 
Figure 9 | Optimisation of assay parameters using the non-specific nuclease DNase I 
a, Calibration curve indicating the fluorescent signal emitted by increasing concentrations of 80 bp 
dsDNA and 13.1 kb plasmid DNA. b, Standard curve composed of 80, 60, 40 and 20 bp sequences. 
The point shown at 0 on the x-axis is an 80-nt ssDNA oligomer to represent the end product of complete 
resection. c, DNase I titration on an 80 bp dsDNA substrate. Dotted grey lines represent controls 
containing standard duplexes of intermediate sizes. d, Extracted maximum gradient from (d) to 
determine the reaction rate at increasing concentrations of DNase I. e, Maximum rate analysis of 
resection per nM DNase I per second. Error bars represent SEM; n=3 in all cases.  
 
A DNase I titration was run with the addition of the standard curve, allowing the 
conversion of the y-axis from fluorescence units to a measurement of the length of 
dsDNA (Fig. 9c). From this it was determined that the rate increases with the 
concentration of DNase I, therefore indicating that the reaction is first order with 
respect to the enzyme (Fig. 9d). Subsequently, the rate of DNase I-mediated digestion 
was calculated to be approximately 0.001 bp nM-1 sec-1 on a 2.5 ng/µL (50 nM) 80-bp 
dsDNA substrate at 37°C (Fig. 9e).  
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FIGURE 10 
 
 
 
Figure 10 | Fluorescence units can be converted to nM concentrations of DNA substrate 
a, Plasmid titration in the presence of 50 nM DNase I. b, Calculated the maximum rate of resection of 
increasing concentrations of plasmid based on the maximum gradients in (a). c, Oligonucleotide titration 
in the presence of 50 nM DNase I. d, Calculated the maximum rate of increasing concentrations of an 
80-mer dsDNA substrate based on the maximum gradients in (c). e, Calculated the value of the rate 
constant for the reaction in (c) 50 nM oligo. 
 
Alternatively, fluorescence units can be converted to nanomolar concentrations of 
substrate as opposed to base pairs of DNA. Utilising the fluorescence units used in 
the samples without DNase I, these figures were used as a calibration curve, allowing 
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us to convert fluorescence units into concentration of substrate. The calibration curve 
was used as a reference point at each time point, which could then be used to convert 
the Y-axis change in fluorescence (ΔF) into a measurement of the number of 
nucleotides cleaved, which was then converted into a value for rate. This method of 
normalising the data circumvents the effect of photobleaching as it subtracts the 
decrease in fluorescence from the controls and the substrates in the presence of 
DNase I, which ensures that the loss of fluorescence observed after normalisation is 
results only from nuclease activity.  
 
The plasmid was titrated in the presence of 50 nM DNase I (Fig. 10a) and the rate of 
DNase I-dependent digestion was obtained at each concentration (Fig. 10b). The 
linear relationship between increasing substrate concentration and DNase I-
dependent digestion indicates that the rate is dependent on the quantity of available 
plasmid. This also suggests that this is a first order reaction with respect to the plasmid 
at this concentration of DNase I.  
 
This titration was replicated on 80 bp DNA substrates (Fig. 10c), and the control 
samples not treated with DNase I were used to generate a calibration curve at each 
time point. This, again, allows for the conversion of the raw fluorescence data to DNA 
concentration. From this the maximum rate in the reaction was obtained and, as with 
the plasmid, there is a linear relationship between the substrate concentration and the 
rate, indicating that this is a first order reaction with respect to the substrate (Fig. 10d). 
To confirm the order of the reaction, the following integrated rate equations was used:  
 
1. ln[oligo]t150 = -kt + ln[oligo]t0 
 
Equation 1 follows the graph of a straight line (y=mx+c).  
The reaction was confirmed as first order by plotting time on the x-axis, and the natural 
log of the concentration of oligo at each time point from 0 to 150 seconds on the y-
axis. These data points fall in a straight line, and therefore the reaction is first order.  
The reaction rate (-k) is calculated from the gradient of the line, and this is 1.36 x 10-3 
(Fig. 10e).  
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These results show that this assay is versatile and can capture a range of kinetic 
information depending on what is required from the experiment. The only difficulty with 
using this method is that nanomolar concentrations of DNA substrate is dependent on 
the length of the oligomer and, as such, creates a situation where the activity of two 
substrates of different lengths cannot be easily compared. Therefore, converting to 
base pairs is a far more straightforward process.  
 
3.10 Modifying DNA substrates to study structure-specific enzymes 
Since the assay has proven to be proficient in garnering detailed kinetic analysis of a 
nonspecific nuclease, the assay then progressed to analysing less tolerant nucleases 
that exhibit structural specificities and directionality. To validate the assay for these 
resection nucleases, the 3’-5’ bacterial Exonuclease III (ExoIII) and the T7 
bacteriophage 5’-3’ T7 exonuclease (T7 Exo) were employed (Fig. 11). 
 
To cater for studying resection nucleases, it was necessary to design substrates that 
directed enzymatic activity to only one end of the substrate. This is due to limitations 
in the maximum length of oligonucleotide that can be synthesised. Therefore, 
generating substrates that are blocked at one end circumvents these limitations. An 
additional benefit of chemically blocking one end of the substrate is that it doesn’t 
require any prior knowledge of inhibitory structures specific to each enzyme, which is 
a technique that has been used to great effect (13).   
 
To account for having enough dsDNA region as well as structurally appropriate 
terminal ends to study nuclease structural preferences, substrates were designed that 
were blocked at one end to direct the enzyme to resect one single strand only, leaving 
a full-length, blocked, single-stranded 80-mer substrate as the end product (Fig. 11a). 
The substrates were blocked with biotin-triethyleneglycol (BITEG) at the necessary 
terminal ends (3’ end for ExoIII and 5’ end for T7 Exo). BITEG alone is insufficient to 
inhibit resection on substrates blocked at both terminal ends (Fig. 11b-c). However, 
inclusion of streptavidin in the reaction mix successfully protects the modified ends 
from resection (Fig. 11b-c). It was noticed that the presence of streptavidin, but not 
BITEG alone, is responsible for preventing total resection, prohibiting ExoIII from 
resecting the final 20 nucleotides (Fig. 11d). This combination of biotin and streptavidin 
has previously been shown to be effective (182). 
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FIGURE 11 
 
 
Figure 11 | BITEG alone is insufficient for preventing nuclease resection 
a, Stick and ball figures illustrate the substrates and the distinguishing features of the BITEG and 
streptavidin modifications. b, Treated a range of substrates with and without the BITEG and streptavidin 
modifications in the presence of 12 nM T7 Exo. c, Treated a range of substrates with and without BITEG 
and streptavidin modifications in the presence of 10 nM ExoIII. d, Presence of streptavidin prevents 
total resection of the substrate.  Error bars represent SEM; n=3 in all cases. 
 
A streptavidin dilution was set up to determine the optimum concentration that would 
suitably prohibit enzymatic resection (Fig. 12). Ultimately, 0.02 ng/µL streptavidin was 
an appropriate concentration, as it appeared that within the range of 0.02 – 1 ng/µL 
the inhibitory effect was negligible. It is suspected that the low level of resection 
observed (10-20%) is attributable to a small proportion of oligonucleotide substrates 
that are shorter in length, or non-biotinylated, and are therefore prone to T7 Exo-
mediated resection.  
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FIGURE 12 
Figure 12 | 0.02 ng/µL streptavidin (SA) is sufficient to inhibit resection by 12 nM T7 Exo 
Increasing concentrations of streptavidin (0.02 – 1 ng/µL) were added to substrates biotinylated at both 
5’ ends to inhibit T7 Exo-mediated resection.  
 
To reduce the background levels of resection and ensure high levels of oligonucleotide 
purity, HPLC purification was deemed the most appropriate. PAGE purification was 
considered as it is the Integrated DNA Technologies-recommended technique for 
oligonucleotides >80 bases in length. However, 3’-BITEG substrates cannot be 
purified using this process. Therefore, as HPLC is capable of purifying 
oligonucleotides with both 5’- and 3’-BITEG modification, and routinely achieves a 
reasonable 85% purity, this was deemed the most suitable technique.   
 
Other methods to block the DNA were considered. Several options are listed on the 
Integrated DNA Technologies website 
(https://eu.idtdna.com/pages/education/decoded/article/modification-highlight-
modifications-that-block-nuclease-degradation), including 2’-O-methyl, 2’ fluoro, 3’-
phosphorylated, and inverted dT and ddT, phosphorothioate bonds. 2’-O-methyl is 
typically used to stabilise RNA duplexes and is not a commercially available 
modification for DNA. Furthermore, 2’-O-methyl only prevents attack by ssDNA 
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endonucleases, but not exonucleases. As a result, this modification is unsuitable for 
this application (398). 2’fluoro is also an RNA modification, and therefore is also 
inappropriate for this assay (399). 3’-phosphorylations are only inhibitory to some 3’ 
exonucleases, Exonuclease III, for example, has intrinsic phosphatase activity, and 
therefore is not inhibited by this modification (400). Inverted dT (3’-3’) or ddT (5’-5’) 
terminal nucleotides were strongly considered, however very few articles have been 
published on their efficacy, and only in terms of stability against RNA nucleases (401). 
As such, inverted nucleotides were not incorporated into the design of this assay. 
Finally, phosphorothioate linkages were initially selected, and have been shown to be 
effective against RNA and DNA nucleases (402–404). However, the yield after 
purification is lower than for BITEG-modified oligonucleotides, and ultimately would 
have been more costly.   
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3.11 Discussion 
PG has previously been used to visualise picogram concentrations of DNA in tissue 
samples (405), gel electrophoresis (383), flow cytometry (384), and discontinuous 
nuclease (387) and polymerase assays (389,390). While it has been used for several 
different applications, its value to continuous assays hasn’t fully been recognised 
(394). 
 
Various aspects of the assay have had to be optimised for this to become a possibility. 
PG had to be stabilised using glycerol to protect it from rapid photobleaching (395).  In 
addition, the DNA substrates had to be edited so as to reduce the likelihood of 
secondary structure formation. This ensures the most efficient binding between the 
two complementary strands, and allows for more PG binding, which correlates to a 
much stronger fluorescent signal. This is important to capture enzymatic activity in the 
most detail.  
 
Further to this, the DNA substrates were modified to cater for resection nucleases. To 
direct nuclease activity to one end of the substrate, BITEG was added to the terminal 
ends of the oligonucleotides. While BITEG alone proved to be insufficient to inhibit 
nuclease activity, the addition of streptavidin provided enough steric hindrance to 
prevent both 3’ and 5’ nucleases from resecting the DNA substrate.  
 
To study the kinetics of nuclease activity, a calibration curve can be included in every 
assay to either convert the fluorescence units to base pairs or to nanomolar 
concentrations of DNA. This has the advantage of eliminating the effect of 
photobleaching and indicates the detail in which nucleases can be analysed. It is 
hoped that this assay will prove to be incredibly powerful when it is used to study more 
structure-specific nucleases, as explored in Chapter 4.  
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4 Validation of a fluorescence-based toolkit for measuring structure-
specific nuclease activity and their substrates 
 
4.1 Summary 
DNA nucleases play a critical role in diverse DNA repair processes. Nevertheless, 
many nucleases have unknown or poorly characterized activities. Elucidating 
nuclease activity specificities and regulatory components can support a more definitive 
understanding of the DNA damage response in physiology and disease. Using 
fluorescence-based methods, a quick, safe, reproducible, cost-effective and 
continuous nuclease assay toolkit that could be used for small- and large- scale 
experimental assays was developed. Additionally, these data can be analysed to 
determine each reaction’s unique enzyme kinetics. A library of DNA substrates has 
been designed that can be used to study resecting nucleases and nickases, conferring 
the ability to ascertain substrate preference and enzyme directionality. The assay is 
sensitive enough to detect kinetics of repair enzymes when confronted with DNA 
mismatches or DNA methylation sites. This assay has also been extended to consider 
analysing the kinetics of human single-strand DNA nuclease TREX2, and DNA 
polymerases, which are also involved in DNA repair, and have been associated with 
various disease conditions. 
 
4.2 The combination of PicoGreen and a DNA substrate library enables the study 
of nucleic acid-active enzymes 
Following the detailed introduction about nucleases and the novel assay developed in 
Chapter 3, potential applications of this novel fluorescence-based nuclease resection 
assay will hereby be elaborated on. The aim is to replace the classical radiolabelling-
based assays (406,407). This toolkit has been optimised for a range of important 
representative nucleases, including: DNase I (a non-specific ss- and dsDNA 
nuclease), T7 exonuclease (a 5’–3’ dsDNA bacteriophage nuclease) (13), 
Exonuclease III (a 3’–5’ dsDNA E. coli nuclease) (408), human Trex2 (a 3’–5’ ssDNA 
nuclease) (409), and a viral nickase, Nt.CviPII (410). These representative nucleases 
were chosen because of their 1) availability, stability, purity, and specificity (DNase I, 
T7, ExoIII, Klenow, and Nt.CviPII) and for their 2) importance for mammalian cell 
function (TREX2). TREX2 is a mammalian keratinocyte-specific nuclease that has 
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been shown to work in a 3’–5’ non-processive manner to promote DNA repair or 
apoptosis in chemically- or UVB-induced carcinomas. Consistent with a role in 
keratinocyte carcinogenesis, polymorphisms in the Trex2 gene, and its aberrant 
expression, have been shown in human squamous cell carcinomas (179,411–414). 
 
Furthermore, a library of DNA substrates was designed to account for these enzymes’ 
differential activities. Due to oligomer length limitations, it was necessary to design 
substrates with biotin-TEG-modified 3’ or 5’ termini to control enzyme directionality. 
The addition of streptavidin to the biotinylated ends protects the substrate from 
resection at the modified end, as was demonstrated in a previous resection assay 
(182). This oligonucleotide library can be used to study a multitude of uncharacterised 
nucleases, and their substrate preferences, to elucidate their roles in DNA repair and 
genomic maintenance. To extend the power of this approach, physiologically relevant 
substrates have been designed that contain mismatches and methyl-cytosines. It has 
been posited that repair nucleases resect along a methylated sequence of DNA, thus 
permanently removing epigenetic markers. Human 5’–3’ exonuclease, Exo1, resects 
through mismatches during mismatch repair (415,416). As such, it would be interesting 
to determine whether this mismatch is permissive to nucleases in general. As the 
assay relies on the loss or gain of the DNA duplex structure, other enzymes that 
reconstitute or compromise the DNA-pairing structure could also be validated in this 
assay. Furthermore, monitoring of polymerase activity has been demonstrated on the 
complementary strand. Picogreen (PG) has previously been used to visualise 
polymerase activity, but to the best of found knowledge, this is the first time it has been 
described in a continuous assay (389).  
 
This work provides a robust and versatile toolkit to characterise DNA nucleases and 
determine their substrate preferences with high resolution and sensitivity. This assay 
can be adapted and modified to suit a wide range of DNA repair applications. 
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4.3 Materials and Methods 
 
4.3.1 Plasmid and oligonucleotide substrates 
DNA substrates were prepared by diluting a 7000 kb plasmid in HyClone waterTM (GE 
healthcare), and unmodified HPLC-purified oligonucleotide substrates (Eurofins) in 1X 
annealing buffer (Sigma-Aldrich). Oligonucleotides were designed and optimised 
against secondary structure formation using the ‘Predict a Secondary Structure Web 
Server’ 
(https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predict1/Predict1.html) 
(114) and annealed at a 1:1 molar ratio. Table 1 shows all the oligonucleotides and 
their respective illustrations, while Table 2 lists the oligonucleotide sequences and 
modifications.  
 
Table 1 
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Table 2 
Oligo 
code 
Sequence (5’–3’) 
RCOL556 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAACTTAG  
RCOL557 CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAGTAATAGACCAACAAACCATC  
RCOL621 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAAC TTAG-BITEG* 
RCOL626 CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAGTAATAGACCAACAAACCATC -BITEG* 
RCOL622 CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAGTAATAGACCAACAAACCATC TT 
RCOL624 CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAGTAATAGACCAACAAACCATC TTTT 
RCOL616 BITEG-GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAACTTAG*  
RCOL620 BITEG-CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTA GTAATAGACCAACAAACCATC* 
RCOL617 TTCTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAGTAATAGACCAACAAACCATC  
RCOL618 
TTTTTTTTTTCTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAGTAATAGACCAACAAACC  
ATC 
RCOL619 
TTTTTTTTTTTTTTTTTTTTCTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAGTAATAGA  
CCAACAAACCATC 
RCOL714 GATGGTTTGTTGGTTTATTACTACTTGGAGTTTGTATGATTTGAAACCTTGGAGTACTTGTCTACTTGGAGTGAACTTAG** 
RCOL715 CTAAGTTCACTCCAAGTAGACAAGTACTCCAAGGTTTCAAATCATACAAACTCCAAGTAGTAATAAACCAACAAACCATC*** 
RCOL710 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAACTTAG**** 
RCOL711 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAACTTAG****  
RCOL648 GTGAACTTAG-BITEG* 
RCOL649 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGA  
RCOL650 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGG  
RCOL645 BITEG-GATGGTTTGT* 
RCOL646 TGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAACTTAG  
RCOL647 GGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAACTTAG  
RCOL611 CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGAATCATACAAGCTCCAAGTAG  
RCOL610 CTAAGTTCACTCCAAGTAGGCAAGTACTCCAAGGTTTCGA  
RCOL609 CTAAGTTCACTCCAAGTAGG 
RCOL562 GATGGTTTGTTGGTCTATTA 
RCOL560 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGAT  
RCOL558 GATGGTTTGTTGGTCTATTACTACTTGGAGCTTGTATGATTCGAAACCTTGGAGTACTTG  
RCOL739 TCGAAACCTTGGAGTACTTGCCTACTTGGAGTGAACTTAG  
RCOL738 CCTACTTGGAGTGAACTTAG 
 
*BITEG represents the biotin-TEG modification 
**T bases in bold indicate sites of C>T base changes to generate a mismatched substrate 
***A bases in bold indicate sites of G>A base changes to generate a mismatched substrate 
****C bases in bold indicate methylcytosines 
 
4.3.2 Nucleases and buffers 
The nucleases used were RQ1 RNase-Free DNase I (Promega), T7 exonuclease 
(New England Biolabs), Exonuclease III (New England Biolabs), Trex2 (Stratech), 
Klenow Fragment (3’ → 5’ exo-; New England Biolabs). In preparation for each 
assay, nucleases used were diluted on ice in their appropriate storage buffers, 
omitting glycerol. All storage buffers and reaction buffers were made according to the 
recipes available on their respective NEB and Thermo Fisher web pages. DNase I 
storage buffer (10mM HEPES (pH 7.5), 10mM CaCl2 and 10mM MgCl2) and reaction 
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buffer (400mM Tris-HCl (pH 8.0), 100mM MgSO4 and 10mM CaCl2), T7 exonuclease 
storage buffer (10 mM Tris-HCl, 5 mM DTT, 0.1 mM EDTA, (Ph 8 at 25ºC)) and 
reaction buffer (50 mM potassium acetate, 20 mM Tris-Acetate, 10 mM magnesium 
acetate, 1 mM DTT), and Exonuclease III storage buffer (5 mM KPO4, 200 mM KCl, 
5 mM β-ME, 0.05 mM EDTA, 200 µg/mL BSA, (pH 6.5 at 25ºC)) and reaction buffer 
(10 mM Bis-Tris-Propane-HCl, 10 mM MgCl2, 1 mM DTT (pH 7 at 25ºC)), Trex2 
storage buffer (20 mM Tris-HCl (pH 8), 200 mM NaCl, 5 mM DTT) and reaction 
buffer (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 
100 µg/mL BSA, (pH 7.9 at 25ºC)) and Klenow Fragment storage buffer (25 mM Tris-
HCl, 1 mM DTT, 0.1 mM EDTA, (pH 7.4 at 25ºC)) and reaction buffer (50 mM NaCl, 
10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, (pH 7.9 at 25ºC)) were all filtered prior to 
use, and autoclaved where possible.  
 
Trex2 (Stratech), Klenow Fragment (3’ → 5’ exo-; New England Biolabs). In 
preparation for each assay, nucleases used were diluted on ice in their appropriate 
storage buffers, omitting glycerol. DNase I, T7 exonuclease, Exonuclease III, Trex2 
and Klenow fragment storage buffers and reaction buffers were all filtered prior to 
use, and autoclaved where possible.  
 
4.3.3 Preparation of PicoGreen 
The PG reagent from the Quant-iTTM PicoGreenTM dsDNA Assay Kit (Invitrogen) was 
prepared immediately before use by making a 1:200 dilution of the PG in TE buffer (10 
mM Tris-HCl, 1 mM EDTA, pH 7.5) and 40% (v/v) glycerol.    
 
4.3.4 Continuous assay experimental procedure 
Each DNA substrate reaction mixture contained 50 nM DNA substrate, 1X reaction 
buffer (specific for each enzyme), 50 µL PG solution, 0.02 mg/mL streptavidin (cat. 
21125, Thermo Fisher Scientific) if required, 0.25 mM dNTPs if required, 5 µL enzyme 
or relevant storage buffer. For the DNA nucleases, Milli-Q water was added to bring 
the total reaction volume to 100 µL. Reaction mixtures were prepared on ice and 
samples were tested in a 96-well, black flat bottom plate (cat. M9685, Sigma-Aldrich). 
The final components added were the storage buffers, then the enzyme mixtures to 
start the reaction.  
 
 90 
 
A CLARIOstar microplate reader (BMG labtech) was pre-heated to 37°C. Samples 
were read every 40-50 s for 30-60 mins. Excitation and emission wavelengths used 
were 483-15 nm and 530-30 nm, with a focal height of 10.2, 20 flashes per well, with 
a shake before each read.   
 
4.3.5 Data analysis 
For statistical analysis of the data, one-way ANOVA with the Tukey’s post-hoc tests 
were used. This was implemented using GraphPad Prism v7.03. An example of the 
workflow is available in the appendix.  
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4.6 Results 
Having optimised PG and the DNA substrates in the previous chapter, this 
fluorescence-based toolkit was subsequently used to study a selection of nucleases 
with different activities and structural preferences. In addition, the substrates were 
further modified to study the processivity of nucleases on physiologically-appropriate 
substrates containing either DNA mismatches, reminiscent of substrates of mismatch 
repair, or methyl-cytosines, to mimic the decorated structures of genomic DNA.  
 
4.7 Validating the assay for 3’–5’ exonuclease: ExoIII 
ExoIII is a well-characterised 3’–5’ exonuclease that resects from blunt end substrates, 
and short 3’-overhangs, but is inhibited by 4-nt 3’-overhangs. These activities were 
replicated in this fluorescence-based assay. For ease, each assay is shown with a 
stick and ball diagram of the substrates used. The table (Fig. 1a) shows the substrates 
that have been used and their respective modifications.  
 
A calibration curve was prepared in order to determine the linear range within which 
the fluorescent signal is directly proportional to the DNA substrate concentration with 
the addition of BITEG and streptavidin (Fig. 1b). The linear range is the same as with 
the unmodified DNA substrate (observed in Chapter 3, Fig. 9).  
 
A range of ExoIII titrations were performed on three different substrates: blunt, 2-nt 
and 4-nt 3’overhangs (Fig. 1c-e). The preference of ExoIII for blunt and 2-nt overhangs 
is known, as is the inhibitory effect of 4-nt 3’-extensions, as these activities are often 
exploited for various sequencing and DNA detection techniques (417–420) (Fig. 1f). 
After determining the rate of resection on each substrate (Fig. 1g), the results suggest 
that the assay can detect previously reported activities and is suitably sensitive to 
determine substrate preference. Indeed, ExoIII is completely inhibited by 4-nt 
overhangs, and is resected at an equally low rate as the negative control, which has 
both 3’-ends blocked with BITEG and streptavidin. Unexpectedly, it appears that the 
reaction rate decreases on the blunt substrate and the 2-nt overhang substrate as 
enzyme concentration increases. It is possible that this inhibition is observed because, 
at higher rates, a larger pool of reaction products will be created, and ExoIII may bind 
to these reaction products instead of the full-length oligonucleotide. These reaction 
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products may function as ‘decoy’ molecules that slow ExoIII-mediated DNA 
degradation. 
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FIGURE 1 
 
Figure 1 | Validation of the continuous assay for 3’ – 5’ nucleases 
a, Key to stick and ball illustrations of the substrates. The parallel horizontal lines (=) represent the 
dsDNA substrate, and the coloured-in circle represents the combination of both biotin and streptavidin 
(●). b, Calibration curve depicting the fluorescent signal according to increasing concentrations of 80-
bp oligomer substrate with one terminal BITEG modification and in the presence of 0.02 mg/ml 
streptavidin. c-e, ExoIII titrations as depicted in the figures on 50 nM substrates presenting a blunt 
terminus (c), 2-nt (d) or 4-nt (e) 3’ overhang (multi-coloured cartoons), and negative controls (black 
cartoons) containing BITEG-modified 3’-ends. Results were normalised against their respective 
negative controls (absence of ExoIII) and converted to bp. The grey curve in (e) shows the equivalent 
reaction without an overhang, highlighting the loss of activity with a 4 bp 3’ overhang. f, Rate of resection 
by ExoIII on the blunt (red), 2-nt (orange) and 4-nt (green) 3’ overhangs and the negative control with 
BITEG-treated 3’-ends. Minimal loss of activity is observed with a 2-nt overhang, in contrast to almost 
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complete loss of activity with a 4-nt overhang. g, Comparison of ExoIII and DNase I activity on their 
respective substrates. Error bars represent SEM; n=3 in all cases.  
 
4.8 Validating the assay for 5’–3’ exonuclease: T7 exonuclease 
Having demonstrated that this assay is suitable for 3’–5’ nucleases, it was then 
confirmed that this assay could also be used to study 5’–3’ nucleases. T7 Exo activity 
was investigated on a selection of substrates, including blunt, 2-, 10- and 20-nt 5’-
overhangs (Fig. 2a). T7 Exo shows no significant difference between the affinity for 
blunt and 2’-nt 5’-overhangs. As had previously been observed, the rate of T7 Exo-
mediated resection with a 20-nt overhang was approximately 50% of a short 
overhang(13) (Fig. 2b). Unexpectedly, as the length of the overhang increased, 
resection was slightly delayed. However, after resection commenced, it appeared to 
take place at a faster rate on the intermediate overhangs, seeing as the reaction 
culminates at approximately the same time point on all substrates (p<0.002 between 
*S and *S+10, and p<0.0001 between *S and *S+20) (Fig. 2b). Regardless, difference in 
rate is rather minimal. In contrast to ExoIII, T7 Exo is able to resect longer overhangs, 
and is restricted, but not inhibited, by the 20-nt overhang.  
 
FIGURE 2 
 
 
Figure 2 | T7 Exo is inhibited by 20-nt 5’ overhangs  
a, 12 nM T7 Exo-mediated resection on 50 nM substrates presenting a blunt (red), 2- (orange), 10- 
(green) and 20-nt (purple) 5’ overhang with. The negative control was synthesised with two 5’-BITEG 
modifications (blue). Results were normalised against their respective negative controls and converted 
to bp. b, Analysis of the rate of resection on the substrates in (a). Error bars represent SEM; n=3 in all 
cases; **p<0.01, ****p<0.0001. 
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4.9 Studying enzyme resection through single-nucleotide mismatches  
During mismatch repair, DNA nucleases resect through the mismatch to generate a 
single-stranded tract of DNA along which DNA polymerases can replicate (75,421–
425). It has been suggested that these resection events may even remove epigenetic 
signatures on the DNA, such as 5-methyl-cytosine (426), which may then be 
permanently lost when repaired with an unmodified cytosine, and not targeted by de 
novo methyltransferases, Dnmt3a or Dnmt3b (427,428). It was therefore tested if this 
assay can detect differences in resection rates through mismatched and methylated 
substrates. 
 
ExoIII activity was investigated on mismatched substrates compared to matching 
substrates and identified some unexpected activities (Fig. 3a–b). First, ExoIII was 
observed to resect the two perfectly matching substrates at substantially different 
rates, resecting *S at a 1.7–2.0-fold faster rate than S* (Fig. 3c). *SC>T contains a 
selection of C>T substitutions, whilst G>AS* contains G>A substitutions, generating T:G 
and A:C mismatches, respectively. The presence of the T:G mismatches slows the 
rate of resection 0.09 – 0.16X compared to its perfectly matching counterpart (p<0.001 
for 5 nM ExoIII; p<0.05 for 10 nM ExoIII; Fig. 3d). Conversely, incorporating A:C 
mismatches increases the rate of resection by 1.5–1.8X (p<0.0001 with both 5 and 10 
nM ExoIII). There is some evidence for a nucleotide preference for ExoIII, although 
this does not appear to have been repeated (170). The rate of resection on both the 
perfectly matching substrate appears to have a delayed start, particularly for S*. 
Interestingly, *S is then resected at an accelerated rate compared to both mismatched 
substrates. The mismatches resect at a slower rate but, as their resection begins at 
the offset, the reaction on the mismatched substrates and *S finish at the same time 
point for both 5 and 10 nM ExoIII.  
 
T7 exonuclease is considered to be sequence-independent as it lacks a defined DNA 
binding-motif, similar to other FEN family nucleases that bind DNA in a nonspecific 
manner (13,429). Nevertheless, it has previously been suggested that it might resect 
different nucleotides with variable efficiency (430). Indeed, T7 Exo was observed to 
resect the perfectly complementary *S with more difficulty than S* (Fig. 3e–g), which 
was noticeable at higher concentrations of T7 Exo (Fig. 3h). Similarly with T7 Exo, this 
assay detected a substrate strand preference (Fig. 3c and 3h).  
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The addition of four T:G mismatches did not slow or accelerate T7 Exo activity. 
However, incorporating A:C mismatches into the more resistant substrate did appear 
to slow resection, and this general trend was observed across all concentrations of T7 
Exo. The effect of the mismatches was more evident at lower T7 Exo concentrations 
(p<0.05 for 7.5 nM and p<0.01 for 2 nM T7 Exo). These data suggest that mismatches 
may only be inhibitory to T7 Exo in certain sequence contexts. Indeed, T7 Exo has 
been shown to recognise single-nucleotide mismatches in an SNP-detection system 
(431).  
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FIGURE 3 
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Figure 3 | ExoIII and T7 Exo resect through single-nucleotide mismatches  
a, 5 nM and b, 10 nM ExoIII was added to perfectly matched substrates (*S and S*) and substrates 
containing four T:G or A:C mismatches, (*SC>T and G>AS*, respectively), and the resection reaction 
followed. Standard curve is represented by the grey dotted lines. c, Calculated resection rate of ExoIII 
on the complementary and mismatched substrates based on maximum gradients in (a) and (b). d, Time 
(seconds) until the ExoIII reaction reaches completion based on the point at which the reaction plateaus. 
e, 2 nM, f, 7.5 nM and g, 10 nM T7 Exo was added to complementary substrates (S* and *S) and 
substrates containing four T:G or A:C mismatches (C>TS* and *SG>A, respectively). Standard curve is 
represented by the grey dotted lines. h, Calculated resection rate of T7 Exo on the complementary and 
mismatched substrates. Error bars represent SEM; n=3 in all cases; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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4.10 Studying enzyme resection through methylated cytosines  
 
FIGURE 4 
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Figure 4 | Increased methylcytosine content delays ExoIII-mediated resection; but does not 
affect the rate of resection of either ExoIII or T7 Exo 
a, 5 nM and b, 10 nM ExoIII was added to a non-methylated substrate, a substrate containing one 
methylated cytosine, and a substrate containing four methylated cytosines (*S, *S1M and *S4M, 
respectively). Standard curve is represented by the grey dotted lines. c, Time (seconds) until the ExoIII 
reaction reaches completion on the methylated and unmethylated substrates based on the point at 
which the graphs plateau in (a) and (b). d, Calculated resection rate of ExoIII based on maximum 
gradients in (a) and (b). e, 6 nM and f, 12 nM T7 Exo on non-methylated and differentially methylated 
substrates. Standard curve is represented by the grey dotted lines. g, Time (seconds) until the T7 Exo 
reaction reaches completion on the methylated and unmethylated substrates based on point at which 
the graphs plateau in (e) and (f). h, Calculated resection rate of ExoIII. Error bars represent SEM; n=3 
in all cases; *p<0.05, **p<0.01, ***p<0.001.  
 
Neither ExoIII nor T7 Exo is substantially inhibited by methylated DNA in this 
experimental system. A non-methylated substrate, a substrate containing one 
methylated cytosine, and a substrate containing four methylated cytosines were each 
treated with either 5 nM or 10 nM ExoIII (Fig. 4a and 4b, respectively). ExoIII shows a 
small but significant trend towards taking longer to fully resect substrates with 
increasing numbers of methylated cytosines (p<0.002 for four methylated cytosines, 
Fig. 4c). This is most apparent at lower concentrations of ExoIII. The maximum 
reaction rate at which ExoIII resects through the methylated sites is not significantly 
different from the non-methylated substrate (Fig. 4d). This indicates that while there 
may be some hindrance in reaction initiation, once ExoIII begins to resect, the methyl 
groups are inconsequential. ExoIII may be indifferent to methylated substrates 
because bacterial DNA is methylated as part of the bacterial immune response against 
incoming DNA, including phages, and also influences bacterial gene expression and 
DNA repair. It therefore would not be farfetched to postulate that ExoIII is required for 
cleaving methylated DNA as well as non-methylated DNA (432). Furthermore, there is 
no significant difference in the time it takes for the reaction to reach completion. T7 
Exo showed no significant effect on either maximum rate or time taken to resect in the 
presence of methylated cytosines (Fig. 4g–h). Currently, there is no data on the effect 
of methyl-cytosine on either ExoIII or T7 Exo resection with which to compare.  
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4.11 Validation of nuclease activity on DNA nicks and gaps, and its use in 
studying DNA nickases in combination with processive nucleases 
 
FIGURE 5 
 
Figure 5 | ExoIII and T7 Exo preferentially resect from a nick than a gap 
a, Schematic of the dsDNA substrate indicating the preferred nicking sites (yellow) and the least 
favourable nicking sites (red) of Nt.CviPII. b–c, Schematic of the dsDNA substrates presenting a nick 
or gap at either the 3’-end for ExoIII, or the 5’-end for T7 Exo. d, ExoIII is active against simulated nicked 
substrates. 40 nM ExoIII was added to a blocked substrate (blue) and related substrates designed with 
either a nick (red) or a gap (orange) towards the 3’ end of one strand, showing similar activity against 
both modified substrates. Standard curve is represented by the grey dotted lines. e, Quantification of 
the Nt.CviPII nickase enzyme activity coupled to ExoIII. Nt.CviPII was added to the blocked substrate, 
either with (purple) or without (green) 40 nM ExoIII. Controls from b) are shown for comparison. f, 
Calculated resection rate of nicked and gapped substrates by ExoIII, extracted from the maximum 
gradient. Addition of the nickase significantly increases the resection rate, highlighting that the nickase 
activity is detected. g, T7 Exo is active against simulated nicked substrates. 12 nM T7 Exo was added 
to substrates with a nick (red) or a gap (orange) towards the 5’ end of one strand. Negative control is in 
blue. Standard curve is represented by the grey dotted lines. h, Quantification of the Nt.CviPII enzyme 
activity coupled to T7 Exo. Nt.CviPII was added to the blocked substrate, either with (purple) or without 
(green) 12 nM T7. Negative control is in blue. i, Calculated resection rate of nicked and gapped 
substrates by T7 Exo, extracted from the maximum gradients in (g) and (h). Addition of the nickase 
significantly increases the resection rate, highlighting that the nickase activity is detected. Error bars 
represent SEM; n=3 in all cases; *p<0.05, ****p<0.0001.  
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Nicks and gaps are introduced as intermediates in DNA repair mechanisms, yet they 
need to be rapidly processed to prevent the accretion of double-strand breaks at 
replication forks, possibly leading to cell death (182,433). Due to the physiological 
relevance of nicks and gaps, the nucleolytic activity of ExoIII and T7 Exo on these 
structures was explored. In order to test this, a combination of substrates was used 
that had been designed to contain a nick or gap, in conjunction with blocking at both 
ends (both 5’ or 3’, respectively) to prevent resection from the terminal ends. A 
recently-purified nickase, Nt.CviPII (410) which is known to possess inherent 
exonuclease activity, was also included. Nickases cleave just one strand of duplex 
DNA, breaking the phosphodiester backbone. Nt.CviPII preferentially cuts CCA and 
CCG, but cuts less efficiently at CCT (410). One strand of the dsDNA substrate 
contains five evenly distributed CCA motifs, while the opposite strand only contains 
two CCT motifs, and therefore most of ExoIII’s activity should be directed on the first 
strand (Fig. 5a). To minimise the exonuclease activity of Nt.CviPII, a low dilution of the 
nickase was used. 
 
These results found that ExoIII functions marginally better on gaps rather than nicks 
(p<0.0001) (Fig. 5d and 5f), and this may reflect its role in base excision repair where 
it resects from an abasic site (408). ExoIII is nevertheless able to resect from a nick, 
and the rate is comparable to its activity on blunt ends, as previously observed (434). 
ExoIII also resected from the nickase-induced nicks at an almost equal rate to the 
substrates designed to contain a single nick (Fig. 5e–f). These data demonstrate that 
Nt.CviPII is a very fast acting nickase against its preferred substrate sequences as 
there is no delay in the start of ExoIII-mediated resection.  
 
As with ExoIII, T7 Exo also resects from both nicks and gaps. It has a more defined 
preference for gaps, showing a rate approximately 2.5-fold greater than for nicks 
(p<0.0001; Fig. 20g and 20i). T7 Exo also resects from nicks generated by a nickase 
almost as efficiently as from a substrate already presenting a single nick (Fig. 5h–i). 
Typically, T7 endonuclease cleaves at nicked sites during infection to generate DNA 
double-stranded breaks that are susceptible to T7 Exo. As such, it is perhaps a 
redundant property of T7 Exo to resect from a nick (435). 
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4.12 Additional DNA enzymes that degrade or synthesise dsDNA can also be 
studied using this assay. 
 
FIGURE 6 
 
Figure 6 | Validation of the assay for alternative enzymes that digest ssDNA and generate dsDNA 
a, Mammalian Trex2 digestion of single stranded DNA quantified using the PG assay. Single-stranded 
60-mer (orange), 40-mer (green) and 20-mer (purple) DNA substrates were treated with 100 and 200 
nM Trex2. Robust digestion was observed in each case. b, Time (seconds) until reaction completion 
based on the point at which the graphs plateau in (a). c, Rate of digestion per nM Trex2. Trex2 degrades 
DNA at a similar rate irrespective of the length of the DNA substrate. d, The polymerase activity of the 
Klenow fragment polymerase determined using the PG assay. Three substrates with a 20-, 40- and 60- 
and overhang with a total 80 bases were incubated with 1 nM Klenow fragment. e, Calculated 
polymerisation rate of the Klenow fragment. A clear preference is shown for longer overhangs. Error 
bars represent SEM; n=3 in all cases; ****p<0.0001. 
 
PG has been demonstrated to be an effective dye that can be used to study dsDNA 
nucleases from viruses and bacteria. Given the low, but not insignificant, fluorescent 
signal observed for the single-stranded 80-mer control in the standard curves, it was 
reasoned that this assay may have the sensitivity to address ssDNA nucleases, such 
as human Trex2 (436). This was confirmed by showing that the assay is sensitive 
enough to detect a Trex2 concentration-dependent decrease in fluorescence from 
ssDNA substrates ranging in size from 60 to 20 nts (Fig. 6a). This indicates that this 
assay has considerable potential for an even wider range of DNA nucleases, and very 
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high levels of sensitivity in order to capture such activity in detail. As expected, it takes 
longer for Trex2 to digest longer substrates (Fig. 6b). In terms of reaction kinetics, rate 
of resection is generally consistent, ranging between 1.7 x 10-4 – 3.4 x 10-4 nt sec-1 
(Fig. 6c), which is comparable to previously published rates (437). 
 
Since this assay has been shown to be powerful tool for observing nuclease activity, 
an attempt was made to study whether this assay could capture the reverse activity 
and visualise an increase in fluorescence upon addition of polymerase. To investigate 
this, the use of the well-characterised Klenow fragment polymerase (KF) was 
employed. KF requires a short DNA primer fragment hybridised to a ssDNA fragment 
along which it can replicate. A selection of 80-mer oligomers hybridised to a 20-, 40-, 
60- and 80-mer oligomer were used (Fig. 6d). The data clearly indicate that KF-
dependent blunting of the 20mer 5’-overhang is possible to visualise in the context of 
this real-time assay. KF appears to be unable to extend the 20- and 40-mer primers 
to produce the full-length 80 bp dsDNA product. KF-elongation of both substrates are 
inhibited once the primers have been extended to 50- or 55-mer lengths (Fig. 6d). It is 
understood that KF is sensitive to secondary structures in the ssDNA template, and 
the presence of a small hairpin adjacent to this region may be responsible for inhibiting 
polymerisation past this point. Previously, a terminal hairpin was not observed to inhibit 
KF processivity,  although an internal hairpin, such as in this case, may have a different 
impact on KF (438). Analysis of the rate of replication suggests a preference for a 
longer ssDNA template, as KF polymerises at a much faster rate on the 60mer 5’-
overhang, while the 40- and 20-mer 5’-overhangs are processed at a three-fold lower 
rate (Fig. 6e). 
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4.13 Discussion 
A highly-sensitive, fluorescence-based nuclease assay was further developed to study 
nuclease activity in a continuous manner. In addition, a library of substrates was 
validated to investigate a wide number of single- and double-stranded DNA nucleases 
and polymerases. This assay can be used to calculate reaction kinetics and reaction 
completion times, providing a powerful quantitative tool for characterising enzymes 
active on nucleic acids. This technique has been successfully validated using well-
studied enzymes and, in the process, identified previously unreported details of their 
mechanisms.   
 
The continuous nuclease assay developed herein has important applications in 
comparing the relative activities of enzymes; both known nucleases and – more 
importantly – yet uncharacterised DNA metabolizing proteins. In our assay, ExoIII was 
validated to hydrolyse the DNA substrate at a faster rate than DNase I. DNase I 
exhibits a relatively low affinity for DNA, and higher affinity strains have been 
engineered for treatment of cystic fibrosis (439,440). DNase I may have evolved to be 
less efficient as it can digest all structures of DNA, irrespective of whether it is single- 
or double-stranded, and deregulation of this activity could be disastrous for the cell. 
This limitation in its binding may exert some control to prevent inappropriate activity 
from causing cellular damage. ExoIII shows a greater rate of resection per enzyme 
protomer, yet this is counteracted by its very limited structural specificity. The product 
of ExoIII resection during E. coli base excision repair is a single-stranded tract of DNA 
that can be much more easily repaired than the damage caused by DNase I (441,442).   
 
Substrate specificities were also compared, as indicated by the preference of ExoIII 
for 3’-overhangs shorter than 4-nt and T7 Exo’s predilection for 5’-overhangs of 10-nt 
or fewer. As T7 Exo typically resects DNA from short 5’-overhangs introduced by T7 
endonuclease during the infection process in E. coli, the results are consistent with its 
behaviour in vitro and in vivo (13,435).  
 
In addition to substrate structures, other physiologically relevant substrates containing 
single-nucleotide mismatches and methylcytosines were considered. Unexpectedly, 
we found that ExoIII and T7 Exo exhibited a preference for one strand of the DNA 
substrate. There is evidence of a nucleotide preference for ExoIII; C>A~T>G, although 
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it seems that it depends on the sequence context (170). Nevertheless, the results of 
their mismatched counterparts do coincide with published ExoIII preferences (170). 
As such, this confirms previously reported preferences in both a qualitative and 
quantitative way. Work is continuing in the Chahwan lab to understand the 
mechanisms of ExoIII, and so it is hoped that its nucleotide preferences will be 
thoroughly elucidated.  
 
As for the methylated substrates, lower concentrations of ExoIII were observed to be 
slightly inhibited by the presence of multiple methyl-cytosines in that resection is 
delayed. The rate of resection, however, remains consistent on all substrates. At 
higher concentrations, ExoIII does not appear to distinguish the methyl-cytosines. T7 
Exo also shows no alteration in activity from the methyl groups. Its host, E. coli, 
contains a small percentage of methylated adenines and cytosines, and it appears 
that T7 Exo does not discriminate against them. This is in spite of a smaller percentage 
of methylated DNA ending up in the bacteriophage’s progeny DNA than is present in 
the E. coli genome (443).  
 
While this assay is predominantly useful for studying processive enzymes, it is 
possible to combine a nickase with an enzyme that resects from nicks, as indicated 
with nickase Nt.CviPII in conjunction with either ExoIII or T7 Exo. This is a powerful 
method to identify nicking or endonuclease activities, and study their efficiency based 
on when resection commences.  
 
The superior sensitivity of PG in this assay also expanded the repertoire of enzymes 
to include ssDNA nucleases, such as Trex2. Trex2 is one of at least eight autonomous 
exonucleases in human cells, and is likely recruited to 3’-termini to alleviate blocks 
during replication arrest (179). It binds DNA very tightly, and this affinity for its 
substrate has been captured here due to its very high processivity. In addition to the 
study of enzymes that digest DNA, the study was extended to enzymes that 
polymerise DNA, such as the nuclease-deficient Klenow fragment polymerase. Its 
polymerase activity is ten-fold more rapid, for example, than ExoIII is at resecting DNA 
in their respective buffers. Therefore, the assay was used successfully to measure 
and differentiate between these vastly different protein kinetics. 
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Characterisation of DNA nucleases is integral for demystifying their roles in 
maintenance of genomic integrity. Loss of nucleases, or mutations in their structural 
or functional domains, can have disastrous effects on the health of an organism.  For 
example, CTIP nuclease has been associated with Jawad and Seckel Syndromes 
(444), Exo1 is involved in mutated in some cancer patients (445–447) and loss of 
TREX1 mediates an auto-immune disease known as Aicardi-Goutières Syndrome 
(448,449). The impact of these mutations could affect resection rates or binding affinity 
to the DNA or interacting partners, and it is posited that this assay may be sensitive 
enough to capture and compare these characteristics. Interacting proteins may also 
influence nuclease activity, as has been observed in the MRN complex (15), or indeed 
by the addition of auxiliary RPA for optimal activity of the RecQ helicase (396,450). 
Nucleases may also represent anticancer targets, and this assay could offer an 
alternative method for studying the effect of future anticancer drugs on the activity of 
their target nuclease (451). In a similar instance, a discontinuous assay using PG was 
successfully performed to study the inhibitory role of actin on DNase I (406).  
 
Many nucleases have been well-characterised, including those used in the 
optimisation of this assay, while many more have yet to be characterised at all, let 
alone identified. As such, this assay represents a safe, easy, rapid, robust, continuous 
study of dsDNA and ssDNA nucleases and polymerases. It is believed that it has the 
potential to revolutionise quantitative assessment of nucleic acid-active enzymes in a 
vast range of applications. Moreover, it is postulated that this assay would be even 
more applicable in studying RNA nucleases, which are historically less known than 
DNA nucleases even though they are more abundant throughout various genomes 
(452–456).  
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5 Chemical inhibition of Kat5 impacts efficiency of class switch 
recombination 
 
5.1 Summary 
Class switch recombination (CSR) is a process of secondary antibody diversification 
whereby the preliminary antibody isotype IgM is exchanged for an alternative isotype. 
This grants B cells different effector functions and is therefore vital for immunity. CSR 
is dependent on both transcription and DNA repair and is orchestrated by key histone 
modifications that recruit appropriate factors to specific sites along the antibody locus. 
Kat5 acetylates histone H4 at numerous sites in its N-terminal tail to unwind the local 
chromatin and make it accessible to transcription factors. Kat5 is also involved in 
canonical DNA repair through activation of DDR signalling (18,26,200). Taken 
together, this evidence suggests that Kat5 may have a role in CSR. An in vitro system 
was used to test this hypothesis. Chemical inhibitors differentially targeting Kat5 
binding and catalytic activities were tested in the context of DNA repair and were 
subsequently used to inhibit Kat5 in cells stimulated to undergo CSR. Results indicate 
that inhibition of Kat5 using the inhibitors iChromo and TH1834, respectively, do affect 
class switching efficiencies, providing evidence for a role for Kat5 in B cell maturation.  
 
5.2 Kat5 is involved in transcription, canonical DNA repair, and antibody 
diversification 
Kat5 is responsible for the acetylation of histones, particularly H2A, H3 and H4 
(200,457). The association of histone acetylation with transcriptionally active regions 
has been well documented. In particular, Histone H4 N-terminal acetylation (H4ac) 
increases sharply at active yeast promoters (202), and early reports found yeast cells 
unable to acetylate their target lysine (K) residues on the H4 tails exhibited altered 
patterns of transcription. Kat5 has been mapped to promoter regions of active genes 
in mouse embryonic stem cells (203), and treatment of mammalian cells with histone 
deacetylase inhibitors enhances gene expression (204).   
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During canonical DNA repair, Kat5 is involved in de-compaction of chromatin during 
canonical homologous recombination (HR). It is thought to play a substantial role 
influencing DNA repair through HR (26), yet mutations in the S. cerevisiae NuA4 
complex, the homologue of mammalian Kat5 complex, renders cells hypersensitive to 
DNA-damage reagents and impairs DSB repair by NHEJ (201). Kat5 has also been 
associated with DSB repair in mammalian cells through nucleosome binding and 
activation of ATM kinase (40,42).   
 
Kat5 may be implicit for CSR through its roles in transcription and DNA repair. Indeed, 
active transcription provides the single strand DNA substrate for AID-induced mutation 
(458–460). Acetylating histones in this vicinity of antibody promoters allows 
transcription machinery clear access to antibody loci; thereby enhancing the 
mutagenic process of AID (246,461).  
 
Equally, CSR is dependent on DSB repair though NHEJ (98,462). Through ATM, Kat5 
mediates phosphorylation of H2AX (γH2AX), which represents a typical marker for 
DNA repair both at DSBs to initiate DDR signalling, and during CSR to stimulate class 
switching (200,224). Furthermore, a histone target of Kat5, H3K9ac, is known to 
associate with S regions that undergo recombination. It precedes AID-dependent 
mutations, and therefore Kat5 may even support AID recruitment (463). One curious 
observation links loss of AID expression with a concomitant depletion of H4ac in B 
cells stimulated for CSR, providing some suggestion of an intimate relationship 
between Kat5 acetylation and AID (464). Additionally, Kat5 is specifically upregulated 
in the GC B cell environment. While, comparatively, the increased expression of AID 
in B cells is far more extreme, the upregulation of Kat5 is potentially biologically 
significant in the context of CSR (319) (Fig. 1). Finally, an unpublished genome-wide 
co-immunoprecipitation CSR screen (Edelmann, Scharff, and Chahwan; unpublished) 
has identified many of the Kat5 complex components to be crucial for antibody 
diversification. 
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FIGURE 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 | Kat5 is marginally upregulated in B cell germinal centres  
Histogram illustrates the relative expression of Kat5 and AID in B cell populations denoted from left to 
right according to their developmental maturity. ProB populations represent cells undergoing primary 
diversification processes of V(D)J recombination, as shown by the increased expression of RAG2. AID 
is specifically upregulated in germinal centre (GC) B cells to drive secondary antibody diversification 
processes, and slightly upregulated post-V(D)J recombination. Kat5 expression fluctuates between 
different B cell populations but is slightly upregulated at later stages of V(D)J recombination and in the 
GC (319). 
 
5.3 Kat5 signalling cascade during DSB repair and implications for cancer 
Immediately following the generation of a DSB, the repressive chromatin complex, 
Suv39h1/kap-1/HP1, is recruited to limit the mobility of the broken ends and hold them 
in close proximity (24,465,466). Kat5 is recruited to the break site by Ago2 and a DSB-
induced RNA guide (467). Kat5 is acetylated by acetyl-CoA, permitting its subsequent 
acetylation of various lysine residues along the H4 tail (H4ac) (468). Alternatively, Kat5 
can be phosphorylated at Tyr44 within its chromodomain by the global, hyperactive c-
Abl kinase (469). The chromodomain is a specialised binding motif that recognises 
methyl groups on lysine residues, particularly on histone proteins (25). This 
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modification permits Kat5 binding to H3K9me3 (469) (Fig. 3). Concordantly, treatment 
with Kat5 preparations from IR-treated cells with λ-phosphatase reduces binding 
affinity of Kat5 to this motif (469). Phosphorylation of the Kat5 chromodomain in turn 
enables Kat5-dependent acetylation of ATM kinase, triggering its monomerisation to 
its active form. Interestingly, the phosphorylation status of Kat5 bears no effect on its 
acetylation of H4, yet interaction between Kat5 and H3K9me3 is necessary to 
stimulate Kat5-mediated acetylation of ATM at Lys-3016 (469). Therefore, H3K9me3 
binding functions as an allosteric regulator by increasing Kat5 catalytic activity (28,43). 
Mutations within the chromodomain that prohibit this interaction also attenuate Kat5 
acetylation of ATM. Correspondingly, mutation of the ATM acetylation site inhibits 
activation of ATM’s kinase activity, indicating Kat5 is required for its activation (43). 
Monomeric ATM phosphorylates a number of targets, including H2AX, which is a 
common marker for DSB repair and also functions as a binding site for repair proteins 
(44,470–472). ATM also phosphorylates the kap-1 chromodomain, removing it from 
H3K9me3, and thus generating more binding sites for Kat5 (24,28). 
 
Dysregulation of Kat5 has been implicated in various cancers. This relationship with 
tumorigenesis is likely due to its interactions with signalling proteins involved in 
maintaining genome integrity (21,28) as well as transcription factors known to 
participate in oncogenic pathways (21,473). Reduced expression of Kat5 has been 
observed in prostate cancer (474) and in 65% of metastatic prostate cancer biopsies 
(475). Similarly, low levels of Kat5 or its aberrant cellular localisation has been linked 
to breast cancer (476,477). 
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FIGURE 2 
 
 
 
Figure 2 | Kat5 DNA damage repair signalling cascade to mediate effective DSB repair 
Following a DSB, Kat5 is recruited to break sites. Phosphorylation by c-Abl kinase permits Kat5 binding 
to H3K9me3 via its chromodomain. This exerts an allosteric effect on Kat5 to acetylate ATM, triggering 
ATM autophosphorylation and monomerization into its active form. ATM then phosphorylates H2AX, 
which recruits downstream DNA repair factors. Independently of c-Abl, Kat5 acetylates H4 induce local 
chromatin unwinding and to ensure the underlying DNA is accessible to transcription and DNA repair 
proteins. 
 
No known role for Kat5 in CSR has yet been described. Due to compounding evidence 
whereby histone acetylation is associated with active transcription and canonical DNA 
repair (Fig. 3), in addition to the specific upregulation of Kat5 in GC B cells (Fig. 1), a 
role for Kat5 in antibody diversification is proposed (18). A role for Kat5 will be tested 
using a well-characterised in vitro mouse model of CSR and chemical inhibitors. This 
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chapter describes the chemical separation of function of Kat5 activities by, 1) inhibiting 
its binding to methylated histone residues via the chromodomain by using inhibitors 
Imatinib (42,478) and iChromo (Kaidi A, unpublished), and 2) inhibiting its catalytic site 
which mediates protein acetylation by using the inhibitor TH1834 (207). In the 
associated Chapter 6, the development of a related genetic model to study the role of 
Kat5 in both mouse and human cells will be discussed.  
 
FIGURE 3 
 
Figure 3 | Kat5 STRING network depicting the protein interaction of Kat5 in mouse cells 
The STRING network for mouse Kat5 identifies a number of interacting proteins that are themselves 
involved in DNA repair (ATM, H2afx), transcription (Crebbp), and chromatin remodelling (RuvBL1, 
RuvBL2). The thickness of the connecting lines represents the level of confidence in the 10 Kat5 protein 
interactions. The interactions appear to have been clustered into histones and histone 
modifiers/chromatin remodelling proteins. 
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5.4 Materials and Methods 
 
5.4.1 CH12F3 cell culture 
CH12F3 B Cells were cultured in RPMI medium (cat. 11875, Gibco,), supplemented 
with 10% FBS (lot. 08F9038K, cat. 10500064, Hyclone), 5% NCTC 109 (cat. N1140, 
Sigma), 5% L-glutamine (cat. 25030024, Gibco), 5% pen/strep (cat. P4333, Sigma) 
and 1% β-mercaptoethanol. (cat. 21985023, Gibco). 
 
5.4.2 DNA damage assays 
For the DNA damage assays, cells were transferred to a 24-well plate (cat. 662160, 
Greiner Bio-One) and pre-treated with either imatinib (cat. ALX-270-492-M025, Enzo 
Life Sciences) for 1 hour, iChromo for 16 hours, or TH1834 (cat. 2339, Axon Med 
Chem) for 1 hour. Stock imatinib was prepared according to manufacturer’s 
instructions; iChromo was reconstituted in DMSO to a final molar concentration of 30 
mM; stock TH1834 was reconstituted in DMSO to a final molar concentration 50 mM. 
Cells were incubated at 37ºC and 5% CO2. Following pre-treatments of inhibitors, 0.25 
or 1 µM CPT (cat. C9911, Sigma) was subsequently added to the cells for 30 minutes 
prior to fixation.  
 
5.4.3 CSR assays 
To activate CH12F3 B cells for the CSR assays, anti-CD40 (1:200, cat.15258437, 
Fisher Scientific), IL-4 (1:1000, cat. 404-ML-050, R&D Systems) and TGF-β (1:1000, 
cat. 240-B-010, R&D Systems) were added to relevant wells alongside appropriate 
concentrations of iChromo or TH1834. IL-4 and TGF-β were prepared according to 
manufacturer’s instructions. iChromo was replenished every 24 hours. TH1834 was 
replenished every 12 hours. Anti-CD40, IL-4 and TGF-β were replenished alongside 
the inhibitors as necessary over the first 48 hours.  
 
5.4.4 Cell fixation and immunofluorescence staining 
Antibodies used were FITC-conjugated anti-γH2AX (1:200 dilution, cat. ab26350, 
Abcam), APC-conjugated anti-IgM (1:200, cat. 17-5790-82, Fisher Scientific) and 
FITC-conjugation anti-IgA (1:200, cat. 559354, BD Biosciences). For DNA damage 
assays, cells were fixed and stained using Fixation/Permeabilization Solution Kit (BD 
Biosciences, 554714); aliquots were extracted (4 µL) and mounted on a slide with 
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DAPI mounting medium (4 µL, cat. ab104139, Abcam). Cells were analysed on ZEISS 
LSM 880 with Airyscan confocal microscope. Excitation wavelength was set at 488 nm 
for GFP-tagged anti-γH2AX antibody and 405 nm for DAPI. All images were recorded 
using Plan-Apochromat 100x/1.4 Oil DIC M27 and processed using ImageJ. For class 
switching assays, cells were stained in 0.01 M PBS and centrifuged 300 x g, 5 mins.  
 
After staining, cells for the flow cytometer were washed in 0.01 M PBS and 
resuspended in 400 µL 0.01 M PBS. Fluorescence was measured using the BD Accuri 
C6 plus according to the manufacture’s specifications (BD Biosciences). Live cells 
were gated for analysis.  
 
5.4.5 Data analysis 
Sequence alignments and building the phylogenetic tree were run on Jalview 
bioinformatics software (479). Flow cytometry results were analysed and presented 
using FlowJo 10.5.0 software. For presentation and statistical analysis of the data, 
one-way ANOVA with Dunnett’s multiple comparisons tests were used. This was 
implemented using GraphPad Prism v7.03. Confocal images were processed on 
ImageJ software (480). 
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5.5 Results 
Kat5 has been highly conserved throughout evolution, as highlighted in the sequence 
alignment (Fig. 4a). Mus musculus (mouse) and Homo sapiens (human) Kat5 protein 
sequences are highly similar, reaching 99.81% sequence identity, and this sequence 
identity perseveres throughout evolution; in Gallus gallus (chicken; 84.27%), Danio 
rerio (Zebrafish; 76.84%), D. melanogaster (57.92%), C. elegans (46.12%), S. 
cerevisiae (41.47%), S. pombe (39.57%) and U. maydis (38.92%) (479). 
 
The sequence alignment of Kat5 from yeast to humans idetifies key domains. As a 
founding member of the MYST (MOZ, Ybf2/Sas3, SAS2, Tip60/Kat5) family of histone 
acetyltransferases, this region is highly conserved (Fig. 4a, pink) (481). MYST family 
members share functional and structural similarities, and all participate in a diverse 
range of cellular processes, including transcription regulation, DNA damage repair and 
apoptosis (481).  
 
The acetyl-CoA binding groups and active site have also been highlighted (Fig. 4a, 
yellow and burgundy), and these sites are all very well conserved, indicating the crucial 
function of this activity. The acetyltransferase reaction requires deprotonation of 
Cys304 by Glu338, generation of a acetyl-Cys304 intermediate, deprotonation of the 
histone lysine residue by Glu338, and transfer of the acetyl moiety to the lysine 
substrate (482). In support of this model, individual mutations in Cys304 and Glu338 
eliminated acetyltransferase activity of Esa1 in vitro, and co-crystals of Esa1 and 
Acetyl-CoA revealed the transfer of the acetyl group from Acetyl-CoA to Csy304. 
Failure of this transfer was observed in co-crystals of Esa1-E338Q and Acetyl-CoA 
(482,483). Critically, both Cys304 and Glu338 remains conserved throughout 
evolution (Fig. 4a, yellow and burgundy). 
 
The zinc finger domain is a curious feature shared between Kat5 in all organisms, 
except for S. cerevisiae. Each protein contains the common CxxxCX12HxxxC motif 
(482). This particular zinc finger motif is associated with forging DNA-protein, RNA-
protein and protein-protein interactions, which all coincide with Kat5’s role in 
transcription, and the observation that Kat5 is often a member of large multiprotein 
complexes (26,203). Deletion studies of Sas3 revealed that this region is required for 
histone acetyltransferase activity (484). Interestingly, structural analysis of the yeast 
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protein indicates that the zinc finger region instead forms a classical TFIIA-type zinc 
finger hold, and zinc fingers of this subtype are also able to mediate DNA-protein and 
protein-interactions (485).  
 
Chromodomains are well-studied functional domains that bind to methylated histones 
(486–488). Nevertheless, some reports have claimed an additional RNA or DNA 
interaction capabilities (489–491). Previously, the yeast Kat5 was presumed to encode 
a chromodomain, and structural analysis identified a well-folded structure that 
exhibited 3–10-fold greater binding affinity for RNA than DNA (492). Loss of this region 
sensitises yeast to DNA damage reagents, alters transcriptional activities and, 
crucially, the RNA-binding activity was found to be essential for viability (492). Whether 
this is the case for mammalian Kat5 is unknown. Critically, the Tyr44 residue is present 
in each organism (Fig. 4a, orange). This site requires phopshorylation for 
chromodomain binding (42).  
 
One interesting feature that appeared in the search for protein domains was the 
identification of DNA polymerase III subunits gamma and tau. Gamma and tau are 
ATPases involved in loading and unloading the DNA polymerase replisome in bacteria 
(493). Based on the diverse range of motifs associated with this domain and the 
functions of gamma and tau, this find is quite dubious. Kat5 does not exhibit ATPase 
activity (494), however it may share some of the DNA-binding properties of these 
subunits.  
 
Each phylogenetic tree of the individual domains within Kat5 shows the evolutionary 
relationships between selected species (Fig. 4b–g). Generally, the outcomes of each 
branch are to be expected; S. pombe and S. cerevisiae appear to share a more similar 
evolutionary history, as does mouse, human, dog and chicken. However, the 
phylogenetic tree formed on DNA polymerase III subunits gamma and tau domain 
shows an unexpected evolutionary history, particularly whereby D. melanogaster and 
S. pombe, and C. elegans and S. cerevisiae, share more common ancestors 
respectively.   
 
Crucially, based on the sequence similarity specifically between mouse and human 
Kat5, it is highly probable that the Kat5 inhibitors will recognise both with equal affinity, 
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and any results captured in the mouse CSR model CH12F3 B cell line should be 
replicable in human B cells. 
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FIGURE 4 
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Figure 4 | Kat5 protein sequence is highly conserved throughout evolution 
a, Sequence alignment of Kat5 lysine acetyltransferase across evolution. Analysed using the Pairwise 
Alignment tool on the Jalview Java alignment editor – version 2 (479) and presented with Percentage 
Identity multiple sequence alignment colour scheme based on 30% minimum conservation.  Conserved 
domains are labelled: RNA-binding Tudor-knot of the chromodomain (turquoise), chromodomain 
(green), site of tyrosine phosphorylation (orange), query DNA polymerase III subunits gamma and tau 
(blue), conserved MYST domain present in MYST histone acetyltransferases (pink), Zinc finger domain 
(purple), Acetyl-CoA binding domains (yellow) and the active site (burgundy). These regions generally 
exhibit higher conservation than other regions. b–g) Phylogenetic trees on the full-length protein 
sequence of Kat5 (b), the MYST domain (c), the Tudor-knot (d), chromodomain (e), zinc finger (ZnF), 
f) and a possible hit for DNA polymerase III subunits gamma and tau. Each tree was rendered using 
MUSCLE multiple sequence alignment, PhyML for phylogenetic reconstruction and TreeDyn for image 
generation. All sequences used the Gblocks programme to eliminate poorly aligned positions and 
divergent regions, except (f) (495).  
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5.6 Imatinib inhibition of c-Abl kinase triggers spontaneous damage and 
eventual cell death 
CH12F3 B cells were treated with small molecule inhibitors; either imatinib, iChromo, 
or TH1834. Each inhibitor mechanistically interacts with Kat5 differently, allowing for 
sensitive analysis of Kat5’s activity during DNA repair and, ultimately, in CSR. The 
mode of action of each inhibitor is further elaborated below. First, these inhibitors were 
tested in the context of DNA repair to study the effect of Kat5 inhibition on DNA 
damage response signalling and, following a clear phenotype, the inhibitors were then 
employed in a class switching assay using the CH12F3 mouse B cell line. CH12F3 
cells express IgM antibodies prior to activation by anti-CD40 and IL-4 and TGF-β 
cytokines, at which point they switch specifically to IgA-presenting cells.  B cells were 
treated with the topoisomerase I inhibitor, camptothecin (CPT), to introduce DSBs 
during S-phase.  
 
Phosphorylation by c-Abl kinase permits Kat5 binding to H3K9me3, eventually 
triggering H2AX phosphorylation (469). Treating CH12F3 B cells with imatinib 
prevents this phosphorylation event, permitting the investigation of this modification 
on DNA repair signalling. Initial treatment with imatinib was based on experiments 
involving fibroblasts whereby the cells had been treated with 0.1, 1 and 10 µM 
concentrations of imatinib (496,497). Following imatinib treatment, it was expected that 
there would be a reduction in gH2AX signalling, preventing the recruitment of 
downstream repair proteins. It should not impact Kat5-dependent chromatin 
remodelling, thereby permitting separation of function analyses of Kat5. Other 
mechanisms are in place to drive H2AX phosphorylation, such as by ATR (ataxia-
telangiectasia and Rad3 related) and DKA-PK (498), so a total loss of γH2AX was not 
expected. 
 
In an attempt to replicate these conditions, cells were pre-treated with 0 or 1 µM 
imatinib.  In these conditions, irrespective of CPT treatment, this concentration of 
imatinib was toxic as observed by the dead cell distribution (100% and 99.98% dead 
cells) in the flow cytometry analysis (Figure 5a; left). Following successive rounds of 
optimisation, a narrow range of imatinib pre-treatments proved to have limited effect 
on Kat5 inhibition and downstream H2AX phosphorylation (Fig. 5b–d). This is not 
entirely unexpected as imatinib is used in treatments against B cell lymphomas (499–
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501), and therefore very effective against B cell malignancies which our cell line 
CH12F3 is a model of (96). However, within a tight range of very low concentrations, 
a trend is observed whereby imatinib shows limited inhibition of DNA repair signalling 
before itself causing spontaneous cell damage and increasing H2AX phosphorylation 
independently from genotoxic treatments (Fig. 5b–d). An approximate 20% reduction 
in γH2AX is observed following treatment with 0.006 µM imatinib (p<0.01) compared 
to the mock treatment, yet with 0.01 µM imatinib, damage signalling is reduced by only 
10%, although this reduction is not significant. Following treatment with 0.05 µM 
imatinib, 70% spontaneous DNA damage is observed independently of CPT treatment 
(Fig. 5b–d). As such, imatinib is clearly not suitable for this assay. Furthermore, c-Abl 
is a hyperactive kinase that phosphorylates a broad range of target proteins (502). 
Without Kat5 specificity, it is impossible to attribute any effect observed in these results 
being solely due to Kat5 inhibition. That is why it was decided to use alternative 
inhibitors which could give a more specific response and a better separation of function 
analysis.  
 
Imatinib was briefly considered as an additional DNA damaging reagent alongside 
CPT. However, this was dismissed because imatinib targets a multitude of proteins 
that are involved in cell growth and survival, oxidative stress and DNA-damage 
responses, and actin-dynamics and cell migration (502). Potentially altering the 
behaviour of many cellular pathways could mask the activity of Kat5, which would 
impede any attempt to isolate its role in DNA repair.  
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FIGURE 5 
 
Figure 5 | Imatinib treatment causes extensive cell death 
a, CH12F3 B cells were treated with 0 or 1 µM imatinib for 1 hour prior to incubation with 1 µM CPT for 1 hour. Cells were fixed and stained with GFP-tagged 
anti-γH2AX antibody. The light and dark purple populations on the scatter plot represent live cells and the light and dark teal populations represent dead cells 
that have ben treatmed with 1 µM imatinib. Values indicate the percentage of live cells in each population. b and c, Performed flow cytometry on cells treated 
with a range of concentrations of imatinib (0.001 – 0.05 µM). d, Histogram representing γH2AX positive populations across all samples tested and quantified 
as a percentage of the total damage inflicted on mock cells treated with CPT. Error bars represent SEM, n=3 in all cases; **p<0.01.
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5.7 iChromo treatment inhibits DNA damage signalling 
iChromo is a competitive inhibitor of c-Abl kinase, and effectively protects the Kat5 
chromodomain against phosphorylation by preventing the docking of c-Abl (A. Kaidi, 
personal communications). In doing so, Kat5 fails to be recruited to sites of DNA 
damage – via the recognition of its chromodomain to H3K9me3 histone mark – thereby 
failing to activate ATM kinase which triggers the DDR signalling cascade. The 
iChromo-Kat5 complex however, is still able to acetylate H4 N-terminal tails (42) 
thereby allowing us to study the separation of function between Kat5 recruitment and 
acetylation activity. iChromo is a far more effective inhibitor than imatinib, successfully 
reducing γH2AX signalling by >20% between 20-50 µM iChromo, and nearly a further 
70% at 75 and 100 µM iChromo, without inducing spontaneous damage (Fig. 6a–b).  
However, it appears that at the higher concentrations of inhibitor, cellular viability is 
significantly reduced (p<0.0001) to approximately 20% live cells, compared to a 
consistent 60–80% live at lower concentrations of iChromo (Fig. 6c). 
 
CH12F3 B cells were subsequently visualised using immunofluorescence microscopy 
(Fig. 6d). It appears that CPT treatment induces DNA damage, and also causes the B 
cells to shrink in size to <10 um in the mock treatment. As iChromo concentration 
increases from 10–50 µM, the diameter of the cells visibly increases to >10 um. At 75 
and 100 µM iChromo, the cells again appear very condensed (Fig. 6d). In addition, as 
iChromo concentration increases, the B cell nuclei appear fragmented in a 
phenomenon described as ‘blebbing,’ and this becomes much more prevalent at 
higher concentrations (p<0.0001; Fig. 6f).  
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FIGURE 6
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Figure 6 | Increasing concentrations of iChromo reduces DNA damage signalling 
a, CH12F3 B cells were pre-treated for 16 hours with 0–100 µM iChromo prior to 30 minutes incubation 
with 0 or 0.25 µM CPT. Cells were stained with GFP-tagged anti-γH2AX antibody and analysed on the 
flow cytometer. b, Histogram quantifies the results in (a) from replicate experiments; results are 
normalised against total damage accrued in the mock treatment. c, Histogram indicates the % of live 
cells remaining following incubation with iChromo and CPT treatment; results are normalised against 
total damage accrued in the mock treatment. d, CPT-treated aliquots from (a) were visualised under a 
cofocal microscope with th addition of DAPI mounting dye for nuclear staining. e, Histogram represents 
the quantification of the observations in (d), normalised as a percentage of total damage accumulated 
in the mock treatment. f, Histogram indicates the % of cells presenting nuclear blebbing in each 
treatment. Error bars represent SEM, n=4 for each condition; *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
 
5.8 TH1834 treatment inhibits DNA damage signalling by blocking Kat5 
acetylation function 
TH1834 is a Kat5-specific histone acetyltransferase (HAT) inhibitor. Its in silico design 
was based on the structures of acetyl-CoA and the non-specific HAT inhibitor, 
pentamidine (207). An in vivo HAT assay indicates that TH1834 inhibition reduces 
γH2AX formation to a greater extent than pentamindine in DT40 cells (207). As 
TH1834 mimics its natural ligand acetyl-CoA it prevents Kat5-dependent acetylation 
of both H4 tails and ATM, thereby impacting on both the DNA repair and chromatin 
decompaction activities of Kat5.  
 
To test the efficacy of the inhibitor, B cells were treated with 0–100 µM TH1834. 
Incubation with 25 and 50 µM TH1834 significantly reduces H2AX phosphorylation 
(p<0.0001; Fig. 7a–b). In addition, cellular survival during this period remains 
unchanged across the different treatments (Fig. 7c).  
 
Following subsequent confocal microscopy (Fig. 7d), the quantification of damaged 
cells were not as significant as the data extracted from the flow cytometer. 
Nevertheless, there is a general trend whereby TH1834 does reduce DNA damage 
signalling (Fig. 7e). Another complementary explanation here could be the technical 
readout between fluorescence imaging and flow cytomerty. Whilst the former 
technique scores individual cell for their average positive or negative value for the 
green γH2AX fluorescence signal, flow cytomery looks at the average γH2AX 
fluorescence signal throughout the cell population. In that vein, it is possible that 
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TH1834 decreases γH2AX fluorescence signal overall per cell but without being able 
to deplete it completely. While iChromo could be more effective in specific cells, 
perhaps during a certain phase of the cell cycle, thereby causing a complete depletion 
of γH2AX signal in those particular cells. This aspect will be elaborated upoin in more 
detail in the discussion below. Unlike the iChromo-treated cells, very few occurences 
of nuclear blebbing were observed, suggesting that TH1834 does not contribute 
towards any morphological changes in B cells for the duration of this assay (Fig. 7f). 
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FIGURE 7 
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Figure 7 | Treatment with TH1834 reduces DNA damage signalling 
a, CH12F3 B cells were pre-treated for 1 hour with 0–100 µM TH1834 prior to 30 minutes incubation 
with 0 or 0.25 µM CPT. Cells were stained with GFP-tagged anti-γH2AX antibody and analysed on the 
flow cytometer. b, Histogram quantifies the results in (a) from replicate experiments; results are 
normalised against total damage accrued in the mock treatment. c, Histogram indicates the % of live 
cells remaining following incubation with TH1834 and CPT treatment; results are normalised against 
total damage accrued in the mock treatment. d, CPT-treated aliquots from (a) were visualised under a 
cofocal microscope with th addition of DAPI mounting dye for nuclear staining. e, Histogram represents 
the quantification of the observations in (d), normalised as a percentage of total damage accumulated 
in the mock treatment. f, Histogram indicates the % of cells presenting nuclear blebbing in each 
treatment. Error bars represent SEM, n=4 for each condition; *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
 
5.9 Kat5 DNA damage recruitment ability contributes to CSR efficiency 
Having determined the appropriate concentrations of iChromo that exert a phenotypic 
response to the inhibitor, the B cells were induced to class switch in the presence of 
0–30 µM iChromo.  
 
By 72 hours, it was clear that 20 and 30 µM iChromo reduces class switching efficiency 
by approximately 25 and 50% on gated live cells, respectively (p<0.0001). 10 µM 
iChromo enhanced class switching efficiency by nearly 20% compared to activated B 
cells in the absence of inhibitor (Fig. 8a). To gain further insight into this inconsistency, 
the survival rate was calculated over the course of the 72 hours (Fig. 8b). The extent 
of cell death substantially increased with iChromo concentration, and the flow 
cytometer counted  a maximum of 400 cells in 30 µM  iChromo at 48 and 72 hours, 
casting doubt on the validity of the results at this concentration.  
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FIGURE 8 
 
 
Figure 8 | Inhibition of Kat5 chromodomain with iChromo affects CSR efficiency 
a, CH12F3 B cells were activated and treated with 0, 10, 20 and 30 µM iChromo. At 25, 48 and 72 
hours post-activation, cells were stained with APC-tagged anti-IgM and FITC-tagged anti-IgA 
antibodies. Cells were analysed on the flow cytometer. The histogram quantifies the IgA in each 
condition from replicate experiments as a % of the activated control at each time point. b, Graph 
represents the % live population of cells at 24, 48 and 72 hours post-activation. Error bars represent 
SEM; n=4 in all cases; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
 
5.10 Kat5 acetylation activity independently contributes to CSR efficiency 
Cells were treated with TH1834 at a range of concentrations; 0, 10, 25 and 50 µM. As 
observed with iChromo, 10 µM TH1834 appears to stimulate CSR by a further 20–
25% compared to the activated controls at each time point, while 25 and 50 µM 
TH1834 reduces CSR efficiency (Fig. 9a).  
 
This assay was first performed in 2016 with very dissimilar results. Indeed, 10 µM 
TH1834 had a minor 15% reduction in class switching at each time point, and both 20 
and 30 µM TH1834 exerted a 30–40% reduction in CSR (Fig. 9c). There is a clear 
dosing effect between 10 µM and 20 µM TH1834, yet it appears that increasing the 
concentration further to 30 µM does not further impede CSR, suggesting that Kat5 
supports CSR to a certain extent, but perhaps other redundant pathways are also 
active to ensure that CSR is not completely abolished upon loss of Kat5-dependent 
acetylation. 
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To tease out the cause of these stark differences between the experiments in 2018 
and 2016, survival rates were compared over the course of each assay.  The survival 
rates for the assay carried out in 2018 mimic those of the iChromo, in which extensive 
cell death occurs swiftly over the course of 72 hours (Fig. 9c). The cell counts however 
counted <50 cells at 48 and 72 hours, casting doubt on the reliability of those results, 
and hence have been omitted from the histogram. However, in 2016, the live 
population remained stable throughout the 96 hours post-activation (Fig. 9d), 
indicating the either the cells are responding differently to the inhibitor, or the media is 
impacting cellular behaviour due to a different batch of FCS. 
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FIGURE 9 
 
 
Figure 9 | Inhibition of Kat5 acetyltransferase activity affects CSR efficiency 
a, CH12F3 B cells from 2018 were activated and treated with 0, 10, 25 and 50 µM TH1834. At 25, 48 
and 72 hours post-activation, cells were stained with APC-tagged anti-IgM and FITC-tagged anti-IgA 
antibodies. Cells were analysed on the flow cytometer. The histogram quantifies the IgA in each 
condition from replicate experiments as a % of the activated control at each time point. b, CH12F3 B 
cells from 2016 were activated and treated with 0, 10, 20 and 30 µM TH1834. At 48, 72 and 96 hours 
post-activation, cells were stained with APC-tagged anti-IgM and FITC-tagged anti-IgA antibodies. Cells 
were analysed on the flow cytometer. The histogram quantifies the IgA in each condition from replicate 
experiments as a % of the activated control at each time point. c, Graph represents the % live population 
of cells at 24, 48 and 72 hours post-activation from the 2018 assay. d,  Graph represents the % live 
population of cells at 48, 72 and 96 hours post-activation from the 2016 assay. Error bars represent 
SEM; n=4 in all cases; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
 
5.11 Discussion 
These results are the first evidence for Kat5 having a fundamentally critical role in CSR 
and immune diversification. Using a range of chemical inhibitors, Kat5 inhibition 
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reduced DNA repair signalling by prohibiting H2AX phosphorylation and affected CSR 
efficiency.  
 
The small molecule inhibitor imatinib targets c-Abl kinase. By preventing c-Abl kinase 
mediated phosphorylation of Kat5 at Tyr44, Kat5 is rendered incapable of binding 
H3K9me3, and is therefore unable to activate ATM kinase and propagate DNA repair 
signalling (469). Whilst imatinib was capable of reducing H2AX phosphorylation, this 
took place within a very narrow range of concentrations and did not have a particularly 
strong effect. Increasing the concentration further then induced spontaneous damage, 
restricting any dose-ranging studiess. CH12F3 B cells are particularly susceptible to 
imatinib as it is used in treatments against B cell lymphomas (499–501). Furthermore, 
c-Abl kinase has many downstream targets including Kat5 and, as such, any 
observations made could not be attributed to only Kat5 inhibition (502). While imatinib 
could have been used as a DNA damage reagent in the same way that cells were 
treated with camptothecin, camptothecin has only one downstream target and 
produces DSBs as a result. Targeting c-Abl kinase would confuse the results as it has 
several protein targets that may impact DNA repair and Kat5 unpredictably and may 
produce a range of DNA damage structures that are not accounted for in the design 
of the assay. Based on these factors, imatinib was rejected as a potential inhibitor of 
Kat5 in subsequent class switching inhibition assays. It could be interesting to 
incorporate imatinib in the fluorescence assay to determine if it interacts with other 
nucleases or helicases to alter their activities, or indeed to determine whether imatinib 
causes DNA damage directly.  
 
iChromo and TH1834 are other inhibitors of Kat5. As their mechanisms of targeting 
Kat5 differ, it was expected that the extent to which its acetylation activities in DNA 
repair or chromatin decompaction is most vital for efficient CSR. iChromo, similarly to 
imatinib, prevents Kat5 binding to H3K9me3. iChromo is a competitive inhibitor of the 
trimethyl group recognised by the Kat5 chromodomain (personal communications). 
iChromo had a much greater impact on DNA damage signalling, reducing the 
indicidence of H2AX phosphorylation, without inducing any spontaneous damage. It 
did, however, cause nuclear blebbing at higher concentrations, which is indicative of 
apoptosis. 
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TH1834 was designed in silico to bind to the Kat5 HAT domain (207), impeding 
acetylation of both ATM and H4 lysines (207,468), and thus having the combined 
effect of hindering DNA damage signalling and chromatin relaxation. This inhibitor 
successfully reduced the occurrence of γH2AX and, unlike iChromo, did not disrupt 
the integrity of the cell and the nucleus.  
 
For both iChromo- and TH1834-mediated inhibition of Kat5, it would be expected that 
TH1834 treatment would produce a stronger phenotype as it influences both ATM and 
H4ac repair mechanisms, in contrast with iChromo which only affects the pathway 
through ATM. This is indeed the case for the DNA damage assay as TH1834 reduced 
γH2AX signalling by 40% compared to 20% by inhibiting chromodomain binding alone. 
Whether this is to be replicated in regards to class switching will wait to be seen. 
Furthermore, an additional chemical inhibitor which alters the tertiary structure of Kat5, 
while maintaining its catalytic functions, will help to expand our understanding of Kat5’s 
catalytic and structural functions. 
 
Both iChromo and TH1834 affect the Kat5 signalling pathway upstream of H2AX 
phosphorylation as the number of cells exhibiting DNA damage signalling was 
reduced, but the size of γH2AX foci in all conditions appeared very similar to controls. 
This suggests that DNA repair is not inhibited downstream of γH2AX as otherwise the 
γH2AX foci would have continued to expand, trapped in a positive feedback loop, as 
the break is left unrepaired (503).  
 
In the presence of TH1834, there is adose-dependent decrease in class switching, 
with approximately 80% CSR taking place in 10 µM TH1834 and 60–70% in  
20–30 µM TH1834. The rates of CSR are very similar between 20 and 30 µM TH1834, 
indicating that inhibition of Kat5 may only reduce CSR by a certain extent, and that the 
cells are not solely reliant on Kat5 for antibody diversification as other pathways must 
be in place to ensure a certain level of class switching takes place. A dose-dependent 
decrease in CSR is also observed with iChromo over the 72 hours, with 30 µM 
iChromo causing a 50% reduction CSR at 72 hours post-activation. Once the 
experimental conditions are optimised to ensure the high level of cell death is avoided, 
it would be interesting to repeat these CSR assays to determine whether TH1834 has 
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a greater impact on CSR than iChromo as observed in the earlier DNA damage 
assays.  
 
It is worth noting that the incomplete DNA damage and CSR phenotype we observe 
in Kat5 inhibition could be attributed to various interpretations. 1) The chemical 
inhibitors used do not offer complete functional inhibition of Kat5 in B cells. There is 
some evidence in the literature that this could be the case. Although the TH1834 
publication (207) suggests that this may not be case for this specific drug, it has not 
been tested specifically in B cells to confirm whether that is the case or not. 2) There 
is potential redundancy in Kat5 recuitment to DDR sites by factors other than 
H3K9me3. The putative RNA binding activity of Kat5 may support this possibility. 
Excitingly, a recent publication offered an interesting link between RNA and chromatin 
remodelling (467). DSB-induced RNAs (diRNAs) are ~21 nt small RNAs generated by 
Dicer and Drosha proteins. They are complementary to the sequences surrounding 
the break site in both plant and human cells (504,505). Ago2 (of the RNA-induced 
silencing complex) interacts with short RNAs, and was proposed to interact with Kat5 
(467). Interestingly, these diRNAs are dispensible for Ago2 binding to Kat5, however, 
knockdown of Ago2 reduced Kat5 binding to the DSB, and the diRNAs were required 
for recuitment of Kat5 to the DSB (467). Ago2 has a much higher affinity for RNA than 
Kat5 (492,506), and it is possible that Kat5’s RNA binding capabilities serve either to 
reinforce or the interaction, or as a contingency. 3) there is potential redundancy in 
ATM acetylation via other non-Kat5 HAT proteins. Some evidence to support this 
hypothesis stems from the role of another HAT protein called INO80 in DDR signaling 
(507) and in CSR (508). In the future it might be interesting to check the inhibition of 
both INO80 and Kat5 to address this question.  
Once the conditions for studying class switching have been optimised, it will be 
possible to determine whether it is the role of Kat5 in DNA repair or transcription that 
is integral for CSR. This can be further determined by first looking into the proportion 
of the activated B cell population that is IgM- and IgA-negative. Accumulation of 
double-negative B cells would suggest transcriptional flaws. If this population of 
double-negative cells does not change significantly, then it is more likely that Kat5 
functions predominately in DNA repair. To confirm this observation, RT-qPCR would 
need to be performed on B cell samples to confirm the transcriptional levels of Kat5, 
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AID, IgM and IgA S regions. Due to time limitations, the results for this experiment 
were never obtained. 
 
As it stands, it is clear that inhibition of Kat5 activity has an effect on class switching. 
The extent to which it supports or hinders CSR remains unclear, including its 
mechanism. Nevertheles, these preliminary results are very promising and indicate 
that Kat5 does play an essential role in the development of highly versatile antibodies. 
And we thereby have contributed yet another piece of the histone code that regulates 
antibody diversification; starting with our protein/histone acetylation by Kat5, followed 
by histone phosphorylation by ATM/ATR/DNA-PKcs (102,328,509), ubiquitination by 
RNF8 (5,510), and poly-ubiquitination by RNF168 (511). Culminating in the 
recruitment of 53BP1 to bridge the 2 ends of DNA and mediating DNA repair (112). 
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6 Design of mouse and human Kat5 degron knockout constructs 
 
6.1 Summary 
Kat5 is essential for cellular viability. As such, generating Kat5 knockout cell lines is 
likely an impossible task. Confirming Kat5 knockdown is equally challenging as 
commercial antibodies raised against Kat5 bind with very low affinity. Generation of 
an inducible Kat5 knockout degron system overcomes both these concerns.  As such, 
the stepwise design of an inducible Kat5 knockout degron system is described herein, 
including a discussion on the potential applications of this approach in terms of quickly 
and reversibly switching the protein expression of Kat5 on or off. 
 
6.2 Kat5-depleted cells are inviable 
As introduced in the previous chapter, Kat5 is an important and essential histone 
acetyltransferase protein. Kat5 is a challenging protein to manipulate intracellularly. 
Kat5 deletions have been found to be lethal in both mice and yeast (205,476,512). 
Indeed, Kat5+/- mice are viable and develop as normal, however double knockout Kat5-
/- mice experience early embryonic lethality (205). As such, developing a Kat5 
knockout CH12 B cell line was not feasible as any successful knockouts would have 
perished. In addition, commercial antibodies raised against Kat5 typically have poor 
affinity (personal communications). As a result, it is troublesome to visualise the 
success of an siRNA/shRNA knockdown via Western blot.  
 
The aim is therefore to design an inducible and reversible system that allows for cell 
survival and Kat5 visualisation. In the system (described below), Kat5 is tagged with 
an intrinsically disordered protein, called a degron, that targets Kat5 for proteasomal 
degradation unless stabilised.  
 
6.3 Tagging Kat5 with an inducible degron should prevent extensive cell death 
To circumvent the issues of visualisation and viability, it was posited that generating a 
cell line with Kat5 tagged with an inducible, reversible degron could prevent extensive 
cell death. Degrons are specific, unstructured degradation systems that target proteins 
to the proteasome for degradation (513). The E. coli dihydrofolate reductase (eDHFR) 
is one example of a degron, and it allows for rapid manipulation of endogenous 
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mammalian proteins by altering their stability (208). As eDHFR is an intrinsically 
disordered protein, proteins tagged with eDHFR are constitutively degraded 
irrespective of their half-lives, unless they are stabilised by the addition of trimethoprim 
(TMP), which is innocuous in human cells (514,515). The aim is to tag the inducible 
eDHFR degron to the C-terminus of the Kat5 locus, integrating it into the genome using 
CRISPR/Cas9 genome-editing (208). While it is possible to generate an N-terminal 
degron, a large insertion at the initiation codon in one of the first exons is more likely 
to disrupt splicing than an insertion at the termination codon, and C-terminal tagging 
is amenable to degron insertion at an innocuous position downstream of the SV40 
ply(A) site at the 3’ end of the cassette (208). This inducible eDHFR degron is 
preferable to siRNAs or shRNAs due to the reversible nature of the system. This is 
especially useful for studying proteins such as Kat5 which are critical for cellular 
viability. This degron system is further advantageous due to the addition of an HA-tag 
inserted between the C-terminus of the protein of interest and the N-terminus of the 
eDHFR. HA is historically very immunogenic, and highly specific antibodies are 
available against this epitope, superseding the dependence on a suitable anti-Kat5 
antibody. Indeed, FLAG-tagged/FLAG-HA-tagged Kat5 proteins are commonly used 
for protein tagging and visualisation (516–519). 
 
6.4 Components of the degron cassette 
The eDHFR degron cassette encodes for: 
 
3xHA – eDHFR – P2A – puroR/blastR – SV40 
 
This cassette will be integrated into the C-terminus of Kat5 in the mouse and human 
cell lines. The HA tags are a highly immunogenic protein that will allow for Kat5 staining 
by proxy (516–519). eDHFR is the intrinsically disordered dihydrofolate reductase that 
is responsible for targeting Kat5 to the proteasome for degradation and concomitant 
reduction in cellular protein levels (208). Both puromycin and blasticidin resistance 
(puroR/blastR) is essential for antibiotic selection. The antibiotic resistance genes will 
be carried in difference eDHFR cassettes to ensure that each eDHFR degron is 
successfully integrated into the two Kat5 alleles. P2A is a self-cleaving peptide that, 
once expressed, separates the degron from the antibiotics (520). P2A derives from 
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the porcine teschovirus-1, and cleaves the C-terminal proline (NPG | P) (521).  Finally, 
SV40 functions as a terminator signal for RNA polymerase II (522).  
 
The design of both the mouse and human Kat5 degron constructs was carried out by 
Emily Sheppard. The experimental data was produced under instruction by Laura 
Reffo and Erasmus student Miriam Lohr, and ligation protocols had previously been 
optimised by Erasmus student Angelina Bloch.  
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6.5 Materials and Methods 
 
6.5.1 Celery juice assay 
A modified version of the Surveyor assay, the celery juice assay, typically screens for 
Cas9 on-target activity. The CRISPR/Cas9 genome editing tool functions as RNA-
guided molecular scissors to introduce a cut at the desired site on the genome. Error-
prone DNA repair mechanisms target this damaged site for repair and may produce a 
frameshift mutation or stop codon to result in a truncated, inactive protein. DNA 
purified from wild type and Cas9-targeted Kat5 is extracted and mixed together to form 
heteroduplexes. Treatment with a mismatch-specific nuclease will cleave the DNA if 
mutation has been successful.  
 
Analysis of the effects of Cas9 at the DNA level is based on a mismatch-specific 
nuclease. The assay consists of four steps; 1) PCR and PCR purification, 2) 
heteroduplex formation, 3) digest with mismatch-specific nuclease, and 4) 
visualisation of the reaction on a gel. The mismatch-specific nuclease was extracted 
from celery using the TILLING protocol (523). 
 
6.5.2 Design of guide RNAs for the pX260 CRISPR/Cas9 and Kat5 knockout cell 
lines 
Kat5 guide RNAs were designed based on scores generated by the  
gRNA prediction software CRISPRdirect (524) and Zhang lab’s Target Finder 
(http://crispr.mit.edu/). The designed gRNAs were synthesised according to the 
Church hCRISPR gRNA synthesis protocol (http://addgene.org/crispr/church/) and 
ligated into the gRNA_Cloning Vector (525) (Addgene, 41824).  
 
mKat5 gRNA F: AAACTGAGTGGCGTGAGTGACGTCGT 
mKat5 gRNA R: TAAAACGACGTCACTCACGCCACTCA 
  
6.5.3 Transfection of 3T3 cells for Kat5 deletion  
3T3 cells were cultured in DMEM media. Transfections for CRISPR/Cas9-mediated 
Kat5 deletion were performed using Lipofectamine 3000® (cat. L3000001, 
ThermoFisher,). Cells were extracted at 48- and 96-hours post-transfection, and 
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genomic DNA purified using GeneJET Genomic DNA Purification Kit (cat. K0721, 
Fermentas Stores).   
 
 6.5.4 Kat5 PCR primer design  
PCR Primers were designed for the mouse Kat5 DNA sequence using Primer3 (526).  
Primers with suitable melting temperatures and location flanking the gRNA site in the  
sequence were chosen.    
 
mKat5 F: GGAAGTGACGTCTCCCAGAG  
mKat5 R: TAGAAAAGCTTTCGGCCACT 
 
6.5.5 Design of guide RNAs for pX330 CRISPR/Cas9 for development of the 
inducible Kat5-degron knockdown cell lines 
Kat5 sequences, primers and guide RNAs were designed using Benchling [Biology 
Software]. 2018. Retrieved from https://benchling.com. Benchling’s CRISPR guides 
tool identified a Cas9 target site adjacent to the stop codon. The gRNAs were selected 
by virtue of distance from the stop codon, low off-target predictions and high on-target 
predictions. The forward gRNA sequence was prefixed with ‘CACCg’ and the reverse 
gRNA sequence was prefixed with ‘CAAA’ and suffixed with ‘c’. The pX330 vector is 
digested by Bbs1 and the annealed gRNA oligos can cloned scarlessly into the vector. 
 
mKat5 gRNA F: CACCgCACGAGAGCTGGCCGAACCA 
mKat5 gRNA R: CAAATGGTTCGGCCAGCTCTCGTGc 
 
hKat5 gRNA F: CACCgCCAAGACGGCAGCAGGACTG 
hKat5 gRNA R: CAAACAGTCCTGCTGCCGTCTTGGc 
 
 
 
 
6.5.6 Design of mouse and human Kat5 gBlocks® Gene Fragment homology 
region 
Kat5 DNA sequence was downloaded onto Benchling. Retrieved a 1000 bp sequence 
spanning approximately 500 nucleotides either side of the Kat5 stop codon. Its 
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complexity is tested prior to order (https://www.idtdna.com/site/Order/gblockentry). 
Benchling’s CRISPR guides tool identified a Cas9 target site adjacent to the stop 
codon. The PAM sequence in homology region was edited from NGG to NGA and the 
stop sequence was deleted. Either side of the homology region were short overhangs 
with complementarity to the pUC18 vector.  
 
5’ overhang: gattacgaattcgagctcggta 
3’ overhang: agttgcgcagcctgaatggcga 
 
The total length of the homology arms was 1000 bp and was synthesised by IDT. The 
mutated PAM site in both homology regions are highlighted in red.  
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Table 1: Mouse and Human Kat5 homology region gBlocks® Gene Fragments 
Target Homology Region Sequence (5’–3’) 
mKat5 GATTACGAATTCGAGCTCGGTAAAGTGAGCCCAAATGCCCACCTGGGGGTTGTGGTTTGG 
TCTGTCTGTTCCTGGGGTTTCTGGGGACAGATGAATATCTTCAGGGGACTGAACTTTCCCC 
CACTTCCACCCCCACAGTGAGATCAGTGAAATCACTAGTATCAAGAAAGAAGATGTCATCT 
CCACACTGCAGTATCTCAACCTCATCAATTACTACAAGGTTAGGAGGCATGCTCAGGGGAT 
AGATGAGATATGGATGCAGGCTCTGAGCTGACATGAGCTGGCTCTATCTCTTGCTCAGGG 
CCAGTATATCCTAACTCTGTCAGAAGACATCGTGGATGGGCATGAGCGGGCTATGCTCAA 
GCGGCTCCTTCGGATTGACTCCAAGTGTCTGCACTTCACTCCCAAAGACTGGAGCAAGAG 
AGGAAAGTGGCACACACTACCCATTGCCATACCACGAGAGCTGGCCGAACCATGTCTAGCAC 
CCTGTCTTGTCCCATTTGAGCTTCGAAGAGGCACGCAAAGTGAGACAGGCCGAAGAACAG 
ACCCAAGAGGAGAAGAGGCCTAGGAGGGGCCCACTAGTGGCCAGTGCCAAGGCAAGCTC 
AGGTCTAGGCCAACTCCGAGGATAACTGGCTTACTGGCCCAGGTCCGCTCTGAACACGTG 
GACCAAAGGGATCCAGGCAGCTGTGTACATTAAGATGGGTGGGGAGCATTCTGTACAGGA 
CCGGTGATTGTAAAAATTTCTTTTATAAAGGAGGAGCTGGAGGGTGGGGTGGGCGCTGGTT 
GCAAAGTTCTGGCCCCTCTTGCCCCCAGAAATAAATTGTTTATATAGGCAGAGCTATCAGGA 
GTTCTTACCAAACTGGGTGCCATGTAATGGCAGCTTCAGGGTGCTAAGGTGCCCACAGACT 
CAGGCATTGTGAAGATCTCATTTATTGGGATAGAAACAGTCGCTCCAAGTGGTGAGAAGGG 
ATCTGTGACAGTTGCGCAGCCTGAATGGCGA 
hKat5 GATTACGAATTCGAGCTCGGTACAGGGCTCCTGGGGACAGATAAAGGTCCTCAGGGAACCT 
GACCTGTGCTCTCCCACAGTGAGATTAGTGAAATCACCAGCATCAAGAAGGAGGATGTCATC 
TCCACTCTGCAGTACCTCAATCTCATCAACTACTACAAGGTAGGGAGGCAGGCAGGGGAGA 
CAGGTGTGTGGGATGCAGAGTGCAGTCCTCTGTGGGCTGACCACCTGCTGAACCCATCTCC 
TCTGCCCAGGGCCAGTACATCCTCACACTGTCAGAGGACATCGTGGATGGCCATGAGCGGG 
CCATGCTCAAGCGGCTCCTGCGGATCGACTCCAAGTGTCTGCACTTCACTCCCAAGGACTG 
GAGCAAGAGGGGGAAGTGGCCAGACACTGCCCACTGCAGTGCCAAGACGGCAGCAGGACT 
GGGACTGATAGCCCACCCCGCCCCCACTGCAGCTCCCACAAAGCACTCTAAGGGAGATGG 
GGCTGAGGACAGCTCAAAAAGGAGAGGACAGGCCTGGCAGGGGCCCACTGGTGCCCAGC 
ACCAAGGCGAGCTCCGGGCTCAGACCAACTCCAAGGTCAGCTGGCCACAGGCCCAGGCCT 
CCTCTGAAGCAGGGACCAGAGGGAGCCAGGCAGCTGTGTACAGTGAGAAGGGATCCGGAT 
GGGGGAGCTCTGTACAGAGGGCTGGTGATTGTAAAAATTTCTTTTGTAAAGTAGAAGTTGGG 
GGTGGGGTGGGTGCTGGCTGCAAAAATTTCTGGCTTCTCTTACCCCTATTGCCCCCGGCAA 
TAAATTGTTTCTATATGCCAGAGCCATGCAAAGTTCTTGGTGGGGAGGGGGAAAGGGCCCAT 
GCTGGCTTAGGGGCTCTAAGGCGCCCAGACTCACAGGTGCTGTGAAGAGCTCCTTTATTGG 
GGTGATGGAATCGGTTCCAAAGAGCTGGTTTACTGCTGTGAAGGGATCGCAGCTTTGAATTT 
CAAGAGTTGCGCAGCCTGAATGGCGA 
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6.5.7 Primers used in the synthesis and validation of the degron constructs 
Plasmid constructs and primers were designed using SnapGene software (from GSL 
Biotech; available at www.snapgene.com). 
 
Table 2 
Template Primer Sequence 
pUC18 Linearise F AGTTGCGCAGCCTGAATGGCGA 
pUC18 Linearise R TACCGAGCTCGAATTCGTAATC 
pUC18-mKat5 
HR 
Linearise F AAACTCATCAATGTATCTTACACACACTACCCATTGCCATACC 
pUC18-mKat5 
HR 
Linearise R TCGTATGGGTAACCGCCTCCGCCGCTGCCCCACTTTCCTCTCTTGCTCCAG 
eDHFR 
(mKat5) 
Amplification F GGAGCAAGAGAGGAAAGTGGGGCAGCGGCGGAGGCGGTTACCCATAC 
 
eDHFR 
(mKat5) 
Amplification R ATGGCAATGGGTAGTGTGTGTAAGATACATTGATGAGTTTGGAC 
pUC18-hKat5 
HR 
Linearise F AAACTCATCAATGTATCTTACCAGACACTGCCCACTG 
pUC18-hKat5 
HR 
Linearise R TCGTATGGGTAACCGCCTCCGCCGCTGCCCCACTTCCCCCTCTTGCT 
eDHFR 
(hKat5) 
Amplification F GGAGCAAGAGGGGGAAGTGGGGCAGCGGCGGAGGCGGTTACCCATAC 
eDHFR 
(hKat5) 
Amplification R CTGCAGTGGGCAGTGTCTGGTAAGATACATTGATGAGTTTGGAC 
Screen for 
final Kat5-
eDHFR 
product 
F (inside 
puroR) 
CCTGGTGCATGACCCGCAAG 
Screen for 
final Kat5-
eDHFR 
product 
R (inside 
puroR) 
GCTCGGTGACCCGCTCGATG 
Screen for 
final Kat5-
eDHFR 
product 
F (inside 
blastR) 
AGTGATGGACAGCCGACGGC 
Screen for 
final Kat5-
eDHFR 
product 
R (inside 
blastR) 
GCCCAGCACCACGAGTTCTGC 
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6.5.8 Overview of cloning Kat5-degron constructs 
 
FIGURE 1 
 
a 
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b  1 
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Figure 1 | Illustrations of the steps involved in cloning the pUC-18 m/hKat5 degron constructs 
a, An overview of the steps required to synthesise the Kat5 degron plasmid. b, Flow chart depicting the 
sequential process that leads to the synthesis of the pUC18-m/hKat5-degron constructs. The numbered 
boxes match the numbered steps in (a).  
Linearise the pUC18 plasmid and perform Gibson assembly to anneal the 
linearised pUC18 with the mouse or human Kat5 homology region. 
The overhangs either side of the homology region are complementary to the 
terminal ends of the linearised pUC18 to facilitate accurate annealing. 
This generates a pUC18-mKat5 or pUC18-hKat5 plasmid. 
Linearise the pUC18-m/hKat5 plasmid.  
 
The primers for this step have overhangs that are complementary to the degron 
cassette, and therefore the linearised product will carry these overhang sequences. 
 
The degron cassette is amplified out from its plasmid using primers with overhangs 
that are complementary to the 5’ and 3’ mKat5 or hKat5 homology regions. 
 
The degron cassette with encode an antibiotic resistance gene. To ensure that both 
mouse and human Kat5 alleles are targeted, two antibiotic resistance markers will be 
necessary for selection. As such, this step will need to be repeated with a second 
degron cassette carrying a different antibiotic resistance gene. 
 
The linearised pUC18-mKat5 or pUC18 hKat5 plasmid and the degron cassette are 
annealed via Gibson assembly to produce the final vector. 
 
Electroporate the final constructs into the mouse CH12F3 and primary human RPE 
cells lines alongside the CRISPR/Cas9 construct that targets the Kat5 locus. 
 
After 24 hours, commence antibiotic selection. 
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6.6 Results 
 
6.7 CRISPR/Cas9 Kat5-targeted knockout 
In the gel below (Fig. 1) A and L are positive control sequences that are provided by 
the Surveyor assay. They are fully complementary except for a single nucleotide 
mismatch. Incubation of A alone with the celery juice enzyme does not form 
mismatches (Lane A). However, mixing A and L forms heteroduplexes that are 
recognised by the enzyme, resulting in 3 bands (Lane A/L), each a product of 1) 
homoduplex formation and 2) the two products that come from cleaving the mismatch 
following heteroduplex formation. It is clear from the single bands observed in Lanes 
4–7 that either Kat5 has not been successfully targeted and cleaved by Cas9, or that 
those cells that have been targeted and cleaved by Cas9 are not viable. Irrespective, 
Kat5 is not a suitable target for Cas9.  
 
FIGURE 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 | Gel of the Kat5-gRNA targeted CRISPR/Cas9  
R, is the GeneRuler, A and A/L, Negative and positive combinations of control sequences showing 
efficacy of the celery juice nuclease. 1, 2 and 3, Genomic DNA extracted from untransfected 3T3 cells 
at 0, 48 and 92 hours. 4 and 5, Genomic DNA extracted and mixed from untransfected and 
CRISPR/Cas9 transfected 3T3 cells at 48 and 96 hours. 6 and 7, Genomic DNA extracted from 
CRISPR/Cas9 transfected 3T3 cells at 48 and 96 hours. Kat5 PCR amplification product is 600 bp. 
DNA stained with midori green.  
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6.8 Linearisation of the pUC18 plasmid 
The first step in the design of the inducible degron system is to linearise the pUC18 
plasmid. This will incorporate the Kat5 homology regions and the 3xHA-eDHFR-P2A-
puroR/blastR-SV40 cassette in a sequential manner.  
 
FIGURE 3 
a            b 
 
 
 
 
 
 
 
 
 
 
Figure 3 | Gel to show the successful linearisation of the pUC18 plasmid 
a, Vector map of pUC18. The size of the plasmid is 2686 bp, and the linearization primers have been 
highlighted. b, The size of the band in the gel corresponds to the size of the pUC18 plasmid, showing 
successful linearization. DNA stained with midori green. 
 
6.9 Isolation of pUC18-mKat5 HR and pUC18-hKat5 HR constructs 
The linearised pUC18 and the mKat5 and hKat5 homology regions are cloned together 
using Gibson assembly. The products were transformed into DH5α E. coli. Colony 
PCR was performed on individual colonies, and the products were screened with 
linearising primers from within the mKat5 or hKat5 homology regions.  
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FIGURE 4 
a           b 
 
 
 
 
 
c                                                        Mouse 
 
 
 
 
 
 
 
 
d                                             Human 
 
 
 
 
 
 
 
 
Figure 4 | Screening of the mouse and human pUC18-Kat5 HR 
a and b, Plasmid vector maps denoting the pUC18-mKat5/hKat5 HR. The forward and reverse 
linearization screening primers have been highlighted. c and d, Gels show the successful incorporation 
of the mKat5 and hKat5 homology regions in Lanes 13 and 4, respectively. DNA stained with midori 
green. 
 151 
 
6.10 Confirmation of the puC18-mKat5/hKat5 HR plasmids 
To confirm the results on the gel (Fig. 4), the selected colonies were cultured and run 
again on a gel using the linearization primers as screening primers.  
 
FIGURE 5 
 
a      b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 | Screening of the pUC18-mKat5/hKat5 HR plasmids 
a and b, Clones 13 and 4 from Fig. 4 were cultured and re-run on the gel to confirm their integration 
into the pUC18 vector. DNA stained with midori green.  
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6.11 Amplification of the degron cassette 
Next, the degron cassette, comprised of the 3xHA-eDHFR-P2A-puroR/blastR-SV40 
sequences, was amplified using primers carrying overhangs that are complementary 
to the mouse or human Kat5 homology regions.  
 
Figure 6 
a        b 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 | Amplification of the degron cassette 
a and b, Plasmid maps of the degron cassette carrying blasticidin (a) and puromycin (b) antibiotic 
resistance genes. c, Gel to show the successful amplification of the degron using amplification primers 
containing overhangs that are complementary to the mKat5/hKat5 homology regions within the pUC18-
mKat5/hKat5 HR constructs. Gels stained with midori green.  
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6.12 Planned pUC18-mKat5/hKat5-3xHA-eDHFR-P2A-puroR/blastR-SV40 
constructs 
The next stage in this process will be to use Gibson assembly to anneal the degron 
cassette into the linearised pUC18-mKat5 HR and pUC18-hKat5 HR plasmids.  
 
FIGURE 7 
 
 
Figure 7 | Plasmid maps of the final mouse and human Kat5 degron constructs 
a–d, Plasmid maps of the final Kat5 degron in both mouse and human, carrying either puroR or blastR.    
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6.13 Construction of mouse and human CRISPR-Cas9 targeting plasmid: pX330-
mKat5/hKat5  
The pX330 plasmids containing mKat5 and hKat5-targeted gRNAs will also need to 
be prepared. The purpose of the CRISPR/Cas9 system is to introduce a DSB break 
near the stop codon of genomic Kat5. The corresponding complementary Kat5 
sequences in the pUC18 degron cassettes will provide a template for homologous 
recombination, and integration of the degron into the genome. 
 
FIGURE 8 
 
 
Figure 8 | Plasmid map of the pX330 vector encoding the mouse gRNA sequences 
a and b, pX330 vector encoding the mouse (a) and human (b) gRNA sequences.  
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6.14 The final intracellular Kat5-degron product 
Once the mouse CH12F3 B cells and primary human RPE cells have been 
successfully transfected and selected, the intention is for one Kat5 allele to integrate 
the degron cassette containing the puromycin resistance gene, and the other to 
integrate the blasticidin resistance gene, which ensures that both Kat5 proteins will be 
tagged with the degron.  
 
FIGURE 9 
 
 
 
Figure 9 | Full length Kat5-degron protein construct 
Once integrated into the genome, the translated protein construct composed of the Kat5, 3xHA, eDHFR 
degron and P2A self-cleaving peptide will total 731 amino acids, 513 belonging to Kat5, and 218 from 
the entire degron.  
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6.15 Discussion 
Kat5 is essential for cellular viability, which has made it challenging to generate a Kat5 
knockout cell line using CRISPR/Cas9 technology. Furthermore, it cannot be easily 
visualised as antibodies raised against it typically have very low affinity. As such, 
siRNA or shRNA-depletion of Kat5 would be difficult to study without being able to 
confirm the knockdown. As such, the degron system appears to offer an option that 
would save the cell line from perishing due to the reversible nature of the system 
(514,515), and the presence of an HA tag would make the Kat5 visible for Western 
blot, immunofluorescent staining for confocal, and possibly immunofluorescent 
staining for flow cytometry (516–519).  
 
Good progress has been made so far in developing the pUC18 and pX330 constructs 
necessary for this degron system to be electroporated into the mouse CH12F3 and 
human RPE cell lines. However, there are a few concerns about this system as the 
degron is a bulky, not insignificant, addition to tag next to Kat5. Indeed, the degron 
itself is large protein made up of 218 amino acids, which is not much shorter than the 
513 amino acid Kat5. Kat5 participates in DNA repair and transcription, and in doing 
so it has numerous interaction partners (16–18). Disrupting its ability to forge these 
interactions could have subtle and widespread implications on the cell (19–23,492), 
and therefore it is essential that the cell lines generated are validated such that any 
data obtained that suggests a role for Kat5 in CSR is reliable. Any successful 
transfections of CH12F3 and primary human RPE cell lines will need careful 
consolidation. A survival assay will be essential. As Kat5 is required for cellular 
survival, any disruption in its ability to function should have noticeable consequences, 
and its proliferation rate and survival rates would be expected to decrease. 
Additionally, Kat5 is involved in transcription activation, and therefore rt-qPCR to 
ascertain mRNA levels of its target proteins will help to validate the inducible degron 
technique (527). The effect of heterozygous incorporation of the eDHFR degron has 
been considered, and the presence of the degron on just one copy of Kat5 may offer 
a more subtle phenotype that could be studied without the risk of cell death, however 
heterozygous knockouts of Kat5 in mice have been reported to exhibit only minor 
defects in DDR signalling in a sensitised, pre-tumoural background (476). As such, it 
is possible that the activity of just one copy of Kat5 is enough to compensate for the 
loss of the other Kat5 protein. Yet again, the partial redundancy in that system could 
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be attributed to compensation of chronic haplo-insufficiency. We hope our DHFR 
system will provide an acute haplo-insufficiency which a cell may not have enough 
time to adapt to in the short span of time during our experiment; ideally between one 
and twelve hours. 
 
In the event that this system is found to be suitable it is hoped that, in combination with 
the Kat5 inhibitors, it should provide an additional element to understand Kat5’s role 
in both DNA repair and immune diversity. The iChromo and TH1834 inhibitors affect 
Kat5’s catalytic activities but have no effect on the structure of the protein (207). As 
such, if Kat5 possesses a structural role in the support of CSR, as in the case for DNA 
uracil glycosylase, then the total loss of Kat5 offer a more holistic, all-encompassing 
view of its involvement in class switching. This would then also allow for the of 
compensation of the inducible deletion cells with point mutant Kat5 plasmids that could 
mimic and extrapolate further the data obtained from the chemical separation-of-
function of Kat5 in genomic maintenance and immune diversity. 
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7 Discussion and future work 
 
7.1 Overall conclusion 
The research presented in this thesis has achieved the overall aim of the project by 
furthering our understanding of the mechanisms involved in the DNA damage 
response. Moreover, the specific research objectives have been completed by 1) 
developing a fluorescence-based assay that can study a wealth of proteins that affect 
the structural integrity of DNA, and 2) by investigating the Kat5 pathway in both 
canonical and non-canonical DNA repair using a combination of chemical inhibitors, 
and with genetic methods on the horizon. Much of the work within has contributed to 
published articles or is currently in submission.  
 
7.2 Design and improvement of the PicoGreen-based nuclease toolkit 
The development of a fluorescence-based toolkit has established itself as a safe, 
robust, rapid and highly sensitive technique for studying nucleases and polymerases. 
It has the capacity to capture reaction kinetics, and the flexibility to expand the DNA 
substrate library and physiologically relevant modifications to include more complex 
structures, including Y-structures, Holliday junctions, hydroxymethylated DNA, 
methylated DNA and hemimethylated dsDNA for characterisation of a wider variety 
enzymes.  
 
PG had previously been used in discontinuous assays measuring the fluorescence 
read-out from dsDNA. Stabilising the dye with glycerol proved to maintain the 
fluorescent signal and slow the effect of photobleaching, allowing for it to be used for 
monitoring nuclease activity in real-time. This, in combination with sequence 
optimisation of the DNA substrates, produces a suitably strong fluorescent signal that 
accurately captures dsDNA nuclease activities, allowing for sensitive analysis of 
reaction kinetics and substrate preferences. 
 
As evidenced, this fluorescence-based assay has much potential. The activities of 
dsDNA nucleases, ssDNA nucleases, nickases and polymerases can all be 
investigated using this system and, theoretically, should encompass all DNA 
denaturing enzymes, such as helicases or splicing proteins (253–255), as well as DNA 
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polymerising enzymes, including translesion polymerases. It is fortunate that, while 
hydrolysis of the phosphodiester bonds in DNA requires different divalent metal ions, 
none of the nuclease activity studied here was altered in the presence of PG (528). 
Indeed, any enzyme that impacts the structural integrity of DNA should be a suitable 
candidate for study using this method. In addition to the technological novelty of this 
new toolkit, it is expected to also offer new mechanistic and kinetic insights into DNA 
metabolizing enzymes in real time. This could generate a step change in the 
understanding of enzyme reaction speeds, transition states, subtle substrate 
preferences, and co-factor preferences and interferences. 
 
7.3 Incorporating an RNA dye could further generate a universal nuclease assay 
Several RNA dyes are available that could be used to characterise RNA nucleases 
(454,529–531). Confirming their utility with well-characterised enzymes, such as 
RNase A (532), would be essential but then have the potential to identify and study a 
wealth of RNA nucleases (452,453,455,456). RNA nucleases are particularly 
interesting as they are often associated with providing antimicrobial and antiviral 
immunity in viruses, bacteria and eukaryotes (452,533–540), in some cases, cancer 
(538,541–543). Ultimately, staining RNA delivers the opportunity to stain RNA/DNA 
hybrid structures and their degradation by RNA and DNA nucleases, such as RNase 
H and DNase I (452,544).  
 
7.4 Nucleases in immunity and tumourigenesis 
The ability to study both DNA and RNA nucleases is vital. Mutations in nucleases that 
impact either catalytic properties or interaction capabilities can have devastating 
effects on immune function and tumourigenesis. CTIP nuclease has been associated 
with Jawad and Seckel Syndromes (444), Exo1 is mutated in some cancer patients 
(445–447), a loss of function mutation in the human Trex1 gene causes the 
autoimmune disorder Aicardi-Goutières syndrome (545), and mutations in human 
WRN cause the autoimmune progeria disorder Werner Syndrome. Understanding the 
nature of the mutations affecting nuclease or helicase activities, protein interactions 
and/or protein stability will provide an accurate assessment of how these autoimmune 
syndromes have developed. Furthermore, meta-analyses have identified key 
polymorphisms in human RNase L that are associated with increased prostate cancer 
risk (546,547), and that RNase L antiviral activity targets Hepatitis C virus, West Nile 
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Virus and HIV (548). Its role in innate immunity can be modulated, and it therefore 
represents a possible target for therapeutic intervention (548).  
 
With so many RNA and DNA nucleases as targets, the fluorescence-based assay can 
be utilised to study potential inhibitors or modulators of nuclease activity. Actin is a 
naturally occurring inhibitor of DNase I, and its inhibitory effects have been studied 
using a discontinuous fluorescence-based method (406).  
 
7.5 Characterisation of nucleases and polymerases involved in SHM and CSR 
with the fluorescence-based nuclease toolkit 
DNA repair is integral for the successful secondary antibody diversification processes 
of SHM and CSR. In canonical DDR, mechanisms are in place to ensure the delayed 
recruitment of error-prone translesion polymerases so as to promote error-free DNA 
replication at the break site (549). Due to a second mechanism dependent on the 
monoubiquitination of PCNA at Lys164, translesion polymerases, such as θ, η and ζ, 
are recruited to the V region during SHM to introduce a swathe of A and T mutations 
to enhance immune diversity (78,550).  It would be worthwhile to compare the activities 
of all error-prone and error-free nucleases, and potential regulatory binding partners, 
to elucidate whether their kinetics of polymerisation represent another form of 
regulatory control.  
 
As for CSR, although the DNA substrates used in the assay were optimised to reduce 
secondary structure formation and improve fluorescence, the assay is not restricted to 
relying on these sequences. Alternative substrates could be synthesised to mimic the 
G-rich S regions for analysis of nucleases involved in CSR. Moreover, R loops, G4- 
DNA and -RNA quadruplex structures are critical for efficient CSR (64,551,552). 
Processing G4 RNA structures, which target AID to transcribed S regions, presumably 
requires 5’ and 3’ RNA nucleases which have yet to be either isolated or characterised 
(144). The assay would be an excellent candidate for such genome wide high 
throughput screens. Possibly integrating it into microfluidics chips that combines 
protein expression droplets with fluorescent spectroscopy readouts in a high 
throughput manner. 
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7.6 Kat5 has a fundamental role in CSR 
Histone “writers” play a crucial role in building the “histone code” which is essential in 
propagating adequate cell function. Evidence herein shows that Kat5, a histone 
acetylation “writer” has an important role in the DNA damage response in general and 
in immune diversification (CSR) in particular. Clearly, optimisation is required to 
quantify the extent to which Kat5 supports or downregulates CSR; nevertheless, 
inhibition of Kat5 distinctly alters CSR efficiency. Both inhibitors, iChromo (Kaidi A, 
unpublished) and TH1834 (207), target Kat5 and impede its activities in subtly different 
ways. iChromo prevents Kat5 propagating H2AX phosphorylation though the 
acetylation and activation of ATM (44,46,47,469,470).  This prevents the subsequent 
phosphorylation of H2AX and recruitment of downstream repair proteins. TH1834 
mimics Kat5’s natural ligand, Acetyl-CoA, functioning as a competitive inhibitor to 
prevent Kat5 acetylating either ATM or histone H4 (207), thereby reducing H2AX 
phosphorylation and histone H4 acetylation, and impacting both DNA repair and 
transcription. As such, the combination of these two inhibitors should help to determine 
the extent to which each function participates in CSR. Further studies using primary 
mouse B cells would consolidate the observed results. 
 
It is exciting that another collaborator has developed another inhibitor of Kat5 that 
distorts Kat5’s tertiary structure but permits its catalytic activities. As Kat5 exists in a 
large protein complex, it would be intriguing to discover how much its function as a 
scaffold helps to drive CSR compared to its catalytic activities. This would offer a third 
separation-of-function element to develop a thorough understanding of the role Kat5 
plays. Indeed, other proteins present in CSR are present as scaffolding proteins, rather 
than for their roles in catalysis, as is expected during canonical DNA repair. The uracil 
DNA glycosylase (UNG) typically contributes in base excision repair to remove 
misincorporated uracil in the DNA, which produces U:A mismatches (553), and UNG-
deficient mice present with drastically reduced CSR. However, its primary purpose in 
CSR may instead be to function as a non-canonical scaffold that recruits essential 
repair proteins for S region recombination (554). The nuclease function of Exo1 is 
similarly dispensable for CSR, yet Exo1-null mice exhibit defective CSR, suggesting a 
non-canonical structural role (124).  
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On the basis that the Kat5 inducible degron constructs for mouse and human cell lines 
are a success, it will be possible to selectively knockdown Kat5 for studies of CSR 
efficiency (208). Combined with the chemical inhibitors, it will offer yet another level of 
detail that combines both the loss of Kat5 catalysis and its structural features. If this 
system works, following successful transfection and selection of a stable cell line, this 
could be a very powerful tool for studying Kat5 and other essential proteins. These 
human and mouse constructs could be introduced to any human or mouse cell line, 
and perhaps could be combined with degrons or inhibitors that target other proteins to 
build up a more complex system of protein depletion. If this system is deemed 
unreliable, and the presence of the degron impedes Kat5 binding to its partners, then 
a more straightforward method of HA- or FLAG-tagging Kat5 may be an option. This 
will enable visualisation of Kat5 during siRNA knockdown as antibodies recognise HA 
and FAG with very high affinity (516–519). While siRNA knockdown is a valuable and 
effective technique, there are a number of disadvantages including, but not limited to, 
the risk of off-target effects (555); furthermore, protein depletion via siRNA is indirect 
and depends on the stability of the target protein itself (556), and allows for 
upregulation of redundant pathways to counteract reduction in the levels of the target 
protein (555). In comparison, the eDHFR degron causes protein knockdown within a 
matter of a few hours as opposed to days. Neither system produces a total knockout, 
but a knockdown, which in the case of Kat5 may be more beneficial pending the low 
levels of Kat5 may be enough for cell survival (514).   
 
7.7 The role of Kat5 in SHM 
As in the case of CSR, a role for Kat5 in SHM has not yet been established. SHM can 
be monitored in Ramos human B cells which constitutively undergo SHM. Using 
FACS, it will be possible to measure the rate of loss of fluorescence released from an 
mCherry reporter protein inserted within the V region through the somatic mutation of 
its DNA sequence.  
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FIGURE 1 
 
 
Figure 1 | Ramos cell line with mCherry reporter. 
Diagram shows the structure of the Ig V region with the mCherry reporter inserted into the V region of 
the Ramos cell line.  
 
Whilst a study into Kat5 and its involvement in SHM was not possible due to time 
constraints, treating Ramos cells with the inhibitors available should indicate whether 
Kat5 has a function in SHM, and whether this influence contributes to immune 
diversity. Interestingly, a role for Kat5 in inducing synthesis of free DNA nucleotides 
(dNTPs) necessary for DNA repair has been proposed (557). dNTP synthesis is 
increased in S phase to meet the demands of DNA replication. Occasionally, dNTP 
levels are insufficient for repair outside of S phase. The enzyme ribonucleotide 
reductase (RNR) controls the rate-limiting step in dNTP synthesis (558). Transcription 
of many RNR subunits is highly inducible in response to DNA damage and replication 
stress in eukaryotes (559). Mutations that reduce yeast RNR activity, or fail to induce 
it, exhibit increased sensitivity to DNA damage. In response to DNA damage, RNR is 
acetylated by Kat5, and is localised to damaged sites in a Kat5-dependent manner 
(560). It is suggested that this produces high local concentrations of dNTPs at the 
damage site, and therefore may provide high local concentrations of dNTPs required 
for optimal function of error-prone translesion polymerases (558). As translesion 
polymerases contribute towards the accumulation of mutations along the V region, 
Kat5 may therefore support SHM. DNA repair factors involved in immune 
diversification fall under four categories: the ones not affecting either SHM or CSR (not 
relevant in this discussion), the ones affecting both SHM and CSR, and the one that 
affect either SHM or CSR. It would be extremely interesting to see in which of the three 
categories Kat5 falls under. 
 
 164 
 
 
7.8 Concluding statement 
There were two main aims for this thesis; 1) to develop a fluorescence-based toolkit 
that has the potential to study dsDNA nucleases in real-time, and to deliver highly 
sensitive kinetic analyses, and 2) to establish a role for Kat5 in CSR.  
 
Having validated the method for well-characterised nucleases, the nuclease assay 
also incorporated studies of ssDNA nucleases, nickases, and polymerases. It is hoped 
that this method will act as a valuable alternative to conventional methods. It should 
be capable of characterising all enzymes that affect the integrity of DNA, and it would 
be interesting to study point-mutants that have been linked to autoimmune disorders 
and cancer.  
 
As for determining the role of Kat5 in CSR, the results suggest that Kat5 does have 
an important function for efficient CSR, yet the specific details remain elusive. 
Nevertheless, these studies have contributed another piece of the histone code that 
orchestrates secondary antibody diversification. Further study should determine 
whether Kat5’s DNA repair, transcription, or scaffolding function is most influential for 
CSR. 
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Appendix 
 
Analysis of nuclease rates  
 
Part 1: Converting fluorescence units to length of duplex DNA 
Raw data from a DNase I-mediated digestion of 80-bp dsDNA: 
 
First the raw data was converted from the standard curve to a measurement of length 
of duplex DNA. To do this, the average fluorescence for each data set was calculated, 
and each column was labelled with the length of dsDNA they each represent. The 
standard curve was produced from the following oligonucleotides: 
 
80 bp = S (556/557) 
60 bp = S60 (556/611) 
40 bp = S40 (556/610) 
20 bp = S20 (556/609) 
 
The latter assays which incorporated substrate variants were normalised as a 
percentage to their controls (no enzyme) before the standard curve was generated. 
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Next, we used these averaged values to determine the equation of the line, as 
indicated in Fig. 1c in the main text. We had to find the values for the gradient (m) and 
intercept (c) in the linear equation y = mx + c.  
 
Equation to calculate the gradient (m): “=SLOPE(known_y’s, $known_x’s)” 
 
E.g., the first equation at 0 seconds is: “=SLOPE(S43:W43,S$42:W$42)” 
 
The “$” locks the known_x’s values, as these values remain constant in all iterations 
of this equation.  
 
Equation to calculate the intercept (c): “=INTERCEPT(known_y’s, $known_x’s)” 
 
E.g., the first equation at 0 seconds is: “=INTERCEPT(S43:W43,S$42:W$42)” 
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Using the calculated values for the slope and intercept, it was possible to convert the 
raw fluorescence values to length of dsDNA. In doing so, we had to solve for ‘x’ in the 
equation y = mx + c at each time point, where ‘y’ = a raw fluorescence value, ‘m’ = the 
gradient, calculated previously, and ‘c’ = the intercept.  
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This data can then be analysed to calculate maximal reaction rates using the equation 
‘x = (y - c) / m) as shown in the above figure.  
 
 
 
 
 
 
 
 
Part 2: Rate analysis 
It is possible to calculate the rate of the reaction by calculating the gradient of the 
substrate vs DNase I concentration at its steepest. This is the maximal velocity at 
which the enzyme digests or resects the DNA substrate. Below, the rate at the highest 
concentration of DNase I (150 nM) and in the absence of DNase I (0 nM DNase I) is 
shown.  
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The rate for this reaction is calculated for each individual sample. An average of the 
rate when there is 0 nM DNase I is taken (0.010493) and this is subtracted from each 
calculation of the slope. This is termed ‘baseline interpolation’ and is a form of data 
normalisation. 
 
The rate is then divided by the concentration of DNase I in nM. Each value is divided 
either by 150 (when treated with 150 nM DNase) or 0 (when treated with 0 nM DNase). 
When divided by 0, the result is ∞, however the result will be reported as 0 as there is 
no reaction when the enzyme is absent.  
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The rate is negative, as we are calculating the decrease in florescence over time. 
However, the rate can be presented in terms of positive integers, and so the negative 
values are multiplied by -1. 
  
Error is represented by standard error of the mean. The equation for this is: 
 
 
σ = standard deviation 
Σ = sum of 
x = term 
х̅ = mean 
n = total number of terms 
 
In excel, this formula is entered as: 
“=STDEV(range)/SQRT(COUNT(range))”. 
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Kat5 FASTA sequences for protein alignment analyses 
 
>Mouse_Kat5 
MAEVGEIIEGCRLPVLRRNQDNEDEWPLAEILSVKDISGRKLFYVHYIDFNKRLDEWVTHER
LDLKKIQFPKKEAKTPTKNGLPGSRPGSPEREVPASAQASGKTLPIPVQITLRFNLPKEREA
IPGGEPDQPLSSSSCLQPNHRSTKRKVEVVSPATPVPSETAPASVFPQNGSARRAVAAQPGR
KRKSNCLGTDEDSQDSSDGIPSAPRMTGSLVSDRSHDDIVTRMKNIECIELGRHRLKPWYFS
PYPQELTTLPVLYLCEFCLKYGRSLKCLQRHLTKCDLRHPPGNEIYRKGTISFFEIDGRKNK
SYSQNLCLLAKCFLDHKTLYYDTDPFLFYVMTEYDCKGFHIVGYFSKEKESTEDYNVACILT
LPPYQRRGYGKLLIEFSYELSKVEGKTGTPEKPLSDLGLLSYRSYWSQTILEILMGLKSESG
ERPQITINEISEITSIKKEDVISTLQYLNLINYYKGQYILTLSEDIVDGHERAMLKRLLRID
SKCLHFTPKDWSKRGKW 
 
>Human_Kat5 
MAEVGEIIEGCRLPVLRRNQDNEDEWPLAEILSVKDISGRKLFYVHYIDFNKRLDEWVTHER
LDLKKIQFPKKEAKTPTKNGLPGSRPGSPEREVPASAQASGKTLPIPVQITLRFNLPKEREA
IPGGEPDQPLSSSSCLQPNHRSTKRKVEVVSPATPVPSETAPASVFPQNGAARRAVAAQPGR
KRKSNCLGTDEDSQDSSDGIPSAPRMTGSLVSDRSHDDIVTRMKNIECIELGRHRLKPWYFS
PYPQELTTLPVLYLCEFCLKYGRSLKCLQRHLTKCDLRHPPGNEIYRKGTISFFEIDGRKNK
SYSQNLCLLAKCFLDHKTLYYDTDPFLFYVMTEYDCKGFHIVGYFSKEKESTEDYNVACILT
LPPYQRRGYGKLLIEFSYELSKVEGKTGTPEKPLSDLGLLSYRSYWSQTILEILMGLKSESG
ERPQITINEISEITSIKKEDVISTLQYLNLINYYKGQYILTLSEDIVDGHERAMLKRLLRID
SKCLHFTPKDWSKRGKW 
 
>Dog_Kat5 
MAEVGEIIEGCRLPVLRRNQDNEDEWPLAEILSVKDISGRKLFYVHYIDFNKRLDEWVTHER
LDLKKIQFPKKEAKTPTKNGLPGSRPGSPEREVPASAQASGKTLPIPVQITLRFNLPKEREA
IPGGEPDQPLSSSSCLQPNHRSTKRKVEVVSPATPVPSETAPASVFPQNGSARRAVAAQPGR
KRKSNCLGTDEDSQDSSDGIPSAPRMTGSLVSDRSHDDIVTRMKNIECIELGRHRLKPWYFS
PYPQELTTLPVLYLCEFCLKYGRSLKCLQRHLTKCDLRHPPGNEIYRKGTISFFEIDGRKNK
SYSQNLCLLAKCFLDHKTLYYDTDPFLFYVMTEYDCKGFHIVGYFSKEKESTEDYNVACILT
LPPYQRRGYGKLLIEFSYELSKVEGKTGTPEKPLSDLGLLSYRSYWSQTILEILMGLKSESG
ERPQITINEISEITSIKKEDVISTLQYLNLINYYKGQYILTLSEDIVDGHERAMLKRLLRID
SKCLHFTPKDWSKRGKW 
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>Chicken_Kat5 
MAEAAEVSEGCRLPVLRRNQDNEDEWPLAEILSVKDISGRRLFYVHYIDFNKRLDEWVTPER
LDLQRVQGPRKEAKTPTKNGLPGSRPDSPERDPKRKVEVVSPATPVPAATETSQASVFPQNG
SARRAVAAQPGRKRKSACLGTDEDSQDSSDGAPSAPRMTGSLVSDRSHDDIVTRMKNIECIE
LGRHRLKPWYFSPYPQELTALPVLYLCEFCLKYGHSLRCLQRHLTKCDLRHPPGNEIYRKGT
ISFFEIDGRKNKSYSQNLCLLAKCFLDHKTLYYDTDPFLFYVMTEYDCKGFHIVGYFSKEKE
STEDYNVACILTLPPYQRRGYGKLLIEFSYELSKVEGKTGTPEKPLSDLGLLSYRSYWSQTI
LEILMGLKAEGGERPQITINEISEITSIKKEDVISTLQYLNLINYYKGQYILTLSGDIVEGH
ERAMLKRVLRIDAKCLHFTPKDWSKRGKWC 
 
>Western_Clawed_Frog_Kat5 
MAEAEIVEGCRLPVLRKNQDNEVEWPLAEILSIKELTGKKLFYVHYIDFNKRLDEWVTHDRL
DLKKIQFPKKEAKTPTKNGLPGSRPSSPEREVRKIPELIPPPVVPPAAGGKSLPVPKRKVDI
VSPATPVPPPPETTQVTVFPQQAPCDVAGVSAHTVMLSQNGAVRRPSAPAVQPGRKRKSNCL
SADEDSQDSSDGIPSAPRMTGSLVSDRSHDDIITRMKNIECIELGRHRLKPWYFSPYPQELT
VLPVLYLCEFCLKYVKSLKCLQRHLTKCNLRHPPGNEIYRKGTISFFEIDGRKNKSYSQNLC
LLAKCFLDHKTLYYDTDPFLFYIMTEYDCKGFHIVGYFSKEKESTEDYNVACILTLPPYQRR
GYGKLLIEFSYELSKVEGKTGTPEKPLSDLGLLSYRSYWSQTILEILMELKTETGERPQITI
NEISEITSIKKEDVISTLQYLNLINYYKGQYILTLSEDIVEGHEKAMQKRVLRIDSKCLHFT
PKDWSKRGKW 
 
>Zebrafish_Kat5 
MAEPTVEIVEGCRLPVLRKNQENEDEWPLAEILSVKDIPGRKLYYVHYIDFNKRLDEWVTPD
RLDLKKLQFPKKEAKTPTKNGLPGSRPSSPEREVRKSLDLNVQSASAPSRGKTLPTPKRKAE
SVSLATQVTAATPVPSLPSSAEASQASVYPAMRDSSFSIKAREEHEQLTSLTTNGTTRRLIP
SQPGRKRKNCVGTEEIVKVFQNNSPRSSTVYLPPGEDSQDSSDGIPSAPRMTGSLVSDRSHD
DIITRMKNIDCIELGRHRLKPWYFSPYPQELTTLPILYLCEFCLKYLKSLKCLQRHLTKCNL
RHPPGNEIYRKGTISFFEIDGRKNKMYSQNLCLLAKCFLDHKTLYYDTDPFLFYVMTEYDSK
GFHIVGYFSKEKESTEDYNVACILTLPPYQRRGYGKLLIEFSYELSKVEGKTGTPEKPLSDL
GLLSYRSYWSQTILEILMNLKSENGERPQMTINEISEITSVKKEDVISTLQYLNLINYYKGQ
YILTLSEDIVEGHERAMHKRHLRIDSKCLHFTPKDWSKRGKW 
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>D_melangoster_Kat5 
MKINHKYEFDDDVASICESTAALTEGCRLPVRMHKTDDWPLAEIVSIKELDGRRQFYVHYVD
FNKRLDEWVNEEDLYTRKVQFPRRDGSQTGTSTGVTTPQRHHSLAGSVSRPTSPQHPGSGAL
AAIPQTPTGASGSVPPPAGIPNSVAPPGTPSSGGELVNGNNLAAALQKRINRKRKNHGGSAH
GHHSLTSQQQQSHPHPTTPQTPTATPVHVTGDGLISGAANDDGDGSQDGKTPTPRQSGSMVT
HQDDVVTRMKNVEMIELGRHRIKPWYFSPYPQELCQMPCIYICEFCLKYRKSRKCLERHLSK
CNLRHPPGNEIYRKHTISFFEIDGRKNKVYAQNLCLLAKLFLDHKTLYYDTDPFLFYVMTEF
DSRGFHIVGYFSKEKESTEDYNVACILTMPPYQRKGYGKLLIEFSYELSKFEGKTGSPEKPL
SDLGLLSYRSYWAQTILEIFISQNPSTDGEKPTITINDICECTSIKKEDVISTLQNLNLINY
YKGQYIVCINRVIIEQHRRAMDKRKIRIDSKCLHWTPKDWSKRSK 
 
>C_elegans_Kat5 
MTEPKKEIIEDENHGISKKIPTDPRQYEKVTEGCRLLVMMASQEEERWAEVISRCRAANGSI
KFYVHYIDCNRRLDEWVQSDRLNLASCELPKKGGKKGAHLREENRDSNENEGKKSGRKRKIP
LLPMDDLKAESVDPLQAISTMTSGSTPSLRGSMSMVGHSEDAMTRIRNVECIELGRSRIQPW
YFAPYPQQLTSLDCIYICEFCLKYLKSKTCLKRHMEKCAMCHPPGNQIYSHDKLSFFEIDGR
KNKSYAQNLCLLAKLFLDHKTLYYDTDPFLFYVLTEEDEKGHHIVGYFSKEKESAEEYNVAC
ILVLPPFQKKGYGSLLIEFSYELSKIEQKTGSPEKPLSDLGLLSYRSYWSMAIMKELFAFKR
RHPGEDITVQDISQSTSIKREDVVSTLQQLDLYKYYKGSYIIVISDEKRQVYEKRIEAAKKK
TRINPAALQWRPKEYGKKRAQIMF 
 
>S_cerevisiae_Kat5_(ESA1) 
MSHDGKEEPGIAKKINSVDDIIIKCQCWVQKNDEERLAEILSINTRKAPPKFYVHYVNYNKR
LDEWITTDRINLDKEVLYPKLKATDEDNKKQKKKKATNTSETPQDSLQDGVDGFSRENTDVM
DLDNLNVQGIKDENISHEDEIKKLRTSGSMTQNPHEVARVRNLNRIIMGKYEIEPWYFSPYP
IELTDEDFIYIDDFTLQYFGSKKQYERYRKKCTLRHPPGNEIYRDDYVSFFEIDGRKQRTWC
RNLCLLSKLFLDHKTLYYDVDPFLFYCMTRRDELGHHLVGYFSKEKESADGYNVACILTLPQ
YQRMGYGKLLIEFSYELSKKENKVGSPEKPLSDLGLLSYRAYWSDTLITLLVEHQKEITIDE
ISSMTSMTTTDILHTAKTLNILRYYKGQHIIFLNEDILDRYNRLKAKKRRTIDPNRLIWKPP
VFTASQLRFAW 
 
>S_pombe_Kat5 
MSNDVDDESKIETKSYEAKDIVYKSKVFAFKDGEYRKAEILMIQKRTRGVVYYVHYNDYNKR
LDEWITIDNIDLSKGIEYPPPEKPKKAHGKGKSSKRPKAVDRRRSITAPSKTEPSTPSTEKP
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EPSTPSGESDHGSNAGNESLPLLEEDHKPESLSKEQEVERLRFSGSMVQNPHEIARIRNINK
ICIGDHEIEPWYFSPYPKEFSEVDIVYICSFCFCYYGSERQFQRHREKCTLQHPPGNEIYRD
DYISFFEIDGRKQRTWCRNICLLSKLFLDHKMLYYDVDPFLFYCMCRRDEYGCHLVGYFSKE
KESSENYNLACILTLPQYQRHGYGKLLIQFSYELTKREHKHGSPEKPLSDLGLISYRAYWAE
QIINLVLGMRTETTIDELANKTSMTTNDVLHTLQALNMLKYYKGQFIICISDGIEQQYERLK
NKKRRRINGDLLADWQPPVFHPSQLRFGW 
 
>U_maydis_Kat5 
MAPRTQKSTSGTPGGSGTPGPDEGPQISPGGTYGLEDVVVGCKAFVQKPDVVTGEMEERKAE
ILSIREKPKPRLTKKQQAELADKPAPTLEETLEYYVHYCEFNKRLDEWVSGTRLITSRELEW
PKKEVTSDKTKRKVIRAGSGATTPSTPLTPTGKGYRGAGASNLLKKAAAQAAKNVQGESGLE
TPQKRKADSGDTSTAQSIRADSIDADADGEDDENGAVVAMEMLGGNDQQEKDDVATESNGGL
TASLNANQGQETFSKKQEIEKLRTSGSMTQSVSEVARVKNLNKIQMGKSEVETWYFSPYPLE
YAHIDTLYICEMCLSYFPSPFTLKRHRSKCTLLHPPGNEIYRHEDISFFEIDGRLQRTWCRN
LCLLSKCFLDHKTLYYDVDPFLYYCMVKRDDLGCHLLGYFSKEKDSAENYNVACILTLPQHQ
RAGYGKLLIEFSYELTKIEGKLGSPEKPLSDLGLLSYRAYWAEIIVELLLKTEDEISIEEIA
QKTAFTHADILHTCMALNMLKQYQGKHMIVLSDLIISKYTAKRPRKRINPQKLHWTAKNWHR
SQLNFGW 
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